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Chronic Achilles tendinopathy (AT) and anterior cruciate ligament (ACL) rupture are multifactorial 
conditions caused by the complex interaction of several intrinsic and extrinsic risk factors.
Polymorphisms within several genes, including those that encode collagen molecules, the basic
structural component of ligaments and tendons, are intrinsic risk factors for the development of
these injuries. Both type V and XI collagens regulate collagen fibril assembly in a concentration-
dependent manner; and collagen fibril structure is associated with the mechanical properties of the
tissue. Functional polymorphisms within the 3’-untranslated region of the COL5A1 gene, which
encodes the α1 chain of type V collagen, have previously been associated with AT risk and may also
modulate the risk of ACL ruptures. In addition, the polymorphic MIR608 gene encoding for Hsa-miR-
608 microRNA plays a role in regulating type V collagen content in tendons and ligaments and has 
previously been associated with AT. The MIR608 gene is therefore also a potential candidate gene
for modulating the risk of ACL ruptures. Due to the functional homology between type V and type XI
collagens, functional polymorphisms within the COL11A1 nd COL11A2 genes, which encode type XI 
collagen, could also modulate the risk of AT and ACL injuries. 
Aim 
The aim of this dissertation was to use a case-control genetic study to investigate the association of 
polymorphisms within the COL5A1, MIR608, COL11A1 and COL11A2, genes with AT and/or ACL 
injuries in Caucasian populations. These aims were explored in three studies: 
i) Determine whether the COL5A1 rs71746744 (-/AGGG) and rs1134170 (A/T)
polymorphisms and the MIR608 rs4919510 (C/G) polymorphism are associated with ACL
rupture risk (Chapter 2).
ii) Determine whether the COL11A1 rs3753841 (T/C) and rs1676486 (C/T) polymorphisms
and the COL11A2 rs1799907 (A/T) polymorphism are associated with ACL rupture risk. A
secondary aim was to determine whether the COL11A1 and COL11A2 polymorphisms
interact with COL5A1 rs71746744 (-/AGGG) to modulate ACL rupture risk (Chapter 3).
iii) Determine whether the COL11A1 rs3753841 (T/C) and rs1676486 (C/T) and COL11A2
rs1799907 (A/T) polymorphisms are associated with AT risk, and investigate whether
these polymorphisms interact with each other, or with the COL5A1 rs71746744 (-














In the ACL studies, 215 participants who had undergone reconstructive surgery for ACL rupture (ACL 
group) and 217 apparently healthy matched controls (CON group) were genotyped for 
polymorphisms within the COL5A1 (rs71746744 and rs1134170) and the MIR608 (rs4919510) genes 
(Chapter 2); as well as functional polymorphisms within the COL11A1 (rs3753841 and rs1676486) 
and COL11A2 (rs1799907) genes (Chapter 3). In the AT study, 182 participants with clinically 
diagnosed Achilles tendinopathy (TEN group), and 336 apparently healthy matched controls (CON 
group) were genotyped for the functional COL11A1 and COL11A2 polymorphisms (Chapter 4). In all 
studies the variants were examined for independent associations as well as for interactions with 
other investigated variants using two-way gene interaction, inferred haplotype or inferred 
pseudohaplotype analysis.  
Results  
The primary finding was that the COL11A1 rs3753841 polymorphism was significantly associated 
with ACL ruptures. The TC genotype of COL11A1 rs3753841 was significantly over-represented in the 
CON group (54.2%) compared to the ACL group (41.4%, p=0.009, OR=1.7, 95% CI= 1.1-2.5) (Chapter 
2). None of the other investigated polymorphisms in the COL5A1, MIR608, COL11A1 and COL11A2 
genes were independently associated with ACL rupture or AT risk.  
The secondary findings were that various allele combinations of the investigated polymorphisms 
were significantly associated with either injury risk or protection. The inferred -/A haplotype 
constructed from COL5A1 rs71746744 (-/AGGG) and rs1134170 (A/T) was significantly under-
represented in the ACL rupture group (25.0%, p<0.001) and the sub-group with a confirmed non-
contact (NON) mechanism of ACL injury (24.7%, p=0.015) compared to the control group (27.6%), 
suggesting a protective effect against ACL rupture (Chapter 2). The inferred CT haplotype 
constructed from COL11A1 rs3753841 and rs1676486 was significantly under-represented (p=0.044) 
in the ACL group (17.5%) compared to the CON group (21.3%). In addition, the inferred CTA 
pseudohaplotype constructed from the COL11A1 and COL11A2 polymorphisms was significantly 
under-represented in the ACL group (p=0.010, 9.5%) and NON sub group (p=0.037, 10.3%) compared 
to the CON group (14.7%) (Chapter 3). The TCT pseudohaplotype constructed from COL11A1 
rs3753841, COL11A1 rs1676486 and COL11A2 rs1799907 was significantly over-represented 
(p=0.006) in the TEN (25.9%) compared to the CON (17.1%) group. The TCT(AGGG) 













COL5A1 rs71746744 (-/AGGG) polymorphism was also significantly over-represented (p<0.001) in 
the TEN (25.2%) compared to the CON (9.1%) group (Chapter 4). 
Conclusion 
Genes encoding the structurally and functionally related type XI (COL11A1 and COL11A2) and type V 
(COL5A1) collagens may potentially interact with one another to collectively modulate the risk for 
AT. They also appear to possibly interact to weakly modulate the risk of ACL ruptures, although 
further work is required to confirm this. Although there are no immediate clinical applications, the 
results of these studies provide additional evidence suggesting that inter-individual variations in 
collagen fibril assembly might be an important molecular mechanism in the aetiology of 
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Chapter 1: Review of Literature 
1.1 Musculoskeletal Soft Tissue Injuries 
The musculoskeletal system is responsible for enabling movement and locomotion and comprises 
the bones (skeleton), muscles, cartilage, tendons, ligaments and joints. The soft tissues of the 
musculoskeletal system include the muscles, tendons and ligaments, which together, play a role in 
moving the bones of the skeleton to bring about locomotion. These tissues are vulnerable to injury, 
especially when exposed to frequent use, or excessive forces. Musculoskeletal soft tissue injuries 
refer to injuries sustained to tendons, ligaments or muscles. These injuries can be the result of an 
acute trauma or chronic overuse; and can occur during occupational activities as well as during 
competitive and recreational sporting activities1. Their aetiology is multifactorial and comprises both 
intrinsic and extrinsic risk factors2. Genetic susceptibility is an intrinsic risk factor that is receiving 
increasing attention: the identification of predisposing genetic variants performs the dual function of 
providing insights into the molecular mechanisms that underlie these conditions, as well as providing 
tools in clinical practice to improve prevention, diagnosis and treatment of the injuries3–5. Two 
common sites of injury, that will be the focus of this dissertation, are the anterior cruciate ligament 
(ACL) of the knee6, 7 and the Achilles tendon of the heel1. In order to understand how injuries to 
ligaments and tendons come about, it is necessary to first understand the anatomy of these 
structures in detail. 
1.2 Structure of Ligaments and Tendons 
1.2.1 Tissue Organization 
Tendons and ligaments are the anatomical structures that connect muscle to bone8, and bone to 
bone9, respectively. Tendons are responsible for transferring the forces produced during muscle 
contraction into movement8, while ligaments help to passively stabilize joints and guide them 
through their normal range of motion9. Tendons and ligaments are highly organized, hierarchically 
structured tissues8–11 (Figure 1.1). The development of organized structure will be dealt with in detail 
in Section 1.3. Briefly, at the molecular level, individual collagen molecules (tropocollagen) aggregate 
to form collagen microfibrils that merge to form collagen fibrils8. Collagen fibrils are the smallest unit 
visible by electron microscope, and their diameter is highly regulated as it determines many of the 















Figure 1.1 The hierarchical organization of tendon and ligaments. Three α-chains combine to form a collagen 
molecule. Collagen molecules aggregate to from fibrils; fibrils combine to form fibres, fibres combine to form 
subfascicles, subfascicles combine to form fascicles and fascicles combine to form a tendon or ligament. 
(Modified from Kastelic J et al., 1978
12




Many collagen fibrils combine to form a collagen fibre, which is the basic unit of tendons and 
ligaments. The fibres combine to form a primary fibre bundle (subfascicle), which in turn combine to 
form a secondary fibre bundle (fascicle). Many secondary fibre bundles make up a tertiary bundle, 
and together, the tertiary bundles make up a tendon or ligament8. At each hierarchical stage, 
starting at the level of the collag n fibre, is a layer of endotenon or endoligament, which binds the 
fibres or bundles together8. Finally, a layer of epitenon or epiligament surrounds the entire tendon 
or ligament respectively8.  
A tendon or ligament may also be divided into distinct regions based on subtle differences in 
biochemical composition14. The myotendinous junction (MTJ) is the site at which the tendon 
attaches to muscle. The mid-substance of a tendon or ligament is the ‘classic’ tendon or ligament 
tissue composed predominantly of collagen fibres arranged parallel to the direction of force, while 
the osteotendinous junction (OTJ) or osteoligamentous junction (OLJ) is a region of fibrocartilage 
that transitions to bone and attaches the tendon or ligament to bone14. Regions of fibrocartilage 
occur at sites where tendons or ligaments experience compression, pass through soft-tissue pulleys, 
lie adjacent to other ligaments or traverse bony prominences, but their most common occurrence is 
at the insertions sites of tendons or ligaments to bone (enthesis)14,15. Injuries to tendons generally 
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which is more often injured in the midsubstance14. There are multiple reasons for increased injury at 
these sites: (i) they are more highly stressed, (ii) they are exposed to repeated shear and/ or 
compressive forces, and (iii) they are relatively less vascularised than tendon midsubstance14.  
1.2.2 The Molecular Components of Ligaments and Tendons 
Tendons and ligaments contain a proportionately small cellular component, made up of 95% 
fibroblasts (tenocytes or ligamentocytes) and 5% other cell types8. The fibroblasts are responsible for 
secreting and maintaining the extracellular matrix (ECM), consisting of collagen fibrils and ground 
substance8. Fibroblasts are the living component of the tissue that is able to respond and adapt to 
mechanical loading forces, thus enabling the tendon or ligament to repair damage or adapt to 
changes in load over time16. Tendons and ligaments are poorly vascularised tissues, and thus have a 
well-developed anaerobic energy generation capacity8. However, this adaptation results in a 
metabolic activity level that is lower than that of skeletal muscle, resulting in a compromised healing 
capacity and a mismatch between the rate of muscle and tendon or ligament adaptation8. 
The ECM is the main component of ligaments and tendons and is made up of collagen fibres and 
ground substance. The collagen fibres are the major protein constituent of tendons and ligaments 
and form dense bands that are arranged parallel to the direction of force 8,11. The ground substance 
consists of proteins such as elastin, proteoglycans, glycoproteins and glycoaminoglycans (GAGs) and 
roughly 68% water. The water content of the tissue is thought to be responsible for the viscoelastic 
properties of ligaments and tendons 9.  
1.2.3 Collagen Types in Tendons and Ligaments 
The most common collagen in tendons and ligaments is type I collagen, however ligaments also 
contain 9-12 % type III collagen, and small amounts of type IV, V, VI, XII and XIV collagen are found in 
both8–10. The OTJ or OLJ where the tendon or ligament attaches to bone, contains a high proportion 
of type II collagen, and some type IX and XI collagen11. The major fibrillar collagens (type I, II and III) 
form elongated fibrils that help maintain the structural integrity of fibrous connective tissue such as 
tendons, ligaments and cartilage17. Type V, XI, XXIV and XXVII collagen are minor fibrillar collagens 
that are less abundant17,18. However, type V collagen plays a vital role in tendons and ligaments, 
where it initiates fibril assembly19–21 and regulates fibril diameter and lateral growth22–27. Type XI 
collagen performs a similar role to type V collagen28, but is expressed more in cartilage29 and at the 
OLJ30. In addition to fibril-forming collagens, there are a number of non-fibrillar collagens with 












consist of type XI, XII, XIV and XX collagens; and are involved in the linkage of various collagen fibres, 
as well as forming interactions with molecules of the ECM31. 
1.3 Fibrillogenesis 
Fibrillogenesis, or fibril assembly, is the highly regulated, multi-step process, by which individually 
translated collagen molecules are modified, transported, combined into larger molecules and 
eventually incorporated into the architecture of the mature tendon or ligament described in Section 
1.2 32. The mechanical integrity of connective tissues is therefore ultimately dependent on proper 
regulation of the fibrillogenesis process32.  
Although fibrillogenesis is a continuous process, it is often described as occurring in three steps32. 
The first step occurs in close association with the fibroblasts and involves the synthesis, packaging, 
secretion and processing of collagen molecules, and their extracellular assembly into collagen 
intermediates32 (Section 1.3.1). The second step occurs extracellularly and consists of the linear
growth of the fibril intermediates; and the final step involves the lateral growth of fibril
intermediates into mature fibrils of larger diameter32 (Section 1.3.2). The tissue-specific structure
and function of different tissue is due to independent regulation of each step, with different
temporal and spatial expression of varying combinations of collagens, collagen-associated proteins,
leucine-rich repeat family proteoglycans and glycoproteins32 (Section 1.3.2.1-3). This review will
focus mainly on type I collagen fibrillogenesis as it is the predominant collagen type in tendons and
ligaments. 
1.3.1 Collagen Synthesis and Transport
The initial stage of collagen synthesis is similar for all collagen types and occurs within the fibroblast
(Figure 1.2). After gene transcription in the nucleus, collagen α-chain mRNA transcripts are
transported to cystolic ribosomes, which are transported to the endoplasmic reticulum (ER) for
translation into procollagen α-chains containing a terminal C-propetide region, a helical collagenous
section and an N-propeptide terminal region32. The α-chains then undergo a series of post-
translational modifications, such as hydroxylation of about 100 proline and 5-10 lysine residues to
hydroxyproline and hydroxylysine respectively, and glycosylation of some hydroxylysine residues
with galactose or glucosylgalactose33. In fibril-forming collagens, the formation of the procollagen
triple helix from the three α-chains is initiated at the C-propeptide nucleation point by a set of intra-
and inter-chain disulfide bonds, catalysed by protein disulfide isomerase (PDI) 34,35. In fibrillar
collagens, the helical domains of each α-chain helical domain are woven together to form a triple

















Figure 1.2 Collagen synthesis and transport inside the fibroblast. Collagen genes are transcribed in the 
nucleus and processed via splicing of introns to form mRNA. The mRNA is transported into the cytoplasm, and 
then to the ribosome, and attaches to the rough endoplasmic reticulum (RER), where it gets translated into the 
pro-collagen α-chain. The pro-collagen α-chains are post-translationally modified by hydroxylation and 
glycosylation. Three pro-collagen α-chains then wind together to form a triple helix, begging from the C-
terminal propeptide and propagating along the three chains. The pro-collagen molecules are then transported 
to the Golgi-apparatus. In the Golgi apparatus, lateral aggregation of collagen molecules occurs, and 
eventually, individual vesicles bud off from the cisternae and form Golgi-to-plasma membrane carriers (GPCs). 
The GPCs transport the laterally aggregated pro-collagen molecules to deep fibril-forming channels that are 
continuous with the extracellular environment, but which extend deep into the cell. Further processing of the 
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The FACIT collagens differ in their NC1 domains, therefore a cysteine-containing motif in the COL1 
domain plays a role in trimer assembly rather than the C-propeptide36. The triple helix is stabilized by 
inter-chain hydrogen interactions between amino acids which repeat in the sequence ‘Gly- X- Y’, in 
which glycine occurs every third residue, X is usually proline and Y is usually 4-hydroxyproline17 . 
The majority of collagens form homotrimers that consist of three identical α-chains; however they 
may also form heterotrimers, which contain more than one type of α-chain in different ratios and 
combinations17,18. Type I collagen, the most abundant collagen type in tendons and ligaments is 
formed by two proα1(I) chains and one proα2(I) chain31. After the triple-helical procollagen is folded, 
the molecules are transported from the ER to the Golgi apparatus, where the organized lateral 
aggregation of procollagen into bundles occurs33. As the procollagens are transported through the 
Golgi, their long length results in distensions of the Golgi cisternae33. The Golgi cisternae slowly 
shrink due to vesicle expulsion of lipids, resulting in a narrowing of the Golgi cisternae lumen, and a 
localized increase in procollagen concentration, which in turns results in lateral aggregation of 
procollagen into tightly bundled parallel arrays32. Eventually, the ends of the cisternae bud off into 
secretory vacuoles called Golgi-to-plasma membrane carriers (GPCs)32,37. The GPCs fuse to an 
extracellular compartment that extends from deep within the cell to the ECM33.  
The final posttranslational modification of the procollagen molecule is the cleavage of the C and N-
terminal propeptides (Figure 1.3). There is some debate as to whether this cleavage occurs within 
the GPC (Kadler Model33,37), in the extracellular compartment (Birk Model33,38), or both. The C-
terminal propeptide is removed by zinc metalloproteinases such as bone morphogenetic protein 
(BMP-1), mammalian tolloid (mTLD) and tolloid-like (TLL-1), while the N-propeptide is cleaved by 
several members of the “A Disintegrin and Metalloproteinase with Thrombospondin motifs” 
(ADAMTS) family, namely ADAMTS-2, ADAMTS-3 and ADAMTS-1433. Removal of the C and N-
terminal propeptides causes a 10 000-fold decrease in the solubility of the triple helical region, 
resulting in a spontaneous self-assembly of the molecules into a rod-like collagen fibril monomers 
~300 nm in length and 1.5 nm in diameter, called tropocollagen32. Tropocollagen can spontaneously 
form string-like aggregates called fibrils that gave a characteristic 67 nm banding pattern caused by 
the quarter-staggered alignment of collagen fibril monomers31. The tropocollagen molecules are 
covalently bonded by cross-links between lysine and hydroxylysine residues, a reaction that is 
catalyzed by the lysyl oxidase enzyme11. These cross-links can form intramolecularly between α 
chains of the same tropocollagen molecule, or intermolecularly between adjacent tropocollagen 
molecules11. Tropocollagen molecules aggregate extracellularly to form collagen fibrils intermediates 















Figure 1.3 Schematic diagram showing the final post-translation modifications of pro-collagen molecules, and 
the spontaneous assembly, and cross-linking that result in the characteristic 67 nm banding pattern. 1) The C-
terminal propeptides are removed by BMP-1, mTLD and TLL-1, and the N-terminal propeptides are removed by 
ADAMTS-2, ADAMTS-3 and ADAMTS-14. 2) The resulting tropocollagen molecules experience a 10 000 fold 
decrease in solubility and spontaneously from fibril monomers 300 nm in length and 1.5 nm in diameter 
(tropocollagen). 3) Adjacent molecules get bonded covalently by the lysyl oxidase enzyme at selected lysine 
and hydroxylysine residues. 4) Collagen fibril intermediates ~10-30 µm in length form that have the 
characteristic 67 nm banding pattern, which occurs as a result of the three-quarter staggered arrangement of 













1.3.2 Collagen Fibril Growth 
The second and third steps of linear and lateral growth occur extracellularly, and involve the fusion
of collagen intermediates into collagen fibrils of increasing length and diameter32. The structure and
strength of the tissue is determined by intra- and inter-molecular cross-links between fibrillar
collagens and collagen-associated proteins, as well as other ECM molecules such as the leucine-rich
repeat family of proteoglycans and glycoproteins32. The expression of these molecules is extremely
complex, and the temporal and spatial expression of molecules in the correct sequence and
combination is required for the proper tissue specific structure and biomechanical properties to
develop32. The role of many of these molecules as regulators in fibrillogenesis was discovered by
knock-out studies in mice39. The next section reviews some of the key regulators of linear and lateral
fibril growth, with a discussion of the mechanism of regulation, temporal expression of the molecule
and the phenotype of the knock-out organism where available. 
1.3.2.1 Fibrillar Collagens 
1.3.2.1.1 Type III Collagen 
Type III collagen often co-localizes with type I collagen and can form heterotypic fibrils with type I 
collagen32. The ratio of type I to type III collagen is thought to regulate the size and uniformity of
type I fibrils, with higher type III collagen c ntent resulting in smaller diameter fibrils32. This 
regulation occurs due to partial processing of the transcript in which the N-propeptide is retained
and interferes with the incorporation of type I monomers40. The expression of type III collagen
differs temporally and spatially during development. Early on in development the expression of type
III collagen is high, however in mature fibrils, type III collagen is usually confined only to the
endotenon, having been removed by protease and collagenase activity32,33. 
1.3.2.1.2 Type V Collagen 
Type V collagen is a minor fibrillar collagen that acts as a nucleator for type I collagen during fibril 
assembly, and regulates fibril diameter in mature tendons via retention of the non-collagenous N-
propeptide23,24 (Figure 1.4). The triple helical domain of type V collagen occurs in the interior of the 
fibril, while the NH2-domain projects outwards
24 and interacts sterically or electrostatically with 
other collagen molecules or with leucine-rich proteoglycans25. Upon reaching a critical density, the 
initiation of new fibrils is favoured over the continued growth of existing fibrils25. Type V collagen is 
essential for life, as COL5A1 -/- mice died at embryonic day 10, and had a virtual lack of collagen fibril 












collagen synthesis, yet deposited less than half the amount of hydroxyproline as controls, showing a 
role for type V collagen in fibril nucleation19. Increasing the amount of type V collagen results in a 
progressive decrease in the mean fibril diameter in vitro23, in cultured fibroblasts25,19 and in mice21. 
In addition, different tissues expressing different levels of type V collagen have different mean 
diameter fibrils41. For example, the chick cornea has a high proportion of type V collagen (20%) and 
has a very narrow range of small diameter fibrils in comparison to tissues containing predominantly 
type I collagen22. The function of type V collagen in musculoskeletal soft tissue injuries will be 
described in more detail in the next chapter (Chapter 2) of this dissertation. 
Figure 1.4 Model for type V collagen regulation of fibril diameter. The negatively charged amino-terminal 
domains of type V collagen project from the fibril surface, and when sufficient numbers have accumulated, 
they block further accretion of collagen monomers and thereby limit growth in diameter Left: Collagen fibrils 
possessing low levels of type V collagen incorporate a large number of type I collagen molecules and have 
large diameters. This results in collagen fibres made up of fewer, larger diameter fibrils, that are less densely 
packed. Right: Fibrils with a high percentage of type V collagen, prevent accretion of type I collagen, and 
therefore have small diameter fibrils. Therefore a greater number of smaller diameter collagen fibrils get 
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1.3.2.1.3 Type XI Collagen 
Type XI collagen shares structural and functional homology with type V collagen28, in that it has a 
collagenous domain that is situated in the core of collagen fibrils29, and a protruding N-terminal 
domain that interacts sterically to control fibril diameter42. However unlike type V collagen, type XI 
collagen is expressed mainly in cartilage43, which consists mostly of type II collagen29. In addition, 
type XI collagen is essential for the interaction of collagens with proteoglycans28. Although Type XI 
protein is predominantly expressed in cartilage 44, it is found in many other non-cartilaginous 
tissues45–48. The function of type XI collagen in tendon and ligament biology will be described in more 
detail in Chapters 3 and 4 of this dissertation. 
1.3.2.2 FACIT Collagens 
1.3.2.2.1 Type XII and Type XIV Collagen 
Collagens in the FACIT subfamily of collagens consist of multiple collagenous domains, separated by 
non-collagenous regions31,36. Type XII and XIV collagens are large disulphide-linked homotrimeric 
molecules with three extended N-terminus globular domains that extend outward and serve as 
attachment points for other molecules36. There are two isoforms of type XII collagen; a long (XIIA) 
form and a short (XIIB) form49. The short XIIB-1 isoform is predominantly expressed in tendons and 
ligaments in response to mechanical loading49. During fibrillogenesis, type XII and type XIV collagen 
have different temporal and spatial expression and perform different functions50. Specifically, type 
XII collagen is involved in integrating and providing stability to the ECM, particularly interfacial 
regions and regions which experience high stress; while type XIV is expressed mainly during early 
development, where its down-regulation plays a role in the transition to linear growth in 
fibrillogenesis 50,51. Type XII and XIV collagens also facilitate sliding of collagen fibrils along each other 
by diminishing interactions between adjacent fibrils via low affinity of the NC3 domain to ligands52. 
Procollagen I N-proteinase binds to collagen XIV, perhaps sequestering the molecule and preventing 
cleavage of the Collagen 1 N-propeptide. Presence of uncleaved N-propeptide on collagen I 
influences fibril morphology and limits collagen aggregation53. Type XII collagen has been shown to 
bind decorin and fibromodulin54. And type XIV collagen has been shown to bind to decorin55 and 
type VI collagen56.  
1.3.2.3 Small Leucine-Rich Proteoglycans 
Several members of the Small Leucine-Rich Proteoglycans (SLRPs), such as decorin, biglycan, lumican 
and fibromodulin, associate with collagen fibrils in tendon and regulate fibrillogenesis39. 
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side chains (GAGs)57. GAGS are linear polysaccharides that bind water and create a hydrated gel that 
resists compressive forces57. Proteoglycan bridges between collagen fibrils affect tendon and 
ligament biomechanical properties by maintaining hydration and increasing the ability of the tissue 
to resist and transmit tensile stresses58.  
1.3.2.3.1 Decorin and Biglycan 
Decorin and Biglycan are members of the Class I family of proteoglycans57. Decorin is a low 
molecular weight chondroitin sulfate proteoglycan, widely expressed in tendon, that regulates fibril 
diameter by regulating the lateral fusion of fibrils during fibrillogenesis59. Decorin-deficient mice 
have uncontrolled lateral fusion of collagen fibrils, resulting in large diameter fibrils with irregular 
outlines59,60. In addition to altered fibril morphology, decorin-deficient mice have skin fragility60 and 
reduced tendon tensile strength and elasticity59. Biglycan has two chondroitin or dermatan sulphate 
side chains attached to its core protein and is found in human tendon59, where it tends to colocalize 
with type VI collagen61. Biglycan-deficient mice have smaller diameter collagen fibrils, less densely 
packed that wild-type fibrils62, with an irregular cross-section that results in mechanical compromise 
of tendon63. There appears to be compensation by these proteins, whereby biglycan is up-regulated 
in decorin-deficient mice59.  
1.3.2.3.2 Fibromodulin and Lumican 
Fibromodulin, a keratin sulphate proteoglycan, and lumican, a glycoprotein, are members of the 
class II family of proteogylcans57. Both are expressed in tendon where they compete for the same 
binding site on type I collagen fibrils. 64. Fibromodulin aids in the maturation of collagen fibrils, from 
thin diameter immature fibrils to larger diameter thicker fibrils65–67. As a result fibromodulin-
deficient tendons have small diameter fibres65–67 with reduced tensile strength65,66. However lumican 
deficient mice have larger diameter fibrils in tail tendon68. Lumican and fibromodulin are both 
expressed early in development; however, although lumican-deficient mice have abnormal fibril 
phenotypes early in development, they resemble the wild-type by maturation, suggesting an early 
role for lumican in fibrillogenesis, and a role in maturation for fibromodulin66. The regulation of 
lumican and fibromodulin concentration is orchestrated; whereby lumican expression is increased in 
the absence of fibromodulin67. In the absence of fibromodulin there is a dosage-dependent effect for 
lumican on tendon strength 65.  
This section has reviewed the complex process of fibrillogenesis and discussed several of the key 
proteins involved in the regulation of tendon and ligament architecture. An aberration in the normal 
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consequences for the mechanical integrity of connective tissues. The relationship between collagen 
fibril structure and biomechanical properties will be discussed in the following section (Section 1.4).  
1.4 Fibril Diameter and Tendon and Ligament Biomechanical Properties 
In a tendon or ligament, the total cross-sectional area is divided into multiple parallel threads69 
(Figure 1.1 and 1.4). This imparts tendons and ligaments with great resilience and elasticity69. The 
increased resilience is a consequence of the hierarchical structure, as tears are diverted and stopped 
at the surface of each fibril rather than propagating across a single larger fibre69.  
The two physical properties most often used to characterize the biomechanical properties of a tissue 
are the ultimate tensile stress and the Young modulus16. The tensile stress is the maximum force (N) 
per unit area that a tissue can withstand before rupture10,70,71. Strain is the degree to which the 
tissue deforms under a given stress, and is usually expressed as a percentage of the original length 
(%). Young’s modulus refers to the slope of the stress-strain curve in the elastic region, and gives a 
measure of elasticity, as it describes the force per area (stress) that is required to cause a given 
change in length (strain) (Figure 1.5) 10,70.  
The collagen bundles along the length of a tendon or ligament exhibit waviness referred to as 
“crimp” (Section 1.2; Figure 1.2). When a sufficient load is applied to a tendon or ligament, the crimp 
straightens and elongates to a point of stiffness or restraint 8,10,72 (Figure 1.5). This is referred to the 
“toe region” in a stress strain curve72. If stress is applied beyond this point, stretching of the helical 
region of the collagen molecules occurs, resulting in further elongation (elastic region)10,71. Should 
the applied load continue to increase, collagen fibre bundles begin to fail, resulting in the 
accumulation of micro-tears15. The accumulation of micro-tears eventually results in an overuse 
injury, with its accompanying symptoms of pain and oedema15. Eventually, as micro-tears 
accumulate or if the load continues to increase, the entire ligament or tendon may rupture.  
The ultimate tensile strength of a tissue depends on the substances of which they are made, and 
their structure69. Generally, a tissue consisting of large diameter fibrils tends to have greater 
ultimate tensile strength73. This is presumably due to an increase in the intrafibrillar covalent cross-
links between collagen molecules73. In addition, the shearing stress exerted at the interface of the 
fibril with the extracellular matrix by the application of a tensile load is lower in larger diameter 
fibrils due to the greater volume to surface area ratio; therefore the larger the fibril diameter the 















Figure 1.5 Mechanism of internal deformation of tendon or ligament. When strain is applied to a tendon, there 
is initially a straightening out of the crimp, resulting in the ‘toe region’ of the stress–strain curve. Strain within 
the physiological range causes elastic deformation of the tendon. Higher levels of strain result in partial or 
complete rupture of fibrils. Image modified from Wang, (2006)
72




The Young Modulus (elasticity) may be affected by diameter, because smaller fibril diameter 
increases the surface area per unit mass of the fibrils, thus enhancing the probability of interfibrillar 
non-covalent cross-links between the collagen fibrils and components of the matrix71,73. For this 
reason, smaller diameter fibrils may reduce flexibility and protect against non-recoverable creep71. 
The structural properties of ligament and tendon connective tissue therefore directly affect the 
biomechanical properties of a tissue. Specifically, tensile stress, which is the maximum load that the 
tissue can tolerate before microscopic-tears and macroscopic rupture, is dependent on fibril 
diameter73. In addition, the elastic potential of a tissue is dependent on the number of interfibrillar 
cross-links, and elasticity is therefore maximised when fibril diameter is smaller and the surface to 
volume to ratio between the collagen fibril and the adjacent ECM is greater69,71.  
The accumulation of micro-tears in response to excessive or repetitive stress is one of the proposed 
mechanism of injury in AT74. In contrast, ACL ruptures are acute events that occur due to excessive 
external or internal forces that exceed the tensile strength of the tissue in a discrete incident75. The 
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1.5 Aetiology of Musculoskeletal Soft Tissue Injuries 
Musculoskeletal injuries are multi-factorial disorders which occur due to the complex interaction of 
intrinsic and extrinsic risk factors (Figure 1.6)2,75,76. Intrinsic risk factors, which are usually biological 
in nature, determine the extent to which an individual is predisposed to an injury2. The predisposed 
athlete then becomes susceptible to injury following exposure to extrinsic factors, which are often 
environmental or behavioural in nature2. However, an inciting event is needed for an injury to occur. 
Although the aetiology of AT76–79,74,14 and ACL rupture75,80 is unique, there are several categories of 
intrinsic risk factors in common, including: biological age, gender, history of previous injury and 
anatomical features. Examples of categories of extrinsic risk factors in common include the duration, 
nature and frequency of physical activity, weather conditions, training surfaces, footwear, nutrition 
and certain medications2. The relative contribution of intrinsic and extrinsic risk factors is likely to 
differ between overuse injuries such as AT, and acute injuries such as ACL rupture2.  
 
Figure 1.6 A schematic diagram illustrating the complex relationship between intrinsic risk factors, extrinsic 
risk factors and a specific inciting event in the causation of musculoskeletal soft tissue injuries. Intrinsic risk 
factors predispose an individual to injury; however extrinsic risk factors, such as behaviour and environment 
contribute to an individual’s susceptibility to becoming injured, and an inciting event is needed to cause an 














1.5.1 Genetic Risk Factors for Musculoskeletal Injuries 
Many of the intrinsic risk factors such as sex81, anatomical variations82,83, flexibility84,85, systemic
disease86 and hormonal factors87,88 are at least in part genetically determined5,89. In addition, 
evidence for a genetic predisposition to musculoskeletal injury is provided by familial studies that
clearly show that a family history of injury is associated with increased risk90–92. Flynn et al showed 
that participants with an ACL rupture were twice as likely to have a relative with an ACL rupture
compared to uninjured individuals90 and a more recent study on 350 families showed that 11.3% of
patients with an ACL rupture had a family history of ACL injury91. Similarly, a study of 310
participants revealed that a family history of Achilles tendinopathy increased the risk of developing
Achilles tendinopathy five-fold93. Discovering which genes are involved in musculoskeletal soft tissue
injuries will be important not only to identify at-risk individuals, but will also aid in understanding the
molecular mechanisms underlying soft tissue injuries3,4.
Previous studies on AT and ACL rupture have used a candidate gene approach to investigate
associations with certain likely candidate genes and injury risk rather than a whole genome
approach, and a number of genes have been associated with AT and ACL rupture to date (Table 1.1). 
Usually these candidate genes are chosen based on evidence for their biological function. However,
musculoskeletal soft tissue injuries are likely to be polygenic in nature, and occur as a consequence
of variants at several genetic loci that act alone or in combination to increase
susceptibility94.Therefore, as no single genetic association will adequately capture injury risk, there is
an increasing tendency to examine the genetic profile of an individual95 which take into account
genetic variants at a number of different loci95, often involved in vastly different processes such as
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Table 1.1 A summary of previous associations between genes and chronic musculoskeletal soft tissue 
injuries 
Gene Function Polymorphism Associated injury Reference 
TNC Encodes glycoprotein TNC, a 
structural constituent of 
tendons and ligaments 
GT repeat in 
intron 17 




COL5A1 Encodes the pro-α1 












ACL ruptures in 
females 
TEN 















MIR608 Encodes the microRNA Hsa-
miR-608 




COL1A1 Encodes the pro-α1 












Ficek et al (2012)
107
  
COL12A1 Encodes the pro-α1 
polypeptide of type XII 
collagen 
rs970547 TEN 
ACL ruptures in 
females 
 




GDF5 Growth/differentiation factor 
5 




MMPs Important in ligament 






















IL-1β* Encodes the IL-1β protein 
which causes the upregulation 
of COX-2 and PGE2 
rs16944 
rs1143627 




IL-1RN* Encodes IL-1ra, the receptor 
agonist of IL-1β 




IL-6* Encodes the IL-6 protein which 
plays a role in cell apoptosis 




CASP8 Encodes a cysteine-aspartic 




TEN Nell et al. (2012)
99
  
Abbreviations: ACL, anterior cruciate ligament; CASP8, caspase 8; COX-2, cyclooxygenase-2; IL-1β, interleukin 
1β; IL-1RN, interleukin 1 receptor agonist; IL-6, interleukin 6; MMP, matrix metalloproteinase; NO, nitric oxide; 
NOS 2; nitric oxide synthase 2; PGE2, prostaglandin E2; PTGER4, prostaglandin E receptor 4 (EP4); TEN, Achilles 
tendinopathy; TNC, Tenascin C.  
 
* The IL-1β, IL-1RN and IL-6 genes were not associated independently with TEN, but significant associations 
were found when analysed in combination with each other and COL5A1.  
 
References in bold refer to studies that investigated ACL rupture. All other references refer to Achilles 
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1.6 Scope of the Dissertation 
Based on the previously discussed role of fibril diameter and density on determining the tensile 
strength and elasticity of ligaments and tendons (Section 1.4), the focus for this dissertation will be 
on genetic variants in genes encoding the minor fibrillar collagens, type V and type XI collagen 
(Section 1.3.2.1), because of their role in the regulation of collagen fibril diameter.  
1.6.1 The COL5A1 and MIR608 Genes 
Type V collagen is a minor fibrillar collagen present in relatively small quantities in tendons and 
ligaments8,9. Type V collagen consists of varying combinations of three α-chains, α1(V), α2(V) and 
α3(V), encoded by the COL5A1, COL5A2 and COL5A3 genes respectively110. There are several 
different isoforms which differ in α chain composition and ratio27. Type V collagen occasionally forms 
α1(V)3 homotrimers or α1(V)α2(V)α3(V) heterotrimers, however the most common isoform is a 
heterotrimer consisting of two α1(V) chains and one α2(V) chain41. The α1(V)2α2(V) isoform is 
capable of forming heterotypic fibrils with type I collagen, where it is thought to aid in collagen 
nucleation and the initiation of fibril assembly19–21 (Section 1.3.2), and regulate fibril diameter22–25,27 
(Figure 1.4).  
Mutations in either the COL5A1 or COL5A2 genes, which encode the α1 or α2 chain of type V 
collagen respectively, result in the heritable connective tissue disease Ehlers-Danlos Syndrome 
(EDS)111,112. The mutations cause a haplo-insufficiency of type V collagen, the consequence of which 
leads to the symptoms of the syndrome, which include: hyperextensible skin, hypermobile joints, 
abnormal scarring and other systemic involvement111,112.  
The COL5A1 gene on chromosome 9q34113 spans 203.07 kb and comprises a coding sequence of 
8468 bps spread over 66 exons114 that encode a 1838 amino acid protein. A number of studies have 
shown an association between injury and performance phenotypes and a common C to T single 
nucleotide polymorphism (SNP rs12722 or BstUI RFLP) within the 3’-UTR of the COL5A1 gene101–
103,115–117. Studies on a Caucasian population showed that individuals homozygous for the C variant of 
this SNP were less likely to suffer from AT101,102. Similarly, a study on ACL injuries showed that CC 
homozygote females were less likely to suffer ACL ruptures103. In a subsequent study investigating 
the effect of the COL5A1 rs12722 SNP on range of motion (ROM), the CC genotype was found to 
protect against an age-related decline in flexibility 116. Additionally, a study examining COL5A1 and 
endurance performance revealed that athletes homozygous for the T variant of the COL5A1 rs12722 
SNP completed the running component of the Ironman triathlon faster than those with a CT or CC 
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properties, which resulted in improved running economy117. Taken together, these studies suggest 
that the CC genotype is protective against musculoskeletal injury and results in decreased flexibility, 
whereas the TT genotype predisposes to injury, decreases flexibility and improves running 
performance. This hypothesis has recently been reviewed110. 
To investigate the functional significance of these associations, the 3’- untranslated region (UTR) of 
the COL5A1 gene was cloned from tendinopathic and control individuals and compared118. Two 
major functional forms containing 7 tightly linked polymorphisms were identified and found to have 
significant differences in mRNA stability118. The C form, which contains the C-allele of rs12722 and 
corresponds to the wild-type sequence, was identified in most of the clones generated from 
asymptomatic controls, while the T form contained the T-allele of rs12722 and was the predominant 
form identified in the AT patients118. Recently, the remainder of these variants have been 
investigated, and the AGGG/AGGG, -/- ATCT and TT alleles of rs71746744, rs16399 and rs1134170 
respectively, which correspond to the T-form cloned from tendinopathic individuals, was associated 
with increased risk of AT104. Using in silico statistical folding algorithms, the variant combinations 
were found to alter mRNA secondary structure which may affect the post-transcriptional regulation 
of mRNA by altering a miRNA binding site104. Changes in mRNA stability can alter mRNA levels and 
thus affect the rate of translation and protein synthesis119,120. This may alter the concentration of 
type V collagen, with potential consequences for the structure and biomechanical properties of 
tendons and ligaments110. Although the COL5A1 variants have been investigated for an association 
with AT, additional variants in the COL5A1 3’-UTR remain to be investigated in ACL rupture. 
Therefore the first aim of this dissertation was to investigate the COL5A1 rs71746744 and rs1134170 
gene variants for an association with ACL rupture (Chapter 2). 
The COL5A1 3’-UTR contai s several putative cis-acting elements including a functional Hsa-miR-608 
binding site 102,104. Two forms of the mature Hsa-miR-608, which are produced from the polymorphic 
(SNP rs4919510, C/G) MIR608 gene on chromosome 10q24, can potentially bind this miRNA binding 
site104. No studies have analysed the functional significance of the rs4919510 (C/G) SNP on Hsa-miR-
608 binding to the COL5A1 3’-UTR; however Hsa-miR-608 was show to bind preferentially to the A 
allele of the rs3196378 (C/A) polymorphism in the COL5A1 3’-UTR118. Although the effect of the 
rs4919510 G allele on COL5A1 3’-UTR binding is unknown the CC genotype of MIR608 rs4919510 
was recently shown to be associated with increased risk of AT104. Therefore an additional aim of this 
dissertation was to investigate the MIR608 rs4919510 gene variants for an association with ACL 













1.6.2 The COL11A1 and COL11A2 Genes 
Type XI collagen is a quantitatively minor fibrillar collagen comprising three polypeptide chains, 
α1(XI), α2(XI) and α1(II), encoded by the COL11A1, COL11A2 and COL2A1 genes respectively. Type XI 
collagen plays a similar role to type V collagen tendons and ligaments, in that it regulates collagen 
fibril diameter in cartilage43, which mostly consists of type II collagen29. In addition type XI collagen is 
essential for the interaction of collagens with proteoglycans28. Type XI protein is predominantly 
expressed in cartilage44, but is also found in the ocular vitreous, nucleus pulposus of the 
intevertebral disc and the inner ear, as well as many other non-cartilaginous tissues45,47,48. 
Mutations in COL11A1, COL11A2 or COL2A1 cause diseases such as Stickler syndrome121, Marshall
syndrome122, Otospondylomegaepiphyseal dysplasia (OSMED)123 and Weissenbacher–Zweymuller
syndrome (WZS)124. These syndromes are known as type XI collagenopathies125, and they are
phenotypically similar disorders that result in facial anomalies, cleft palate, hearing defects and a
spectrum of epiphyseal dysplasias with wide metaphyses and spondylar abnormalities with 
occasional ocular changes125. Stickler syndrome causes joint hypermobility, similar to that seen in
Ehlers-Danlos syndrome, a disorder of type V collagen production, however in Stickler syndrome the
hyperextensibility occurs only in childhood and decreases in adulthood, often to be replaced by a 
degenerative arthropathy121. 
The COL11A1 gene is located on the reverse strand of chromosome 1p21.1 and spans 232.03 Kb. The
mRNA transcript is 7286 bp in length, made up of 67 exons that encode an 1806 amino acid protein. 
A number of multifactorial conditions or syndromes have been investigated for associations with
COL11A1, such as early-onset arthritis126, osteoarthritis127, lumbar disc pathologies128–130, cleft 
palate131,132 and cancer133. Two common functional polymorphisms were identified by these previous
studies. The rs3753841 (T/C) polymorphism is a T>C single nucleotide substitution that results in an
amino acid change from a leucine to a proline at amino acid 1323, and the C- allele has been
associated with lumbar disc herniation (LDH)129. The rs1676486 (C/T) polymorphism is a C>T
nucleotide change that results in a non-synonymous amino acid change from a proline to a serine at
position 1535, and may have an effect on COL11A1 mRNA stability129, and the T-allele of this variant
has been associated with LDH129 and limbus vertebra in gymnasts130.
The COL11A2 gene is located on chromosome 6p21.32 and is 29.82 Kb in length. The mRNA 
transcript is 6209 bp long spread over 64 exons, and encodes a 1650 amino acid protein. The 
COL11A2 gene has been investigated for associations with osteoarthritis126,127, rheumatoid 
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spine (OPLL) 136–139, lumbar128,140,141 and intevertebral 142,143 disc disease144 and cleft palate 131,132. 
These studies have identified a gene variant, rs1799907 (A/T), which is located 4 bp upstream of the 
start of exon 6, and appears to result in alternative splicing of the COL11A2 gene137. The T allele of 
COL11A2 rs1799907 was associated with risk of lumbar disc desiccation128, lumbar spine stenosis141 
and OPLL136–139. 
Although the COL11A1 and COL11A2 genes have been associated with a number of musculoskeletal 
disorders that affect the spine and cartilage128–130,134,136,137,141,142, these genes have never been 
investigated for an association with conditions that affect tendons and ligaments, despite the fact 
that these genes are known to be expressed in tendon in early development48,145,146. Therefore, an 
additional aim of this dissertation was to investigate the COL11A1 rs3753841 and rs1676486 
polymorphisms, and the COL11A2 rs1799907 polymorphism for associations with ACL rupture 
(Chapter 3) and AT (Chapter 4).  
1.6.3 Interactions Between Type V and Type XI Collagen 
The structural and functional properties of type V and type XI collagen are closely related and their 
primary structures are highly conserved at the gene and protein levels28. Homology is greatest 
between the proα1(XI), proα2(XI)  and proα1(V) chains, and this is particularly noticeable in the NC3 
domain, which is composed of two sub-domains in these proteins, suggesting a strong topological 
homology between the N-terminal propeptide extensions of the proα1(XI), proα2(XI) and proα1(V) 
chains28. Both proteins are usually buried within the major collagens, however they contain cell 
adhesion and heparin binding sites that enable them to interact with other ECM molecules28.  
Proα1(XI) and proα2(V) chains have been shown to form heterotrimers of [α1(XI)]2α2(V)], in vivo 
147,148 and invitro28. The α1(XI) chain is present in collagen V extracts from bone149 and the human 
rhabdomyosarcoma cell line A204, which synthesizes type V collagen as its only fibrillar collagen, 
expresses COL11A1 and forms [α1(XI)]2α2(V)] hybrid molecules
147. Although it was generally thought 
that the tissue expression patterns of type V and type XI collagen do not overlap, it is becoming 
increasingly evident that several molecules are in fact heterotypic molecules of type V and XI28. 
Recently Wenstrup et al (2011)146 provided phenotypic evidence that collagens V and XI may have 
shared or synergistic roles in developing tendon146. Type V and type XI collagen procollagen α-chains 
transcripts were expressed at similar levels in early development; however collagen V predominated 
in later developmental stages. When flexor digitorum longus (FDL) tendons from wild-type (WT) 
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, and (v) COL5A1 +/-, COL11A1-/- knock-out mice, there was a decrease in fibril number in all of the 
genotypes. However while there was almost normal fibril appearance in the COL5A1+/- mice, the 
most severe phenotype was observed in the COL5A1+/-, COL11A1-/- compound heterozygotes. This 
suggests that there is biological redundancy between these two collagen types and that COL11A1 
expression may partly rescue low expression of COL5A1 in haplo-insufficient mice.  
Since there is evidence for an interaction between type V and type XI collagen, and variants in the 
COL5A1 gene have previously been associated with both ACL rupture in females 103 and AT101,102,104, 
the previously described COL11A1 and COL11A2 variants were investigated for interactions with the 
COL5A1 rs71746744 variant in determining the risk of ACL rupture (Chapter 3) and Achilles 
tendinopathy (Chapter 4).  
 
1.7 Dissertation Objectives  
1.7.1 Hypothesis 
This dissertation hypothesises that genetic variants in the COL5A1, COL11A1 and COL11A2 genes 
that encode for type V and XI collagens respectively, may alter injury risk because of their role in 
determining musculoskeletal soft tissue structural properties. Subtle changes in tissue architecture 
may alter the mechanical properties of the tissue such that they are less resilient to repeated 
mechanical loads110. In the case of AT, this may make the tissue more susceptible to accumulated 
micro-trauma due to decreased tensile strength of thin diameter fibrils, and in the case of acute ACL 
rupture, a less resilient tissue may be more likely to rupture when exposed to an excessive load110. 
The effect size of the genetic variants in the genes encoding for type V or type XI collagen may differ 
between the injuries, as the tissues differ slightly in structure, and the injuries differ in aetiology. 
These genes will be investigated together, because of a possible interaction effect. 
1.7.2 Objectives 
The objectives of this dissertation are: 
i) To determine whether the rs71746744 and rs1134170 polymorphisms in the COL5A1 
gene and the rs4919510 polymorphism in the MIR608 gene are associated with ACL 
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ii) To determine whether the rs3753841 and rs1676486 polymorphisms in the COL11A1 
gene and the rs1799907 polymorphism in the COL11A2 gene are associated with ACL 
rupture in a Caucasian South African population. A secondary aim will be to determine 
whether the COL11A1 and COL11A2 polymorphisms interact with the rs71746744 
polymorphism in the COL5A1 gene to modulate ACL rupture risk (Chapter 3).  
 
iii) To determine whether the rs3753841 and rs1676486 variants in the COL11A1 gene and 
the rs1799907 variant in the COL11A2 gene are associated with AT in a Caucasian South 
African and Australian population. In addition, to investigate whether these variants 
interact with each other, or with the rs71746744 variant in COL5A1, to modulate the risk 














Chapter 2: Association of Variants in the COL5A1 3’-UTR and 
MIR608 with Anterior Cruciate Ligament Rupture 
2.1 Introduction 
The ACL is a major intra-articular ligament of the knee and a common site of acute musculoskeletal 
injury in young, physically active individuals75. The ACL acts as a primary restraint against anterior 
tibial translation and a secondary restraint against rotary loads7. During dynamic movement the ACL 
works together with the posterior cruciate ligament (PCL) to stabilize the knee, and guide it through 
its normal range of motion7,150–152. There are three major mechanisms of ACL rupture: non-contact, 
direct contact, and indirect contact153. Non-contact injuries comprise approximately 70% of injuries, 
and occur due to excessive internal forces75. The remainder of the injuries are made up of direct 
contact mechanism of injury, in which there is a collision with a solid object at the injured knee, or 
indirect contact mechanism in which contact is made at a location other than the knee154. A further 
mechanism of injury is rare and unique to skiing activities, and is referred to as the “phantom foot” 
mechanism, in which the tail of the ski acts as a lever155, generating excessive internal tibial torque 
while the knee is in flexion beyond 90° or in hyperextension156–158.  
 
Although the incidence of ACL ruptures in the South African population has not been documented, it 
is known that the incidence of ACL rupture in New Zealand is approximately 36 ruptures per 100 000 
citizens per year159 and Norway reports a similar incidence of 34 ruptures per 100 000 citizens per 
year160. The mean age at which ACL ruptures occur is 27 years160, however the highest number of 
injuries occur within the 16-18 year age group159. Individuals who suffer from ACL ruptures are 
forced to decrease activities of daily life while injured161 and may require reconstructive surgery and 
extensive rehabilitation in order to return to an active lifestyle. These injuries are costly162 and can 
shorten a sporting career163 and affect academic performance due to absenteeism164. In addition, 
ruptures to the ACL place individuals at a higher risk of other chronic knee pathologies such as 
osteoarthritis165,166.  
 
There is no single cause of ACL ruptures, as these conditions, like other musculoskeletal soft tissue 
injuries, have complex aetiologies75,80. Although several intrinsic and extrinsic risk factors have been 
identified, an individual’s genetic profile has been proposed to be a strong intrinsic risk factor3,167 
(Chapter 1, Section 1.5.1). Genetic variants may influence injury risk via subtle changes in biological 













functional variants within the COL1A1 gene have been shown to be associated with ACL ruptures in 
Swedish105, South African106 and Polish107 populations. In addition, a variant in the matrix 
metalloproteinase 12 gene (MMP12), part of a cluster of four MMP genes on chromosome 11, has 
also been independently associated with protection against ACL rupture, as have haplotypes 
consisting of variants from each of MMP10, MMP1, MMP3 and MMP1297. Although associated with 
AT109, a functional variant within the GDF5 gene is not associated with ACL ruptures168.The total 
incidence of ACL ruptures is higher in males than females, however females have a higher risk of 
rupture159,169,170. Previous studies have shown that genetic factors that predispose to injury may 
differ between males and fermales103,108. In support of this, variants within the COL5A1 103 and 
COL12A1108 genes have been shown to be associated with ACL ruptures in females.  
 
With respect to COL5A1, previous studies have associated the common single nucleotide 
polymorphism (SNP) rs12722 (C/T) in its 3’ UTR, with AT101,102, ACL rupture in females103, range of 
motion (ROM)115,116 and endurance running performance117; suggesting a role for this region in 
multiple sports injury and exercise-related phenotypes110. The COL5A1 gene encodes the α(I)V chain 
of type V collagen, a minor fibrillar collagen that is vital for nucleation of collagen fibrils and the 
regulation of collagen fibril diameter (Chapter 1, Section 1.3.2.1 and 1.6.1). Collagen fibril diameter 
and density directly affect the biomechanical properties of a tissue, such as tensile strength and 
elasticity (Chapter1, Section 1.4).  
 
The 3’-UTR of eukaryotic genes contain elements such as poly(A) signals171, protein binding sites172 
and microRNA (miRNA) binding sites, that play an important role in post-transcriptional regulation of 
the mRNA transcript173,174. MicroRNAs175,176 are non-coding RNAs 18-25 bp in length, that bind to 
complementary sequences in the 3’-UTR of mRNA transcripts; resulting in them being silenced or 
targeted for degradation175,176. This post-transcriptional regulation of mRNA transcripts has been 
shown to play an important role in disease aetiology177.  
 
Collins and Posthumus have thus recently proposed that COL5A1 3-UTR variants may alter type V 
collagen concentration, which in turn alters collagen fibril diameter, consequently affecting the 
tensile strength and elasticity of the tissue110. Recently, two functional forms of the 2.5 kb COL5A1 
3’-UTR, containing seven tightly linked polymorphisms; rs13948 (C/T), rs12722 (C/T), rs3196378 












Figure 2.1 Schematic representation of the COL5A1 gene on chromosome 9q34 and the MIR608 gene on
chromosome 10q24. The 66 exons in COL5A1 are represented by vertical lines, and introns are represented by
adjoining horizontal lines. The 2.5 kb COL5A1 3’-UTR is encoded by exon 66. A 858 bp region, containing
rs12722 (grey box), as well as, rs3196378, rs71746744, rs16399 and rs1134170 (white boxes) of the 3’-UTR is
shown. SNP rs12722 (grey box) has previously been associated with ACL ruptures in females and other exercise
associated phenotypes
101–103,115–117,178
. The black box containing rs11103544 is within a putative miRNA binding 
site, which has not been associated with Achilles tendinopathy
102
. The MIR608 gene contains SNP rs4919510
and encodes for Hsa-miR-608, which binds to a polymorphic binding site in the COL5A1 3’-UTR as indicated in
the diagram. The rs71746744 and rs1134170 polymorphisms in COL5A1 and the rs4919510 SNP in MIR608
have been selected for investigation for an association with ACL rupture (dashed boxes). The accession
numbers and/or RFLP associated with the polymorphism are indicated, together with the nucleotide changes. 
The nucleotide positions for the polymorphisms within the 3’-UTR are for the wild-type sequence (C-functional
form). The two miRNA binding sites are indicated by a black solid circle and a line. The location of a previously
described 57 bp deletion (∆) containing rs71746744 and the second polymorphic miRNA binding site
(rs11103544) is indicated
118
. This figure is modified from Abrahams, et.al., (2013)
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from tendinopathic and control individuals and found to have significant differences in mRNA
stability118 (Figure 2.1). The C form, identified in most of the clones generated from asymptomatic
controls contains the polymorphisms in the sequence C-C-C-(AGGG)1-(ATCT)2-A-T and is associated
with decreased mRNA stability118; while the T form was the predominant form identified in the AT
patients, contains the polymorphisms in the sequence T-T-A-(AGGG)2-(ATCT)1-T-C, and was
associated with increased mRNA stability118. Deletion of a 57 bp region containing a putative 
polymorphic, rs11103544 (T/C), miRNA binding site and the short tandem repeat polymorphism
(STRP) rs71746744 (-/AGGG), abolished the difference in mRNA stability between these two forms118
(Figure 2.1). SNP rs11103544, within the putative miRNA binding site, has previously been reported 
not to associate with AT102. STRP rs71746744 (-/AGGG), within the 57 bp deleted region, as well as
the two upstream polymorphisms, rs16399 (ATCT/-) and rs1134170 (A/T), have recently been shown
to be associated with AT104. The AGGG/AGGG, -/- and TT genotypes of rs71746744, rs16399 and
rs1134170, respectively, were significant over-represented in the tendinopathy group104. The
variants are thought to alter the secondary structure of the mRNA transcript, changing the
accessibility of microRNAs or other as yet unidentified RNA stability proteins to bind to the
transcript, and therefore altering the stability of the mRNA118.
Additionally, an upstream polymorphic (rs3196378, C/A) miRNA binding site for Hsa-miR-608 in the 
COL5A1 3’-UTR has also been shown to be functional118 (Figure 2.1). The mature 25bp Hsa-miR-608
microRNA is encoded by the MIR608 gene situated on chromosome 10q24 and is itself polymorphic
(rs4919150, C/G). Hsa-miR-608 has the sequence: 5’-AGG GGT GGT GTT GGG ACA GCT SCG T-3’,
where S is a cytosine (C) or guanine (G). Hsa-miR-608, containing the wild-type C allele, binds 
preferentially to the A allele of the COL5A1 rs3196378 (C/A) polymorphism in118. Although the effect
of the rs4919510 G allele on binding to the 3’-UTR is unknown the CC genotype of rs4919510 was
independently associated with AT104. 
Since the COL5A1-3’-UTR SNP, rs12722, has previously been shown to associate with ACL ruptures in 
females103, the aim of this study was to investigate the association of rs71746744 (-/AGGG) and 
rs1134170 (A/T), within the potentially functional region of the 3’-UTR, with ACL ruptures in a South 
African Caucasian population. It was hypothesised that the AGGG/AGGG and TT genotypes of these 
polymorphisms would be associated with ACL ruptures in females. In addition, the association of the 
MIR608 gene variant (rs4919510, C/G) with ACL ruptures was also investigated in this study. It was 












2.2 Materials and Methods 
2.2.1 Study Design 
A case-control genetic association study was conducted on individuals of self-reported European 
descent recruited from the South African population. Approval for the study was obtained from the 
Research Ethics Committee of the Faculty of Health Sciences within the University of Cape Town 
(reference number 164/2006) (Appendix B, B1.1). 
2.2.2 Participants 
Two hundred and fifteen Caucasian participants (160 male and 55 female) with surgically confirmed
ACL rupture (ACL group) were recruited from the Sports Science Orthopaedic Clinics at the Sports
Science Institute of South Africa (SSISA). Prior to participation, participants were required to sign
informed written consent forms in accordance with the declaration of Helsinki (Appendix B, B1.2).
Participants were provided with information about the study (Appendix B, B1.3) and were required
to complete questionnaires (Appendix B, B1.4) containing detailed information on personal and
sporting particulars, injury details and medical history. Information on the mechanism of injury was
used to identify participants that sustained their injury through non-contact mechanisms (NON,
55.8%, n=120), as these individuals are likely to represent a more susceptible group. The NON group
was therefore analysed as a sub-group of the ACL group in all statistical analyses. The remainder of
the participants in the ACL group had sustained their injuries via direct contact (10.7%, n=23), 
indirect contact (15.3%, n=33) or ski (5.6%, n=12) mechanisms. Several of the participants had no
clear mechanism of injury and could not be classified (12.6%, n=27).
In addition, 217 apparently healthy, unrelated, physically active Caucasians (134 male and 83
female) without any self-reported history of ligament or tendon injury were recruited as control
(CON) participants from sports clubs and the Sports Science Institute (SISSA) wellness centre within
the Southern Suburbs region of Cape Town, South Africa. Both the ACL and CON groups completed
detailed sports participation particulars. Sports participation of the CON and ACL groups was
characterised into contact sports, non-contact jumping sports, non-contact non-jumping sports and
skiing sports as previously defined,90 with slight modification108. On average, the female ACL and
CON groups were matched for participation in non-contact non-jumping sports as well as skiing
sports. The male ACL and CON groups were however only matched for non-contact non-jumping
sports. On average, more females and males from the ACL groups participated in both contact sports 
and non-contact jumping sports in comparison to the CON groups. In addition, this study noted that













2.2.3 DNA Extraction 
Approximately 4.5ml of venous blood was collected via venipuncture of a forearm vein into EDTA 
vacutainer tubes and stored at 4 °C until total DNA extraction. Total DNA was extracted from blood 
using a method described by Lahri and Nurnberger179 and modified by Mokone et al100 (See appendix 
C1 for details). The DNA was stored at -20 °C until polymerase chain reaction (PCR) analysis. 
2.2.4 COL5A1 and MIR608 Taqman® Genotyping 
Genotyping of the rs71746744 STRP and rs1134170 SNP in the COL5A1 3’-UTR and the rs4919510
SNP in MIR608 was performed using custom designed Fluorescence-based Taqman PCR assays 
(Applied Biosystems, Foster City, CA, USA). Inventoried allele specific probes and flanking primer sets
(sequences available from manufacturer on request) were used along with a pre-made PCR
mastermix containing ampliTaq® DNA polymerase Gold (Applied Biosystems) in a final reaction
volume of 8 µl. For quality control purposes, a minimum of three DNA samples of known genotypes,
together with at least four DNA free control samples were included on each PCR plate. The PCR was
performed on a StepOnePlusTM real-time PCR machine (Applied Biosystems). The PCR conditions
consisted of a 10 minute heat activation step (95°C), followed by 40 cycles of 15 seconds at 92°C and
1 minute at 60°C. Genotypes were determined by end-point fluorescence and analyzed using the
StepOne Software Version 2.2.2 (Applied Biosystems) (Figure 2.2). 
Figure 2.2 An example of a typical end-point fluorescence allelic discrimination plot using StepOne Software 
version 2.2.2 (Applied Biosystems). This plot shows MIR608 rs4919510. The primer for Allele 1 (C) is labelled 
with a VIC probe, and allele 2 (G) is labelled with a FAM probe. The different genotypes cluster according to 
their fluorescence, resulting in 3 clusters, containing VIC only (C/C), VIC and FAM in equal amounts (C/G) and 














2.2.5 COL5A1 rs1134170 RFLP Genotyping 
Due to difficulties discerning between the AT and AA genotypes of SNP rs1134170 using the 
TaqMan®-based methods, 220 samples were regenotyped using restriction fragment length 
polymorphism (RFLP) analysis. The PCR reactions were performed in a total volume of 50 μl 
containing at least 100 ng of total genomic DNA, 20 pmol of each of the respective forward (5’- CAG 
AGC CTG ATG GGA GAA TGT CCA GGG CA -3’) and reverse (5’- GGA TAA AGA AAG CAG GGA GAA CGA 
GGC ATG ACC AG -3’) primers, 1X reaction buffer (20 mM Tris-HCl, 10 mM (NH4)2SO4, 10 mM KCl, 2 
mM MgSO4, 0.1 % Triton X-100), 200 μM of each dNTPs and 1 unit of Taq DNA polymerase (New 
England Biolabs, Ipswich, Massachusetts, USA). The cycling conditions included an initial denaturing 
step at 95°C for 2 minutes followed by 30 cycles of denaturing at 95°C for 30 seconds, annealing at 
65°C for 30 seconds, extension at 68°C for 1.5 minutes and a final extension step at 68°C for 5 
minutes using the XP Thermal Cycler Block (Bioer Technology Co., Tokyo, Japan). The PCR products 
were restricted using 5U PShAI restriction enzyme in 1x NEBuffer 4, supplemented with 100 µg/ ml 
BSA (New England Biolabs). The products were digested overnight at 37° C to produce 159-bp and 
34-bp fragments for the A allele and an uncut 193-bp fragment for the T allele. The digestion 
products were separated on 2% agarose gels and visualized using SYBER Gold staining (Invitrogen 
Molecular probes, Eugene, Oregon). The gels were photographed under UV light using a Uvitec 
photodocumentation system (Uvitec Limited, Cambridge, UK). The O’GeneRuler DNA size standard 
(Fermentas) was included on all gels to facilitate sizing of the fragments. The genotypes were 
derived from the sizes of the DNA fragments obtained (Figure 2.3).  
 
It should be noted that not all DNA samples were successfully genotyped for each polymorphism 
investigated. Although there are numerous possible reasons for failure to amplify, the exact reasons 
are not known. It is possible that a reagent used during DNA extraction, or present in the buffer in 
which the sample is suspended, may interfere with primer binding. Alternatively, participants may 
harbour a unique polymorphism at the primer binding site. Repeated genotyping of a sample that 
has failed to amplify may produce a false result, and therefore samples were excluded from analysis 




















Figure 2.3 A) Schematic representation of the rs1134170 (A/T) polymorphism in the 3’-UTR of the COL5A1 
gene. Exons are represented by vertical lines, and introns are represented by adjoining horizontal lines. An 800 
bp region of the 3’-UTR is indicated showing the location of the rs1134170 (A/T) polymorphism. Sequence 
numbers refer to 3’-UTR position. The 193 bp amplicon used for RFLP analysis is indicated in bold, flanked by 
the forward (FWD) and reverse (REV) primers (black arrows). The recognition sequence of the PshAI restriction 
endonuclease is indicated (dashed box). B) An example of a typical 2% agarose gel showing the genotypes of 
the COL5A1 rs1134170 polymorphism. The genotype of each sample is indicated at the top of each lane. The 
left lane (L) contains the DNA ladder: O’GeneRuler 100 bp DNA Ladder (Fermentas). The PShAI enzyme only 
restricts in the presence of an A-allele. Therefore the TT genotype remains undigested, the AA genotype 
produces a product of 159 bp and 34 bp, and the AT genotype produces three fragments of 193 bp, 159 bp 
and 34bp. [RFLP analysis was used to discern between AT and AA genotypes, and TT genotypes and undigested 













2.2.6 Statistical Analysis 
Quanto version 1.2.4. was used to determine the statistical power of the study for a given sample 
size and allele frequencies180. Assuming a minor allele frequency of 0.29, 0.28 and 0.19 for 
rs71746744, rs1134170 and rs4919510 respectively, a sample size of approximately 215 cases and 
an equal number of controls would be adequate to detect a genetic effect size of at least 1.5, 1.5 and 
1.6 respectively, at a power of 80% and a significance level of 5%. GenePop was used to determine 
whether the SNPs were in Hardy-Weinberg equilibrium (HWE) 
(http://genepop.curtin.edu.au/genepop_op1.html). Data were analysed using STATISTICA Version 
10.0 (Stat- Soft, Tulsa, OK, USA) and GraphPad Prism version 5.0d for Mac OS X (GraphPad Software, 
San Diego, CA, USA) programs. Continuous variables, such as weight, age, height and BMI were 
compared between the CON, ACL and NON groups using one-way analysis of variance (ANOVA), and 
were co-varied where necessary. Pearson’s chi-squared tests, or Fischer’s tests when required, were 
used to determine whether there were any significant differences in allele frequencies or other 
categorical variables between the CON and ACL groups and NON subgroups. Females and males 
were analysed separately and together to look for sex-specific associations. Chaplin Case-control 
haplotype inference package (Epstein Software) was used to infer haplotypes and 
pseudohaplotypes181,182. Linkage disequilibrium (LD) between the COL5A1 rs71746744 STRP and 
rs1134170 SNP was calculated using Cubex software (http://www.oege.org/cgi-bin/cubex.py)183. In 















2.3.1 Participant Characteristics 
Age, height and weight are self-reported values at the time of the first ACL rupture for the ACL group 
and NON subgroup, and at recruitment for the CON group. The participants in the CON and ACL 
groups, as well as the NON subgroup, were matched for age and country of birth (Table 2.1). There 
were significantly fewer males in the CON group (61.6 %) compared to the ACL group (74.4%) 
(p=0.004), as well as the NON subgroup (75.8%) (p=0.008). After adjustment for sex, there were no 
significant differences in height between the CON and ACL (adjusted p=0.368) groups and NON 
(adjusted p=0.167) subgroup. However, after adjusting for sex, the ACL group and NON subgroup 
were significantly heavier (ACL, adjusted p=0.005; NON, adjusted p=0.015) than the CON group, with 
a correspondingly higher BMI (ACL, adjusted p<0.001, NON, adjusted p=0.002). The ACL participants 
were recruited on average 4.5 ± 8.8 years after the initial injury and had gained on average 2.1 ± 
12.4 kg in that time. There were no significant genotype effects on height, weight or BMI, and there 
were no significant genotype distribution differences between sex and age (Appendix A: Table A1.1). 
 
Table 2.1 Characteristics of the participants within the asymptomatic control group (CON), anterior cruciate 
ligament rupture group (ACL) and the ACL subgroup with a non-contact mechanism of injury (NON).  
 CON ACL P-value ‡ NON P-value § 
Age (years) 28.7±11.2 (210) 27.1±11.0 (187) 0.167 26.8±10.5 (114) 0.130 
Sex (% male) 61.6 (216) 74.4 (215) 0.004 75.8 (120) 0.008 
Height (cm) 175.2±9.2 (210) 177.6±9.4 (194) 0.368
a
 178.3±9.2 (116) 0.167
 a
 
Weight (kg) 74.2±15.1 (211) 80.7±16.8 (194) 0.005
a





) 24.1±3.5 (208) 25.9±4.1 (191) <0.001
a
 25.7±3.9 (115) 0.002
 a
 
Country of birth 
(% South African) 
86.5 (207) 83.2 (196) 0.354 82.9 (117) 0.385 
Participants who were genotyped for at least one of rs71746744, rs1134170 or rs4919510 were included in the 
analysis. Except for sex and country of birth, the variables are expressed as mean ± standard deviation (n= 
number of participants for which valid data was available). Sex and country of birth are expressed as a 
percentage. Age, height and weight are self-reported values at the time of the first ACL rupture for the ACL 
group and NON subgroup, and at recruitment for the CON group. Significant p-values <0.005 are indicated by 
bold typeface.  
 
‡ CON vs ACL,  
§ CON vs NON,  
a 













2.3.2 Genotype and Allele Frequency Distributions 
2.3.2.1 COL5A1 rs71746744 (AGGG/-) 
There were no significant COL5A1 rs71746744 genotype (p=0.840) or allele (p=0.830) frequency
differences between the ACL (n=214) and CON (n=216) groups for the combined participants.
Similarly, there were no significant genotype (male, p=0.802; female, p=0.309) or allele (male, 
p=0.717; female, p=0.343) frequency differences between the male CON (n=133) and male ACL (159)
participants, or the female CON (n=83) and female ACL (n=55) participants. When analysing the NON
subgroups, there were no significant genotype or allele frequency differences between the
combined (p=0.971 and p=1.000, respectively), male (p=0.401 and p=0.643, respectively) or female
(p=0.479 and p=0.485, respectively) NON subgroups when compared to their respective CON
groups. Except for the male CON group, which was not in HWE (p=0.050), all the other groups and
subgroups were in HWE. The previously investigated SNP rs12722 (C/T) was in high LD with
rs71746744 for the CON group (D’=0.964; r2 =0.461), ACL group (D’=0.944, r2=0.520) and combined 
groups (D’=0.956, r2=0.481).
It should be noted that, although not significantly different, the -/- genotype distribution within the
female CON subgroup (10.8%, n=9 of 83) was higher than the female ACL group (3.6%, n=2 of 55,
p=0.126) and NON subgroup (3.5%, n=1 of 29, p=0.229) (Table 2.2).
2.3.2.2 COL5A1 rs1134170 (T/A) 
There were no significant COL5A1 rs1134170 genotype (p=0.519) or allele (p=0.339) frequency
differences between the ACL group (n=215) and CON (n=216) group for the combined participants
(Table 2.3). Similarly, there were no significant genotype (male, p=0.746; female, p=0.733) or allele
(male, p=0.519; female, p=0.489) frequency differences between the male CON (n=134) and ACL
(n=160) participants, or female CON (n=82) and female ACL (n=55) participants. When analysing the 
NON subgroups, there were also no significant differences in genotype or allele frequency
distribution of the combined (p=0.624 and p=0.395 respectively), male (p=0.781 and p=0.524
respectively) or female (p=0.833 and p=0.621 respectively) NON subgroups when compared to their 
respective CON groups. The CON group (p=0.030) and male ACL (p=0.022) subgroups were not in
HWE. All the other groups and subgroups were in HWE. The previously investigated SNP rs12722
(C/T) was in high LD with rs1134170 for the CON group (D’=0.947; r2 =0.463), ACL group (D’=0.907,












Table 2.2 Genotype and allele frequency distribution of COL5A1 rs71746744 (AGGG/-) in the asymptomatic 










HWE AGGG - 
P-
Value 
All Participants 430 






































Male Participants 292 






































Female Participants 138 






































Values are percentages, with sample number (n) displayed in parenthesis. N is the total number of successfully 
genotyped participants in each group. HWE is the p-value for the exact tests for HWE. Significant values,

















Table 2.3 Genotype and allele frequency distribution of COL5A1 rs1134170 (T/A) in the asymptomatic 







N TT AT AA 
P-
Value 
HWE T A 
P-
Value 
All Participants 431 
    
 
   






































    
 
   
Male Participants 294 
    
 
   





































    
 
   
Female Participants 137 
    
 
   



































Values are percentages, with sample number (n) displayed in parenthesis. N is the total number of successfully 
genotyped participants in each group. HWE is the p-value for the exact tests for HWE. Significant values, 












Table 2.4 Genotype and allele frequency distribution of MIR608 rs4919510 (C/G) in the asymptomatic 
control (CON) group and ACL rupture (ACL) group and non-contact (NON) ACL rupture subgroup. 
Genotype Allele 
N CC CG GG 
P-
Value 
HWE C G 
P-
Value 
All Participants 430 






































Male Participants 293 






































Female Participants 137 






































Values are percentages, with sample number (n) displayed in parenthesis. N is the total number of successfully 
genotyped participants in each group. HWE is the p-value for the exact tests for HWE. Significant values,













2.3.2.3 MIR608 rs4919510 (C/G) 
There were no significant MIR608 rs4919510 genotype (p=0.543) or allele (p=0.572) frequency 
differences between the ACL (n=213) and CON (n=217) groups (Table 2.4). Similarly, there were no 
significant genotype (male, p=0.277; female, p=0.254) or allele (male, p=0.169; female, p=0.307) 
frequency differences between the male CON (n=134) and ACL (n=159) participants, or female CON 
(n=83) and female ACL (n=54) participants. When analysing the NON subgroups, there were also no 
significant differences in genotype or allele frequency distribution of the combined (p=0.878 and 
p=0.689 respectively), male (p=0.340 and p=0.157 respectively) or female (p=0.294 and p=0.133 
respectively) NON subgroups when compared to their respective CON groups. All of the groups were 
in HWE.  
It should be noted that, although not significantly different, the CC genotype distribution within the 
female NON subgroup (75.0%, n=21 of 28) was higher than the female CON group (61.5%, n=51 of 
83, p=0.294) (Table 2.4). Similarly the GG genotype, although present within the female CON group 
(4.8%, n=4 of 83), was absent from the female ACL group and NON subgroup (Table 2.4) 
2.3.3 Inferred Haplotype and Pseudohaplotypes  
As the polymorphisms investigated in this study could theoretically interact with one another to 
regulate type V collagen production, gene-gene interactions were investigated.  
2.3.3.1 Inferred Haplotype Analysis of COL5A1 rs71746744 and rs1134170 
Inferred haplotypes consisting of COL5A1 rs71746744 and rs1134170 were constructed separately 
for the male and female CON and ACL groups (Appendix A: Table A1.2.1), as well as NON subgroups 
(Appendix A: Table A1.2.2). Since rs71746744 and rs1134170 were in high LD for the CON group 
(D’=0.977; r2=0.922), ACL group (D’=0.973, r2=0.809) and combined groups (D’=0.975, r2=0.866), 
three of the four possible haplotypes, AGGG/T, AGGG/A and -/A, were inferred with a frequency 
greater than 1% (Figure 2.4). The AGGG/T inferred haplotype, which was hypothesised to be 
associated with increased risk for AT, was the major haplotype in all the groups (68.0%). However in 
agreement with the hypothesis, the opposite -/A inferred haplotype was significantly 
overrepresented in the male CON (27.6%, n=36 of 134) group compared to the ACL group (25.0%, 
n=39 of 160) and NON (24.7 %, 22 of 120) subgroup (CON vs ACL, p=0.001; CON vs NON, p=0.026) 













Figure 2.4 Inferred haplotype frequencies for COL5A1 rs71746744 and rs1134170 in asymptomatic controls 
(CON, solid black bars), anterior cruciate ligament group (ACL, white bars) and non-contact (NON, grey bars) 
subgroup, in (A) combined participants, (B) males and (C) females. The number of participants (n) in each 
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Although similar frequencies were observed for the female CON group (28.3%, 23 of 81), ACL group 
(25.5%, 13 of 53) and NON subgroup (25.9%, 7 of 29), the -/A inferred haplotype was not 
significantly different (CON vs ACL, p=0.206; CON vs NON, p=0.319) (Figure 2.4C). When the male 
and female groups were analysed together the -/A inferred haplotype was also significantly over-
represented in the CON group (27.9%, 60 of 217) compared to the ACL group (25.1%, 53 of 215) 
(p<0.001) and NON subgroup (25%, 29 of 120) (p=0.015) (Figure 2.4A). 
 
The rare -/T inferred haplotype (<6%) of rs71736744 and rs1134170 was over-represented in the 
combined ACL (3.5%, 7 of 215) group and male ACL (4.7%, 7 of 160) group compared to the 
combined CON group (1.2%, 2 of 217) (p=0.016) and male CON group (0.0%, 0 of 134) (p<0.001); 
however in females the -/T haplotype was over-represented in the CON (2.4%, 2 of 83) group 
compared to the ACL (0.0%, 0) group (p=0.042). The frequency of the -/T haplotype in NON 
subgroups were similar to the ACL group, and remained significant for the combined (4.2%, 5 of 120) 
(p=0.012) and male (5.5%, 5 of 91) (p<0.001) participants. There was however no significant 
difference in -/T haplotype frequency between the female CON group and NON subgroups 
(p=0.120).  
 
2.3.3.2 Pseudohaplotype Analysis of COL5A1 rs71746744 and rs1134170 and MIR608 rs4919510 
As before, inferred pseudohaplotypes were constructed separately for the male and female CON and 
ACL groups (Appendix A: Table A1.3.1), as well as NON subgroups (Appendix A: Table A1.3.2). Five of 
the possible eight pseudohaplotypes (AGGG/T/C, AGG/T/G, -/T/C, -/A/C and -/A/G), were inferred 
with a frequency greater than 1% from the rs71746744 and rs1134170 polymorphisms in COL5A1 
and the rs4919510 polymorphism in MIR608 (Figure 2.5).  
 
The AGGG/T/C inferred pseudohaplotype, which was hypothesised to be associated with increased 
risk of AT, was not significantly different in the combined ACL group (p=0.715) or NON subgroups 
(p=0.370) (Figure 2.5A), however it was significantly (p=0.032) over-represented in the female ACL 
(63.4%, 34 of 55) group compared to the female CON (54.1%, 44 of 83) group (Figure 2.5C). The 
AGGG/T/C inferred pseudohaplotype was however significantly (p=0.040) under-represented in the 


















Figure 2.5 Inferred pseudohaplotype frequencies for COL5A1 rs71746744 and rs1134170 and MIR608 
rs4919510 for (A) combined participants (B) males and (C) females in asymptomatic controls (CON, solid black 
bars), anterior cruciate ligament group (ACL, white bars) and non-contact (NON, grey bars) subgroup. The 
number of participants (n) in each group is in parenthesis. Significant p values <0.05 are indicated by a line on 




















• CON (n=217) 
D ACL (n=215) 
D NON(n=1 20) 
~(j 
~(j ~(j \>' 




'" !!- 40 
p=O.040 
• CON (n=134) 
D ACL (n=160) 























• CON (n=83) 
D ACL (n=55) 
D NON (n=29) 
~(j 
\>' ~(j 












The -/A/C inferred pseudohaplotype was significantly over-represented in the combined CON 
(24,0%, 52 of 217) group compared to the ACL (18.4%, 39 of 215) group (p=0.004). The -/A/C 
haplotype was also significantly over-represented in the male CON (25.2%, 33 of 130) group 
compared to the male ACL group (17.9%, 28 of 156) (p=0.008) (Figure 2.5B). There was no significant 
difference between the -/A/C haplotype in the female ACL group (p=0.221) or in the combined 
(p=0.107), male (p=0.106) or female (0.603) NON subgroups. 
Finally the rare -/T/C inferred pseudohaplotype was significantly over-represented in the combined 
ACL group (2.8%, 6 of 215) and NON subgroup (3.0%, 3 of 120) compared to the CON group (0.8%, 1
of 217) (CON vs ACL, p=0.024; CON vs NON, p=0.027). This relationship was also observed in the 
male participants, with the -/T/C inferred pseudohaplotype being over-represented in both the male
ACL (3.9%, 6 of 160) group and male NON (4.0%, 3 of 91) subgroup compared to the male CON














The common SNP, rs12722 (C/T) in the 3’-UTR of the COL5A1 gene, has previously been associated 
with AT100, 102 and ACL rupture in females103. Recently, several additional polymorphisms, rs71746744 
(-/AGGG), rs16399 (ATCT/-) and rs1134170 (A/T), in close proximity to the rs12722 SNP were 
investigated for associations with AT104. The AGGG/AGGG -/- ATCT and TT genotypes of COL5A1 
rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 (A/T) respectively were found to associate 
with an increased risk of AT104. Since rs12722 has previously been associated with ACL rupture in 
females, this study investigated the COL5A1 rs71746744 (-/AGGG) and rs1134170 (A/T) SNPs for an 
association with ACL rupture.  
The first main finding of this study was that there were no significant independent associations 
between the COL5A1 rs71746744 (-/AGGG), COL5A1 rs1134170 (A/T) and MIR608 rs4919510 (G/C) 
polymorphisms and risk of ACL rupture. In addition, the genotype and allele frequencies remained 
non-significant when participants were analysed according to sex or mechanism of injury.  
Since it has previously been shown that the COL5A1 rs12722 SNP is associated with increased risk of 
ACL rupture in females108, it was hypothesised that the AGGG/AGGG and TT genotypes of 
rs71746744 and rs1134170 may also be associated with ACL rupture in females. Although there 
were no significant associations in the female group, it was noted that the rare -/- genotype 
distribution of rs71746744 within the female CON subgroup (10.8%) was higher than the female ACL 
(3.6%) and NON (3.5%) subgroups. This trend is consistent with previous findings that showed that 
the rs71746744 -/- genotype was protective against AT104. Further research within a larger cohort of 
female participants is required to establish if this gene variant is a risk factor for ACL ruptures. In 
agreement with previously published findings, where rs12722 (C/T) was not associated with ACL 
ruptures in males103, the two additional COL5A1 3’-UTR polymorphisms analysed in this study were 
also not associated with ACL ruptures in males. The sample size of the male participants included in 
this study was large enough to detect associations with a genetic effect size of between 1.6 and 1.7, 
with a power of 80% and significance level of 5%. The allele and genotype frequency distributions of 
the two COL5A1 polymorphisms were similar to previously published values for a Caucasian South 
African population104. 
 
The CC genotype of the MIR608 gene was previously associated with an increased risk of AT104, 
however there was no association between the CC genotype and risk of ACL rupture. It should be 
noted however, that in females, the CC genotype was higher in the NON subgroup and the GG 













Although insignificant, this trend is in agreement with the hypothesis that CC genotype of MIR608 
could be associated with ACL ruptures in females. It has been proposed that Hsa-miR-608 binds to 
COL5A1 3’-UTR, altering mRNA stability, and potentially changing the concentration of type V 
collagen, with subsequent effects on collagen fibril diameter and biomechanical properties110. The 
allele and genotype frequency distributions of the MIR608 polymorphisms were similar to previously 
published values for a Caucasian South African population104. 
 
There was a departure from HWE for the COL5A1 rs71746744 and rs1134170 markers in both the 
ACL and CON groups. The departure may be due to the sample sizes being too small; or it may be a 
sign that the sample does not represent a random mating population184,185. Since the ACL groups 
were selected based on their clinical diagnosis, the departure may also be a true reflection of a 
difference in genotype frequency distribution in the injured group. 
 
COL5A1 haplotypes were constructed separately for males and females as previous studies have 
identified different genetic risk factors in males and females103,108 . An additional finding of this study 
was that, although a small and probably not a practically relevant difference, the -/A inferred 
haplotype constructed from COL5A1 rs71746744 and rs1134170 was significantly (p=0.001) under-
represented in males with ACL ruptures when compared to controls. This finding could indicate that 
variants within the COL5A1 3’-UTR are “weak” modulators of ACL ruptures in males. An association 
with the -/A haplotype and protection is consistent with previous studies on the COL5A1 3’-UTR118 
and AT104, and agree with the C-form of the COL5A1 3’-UTR identified from asymptomatic controls118 
(Figure 2.1).  
 
Inferred pseudohaplotypes consisting of the COL5A1 rs71746744 (-/AGGG), and rs1134170 (A/T) 
polymorphisms and the MIR608 rs4919510 (G/C) SNP were constructed because the COL5A1 3’-UTR 
contains a functional binding site for Hsa-miR-608 118. The additive contribution of the C, rather than 
the G, allele of the MIR608 (C/T) SNP to a protective effect against ACL rupture when combined with 
the -/A COL5A1 inferred haplotype, was however unexpected, and we cannot exclude the possibility 
that this is a false positive. Much larger samples sizes are required to test whether the COL5A1 3’-
UTR polymorphisms are weak modulators of risk for ACL ruptures in males.  
 
There was no significant difference in the distribution of the proposed at risk AGGG/T inferred 
haplotype constructed from COL5A1 rs71746744 and rs1134170 between the female ACL rupture 













proposed at risk AGGG/T/C inferred haplotype, constructed from the two COL5A1 and one MIR608 
polymorphism, was significantly (p=0.032) associated with increased risk of ACL ruptures in females. 
 
It has been hypothesised that differences in the secondary structure of the COL5A1 mRNA alters its 
stability, either via its accessibility to microRNAs or other as yet unidentified mRNA stability 
proteins104,118. As a result, more α1(V) chains can be translated from the more stable transcript. 
Synthesis of the α1(V) chain is the rate-limiting step in type V collagen production, and type V 
collagen is known to regulate collagen fibril diameter and density19,21,23. This has potential effects on 
the biomechanical properties of the tissue as fibril diameter and density have been associated with 
both the tensile strength and elasticity of a tissue73. Thus the COL5A1 3’-UTR polymorphisms may 
exert their effects via changes in biomechanical properties110. The significant haplotype association 
of -/A suggests that the genetic variants may not be significant individually, but in combination, due 
to the effect that the combined variants have on the mRNA secondary structure. 
 
Although the results of this study largely support previous findings on risk allele combinations for 
AT104, there were no significant independent associations detected, despite a sample size that should 
have been able to detect an effect size of 1.6. The reason for the different effect size of these 
polymorphisms in AT compared to ACL injury may be due to the difference in the aetiology of these 
two injuries. AT is an overuse injury that results from the accumulation of microtrauma to the 
tendon over a long period. Thus tendinopathic tissue often has many pathological changes, 
concomitant with the altered regulation of many proteins and the dysregulation of numerous 
biological pathways. One such change measured in degenerative tendons, is an increase in type III 
and V collagens, and a decrease in type I collagen186. However ACL rupture is an acute event, and 
thus degeneration and altered regulation of proteins, such as type V collagen is less likely. 
Nonetheless, COL5A1 may still influence ACL risk via altering the tensile strength of the tissue.  
 
The fact that neither of the COL5A1 genetic variants was independently associated with ACL rupture 
in this study does not necessarily mean that these variants do not play a role in its aetiology. It is 
possible that the COL5A1 gene does not play an important role in ACL rupture in males, but does 
play a role in female injury. Alternatively, the effect size of the COL5A1 variant may be smaller in ACL 
rupture compared to AT due to its different aetiology, and may therefore require larger samples 














In conclusion, we propose that rs71746744 and rs1134170 gene variants in the COL5A1 3’-UTR cause 
changes in mRNA stability that alter type V collagen production and therefore modify the 
architecture of the collagen fibres. Individuals with a -/A haplotype will have decreased COL5A1 
mRNA stability, decreased type V collagen synthesis and therefore larger mean diameter fibrils. We 
propose that as a result of increased fibril diameter, the ligaments of -/A individuals will have 
increased tensile strength, and thus a decreased risk of rupture when exposed to excessive internal 


























Chapter 3: The COL11A1 and COL11A2 Genes and  
Anterior Cruciate Ligament Rupture 
3.1 Introduction 
As reviewed in Chapter 1 (Section 1.5.1), an individual’s genetic profile has been identified as one of 
the important intrinsic risk factors for ACL ruptures, and a number of genetic variants have been 
shown to associate with ACL rupture to date (table 1.1). One such variant, a common C/T single 
nucleotide polymorphism (SNP rs12722) within the 3′ -UTR of COL5A1, was shown to associated 
with ACL ruptures in females103. Specifically, the CC genotype was shown to be over-represented in 
the asymptomatic female controls103. Both increased knee hyperextension (genu recurvatum)187,188 
and hamstring flexibility189 have also been associated with risk of ACL ruptures. Interestingly, the CC 
genotype of COL5A1 rs12722, which was under-represented in females with ACL rupture, was also 
associated with decreased knee hyperextension and general joint laxity in females190. This suggests 
that the COL5A1 rs12722 genotype influences injury risk via changes in joint laxity (the 
biomechanical properties of the ligament). In addition, an age-related increase in lower limb range 
of motion measurements has also been reported in individuals with the COL5A1 rs12722 CC 
genotype116. These findings suggest that variants within the COL5A1 gene and other related genes 
may be important genetic risk factors for ACL ruptures.  
As previously discussed, COL5A1 encodes the α1 chain of type V collagen, which plays an important 
role in collagen fibril nucleation and the regulation of fibril diameter (fibrillogenesis) 19,20. In the 
previous chapter, two additional polymorphisms, rs71746744 (-/AGGG) and rs1134170 (A/T), within 
the COL5A1 3’-UTR, were investigated for an association with ACL ruptures. These variants have 
previously been associated with AT102,104 and are believed to be functional, altering COL5A1 mRNA 
stability within the cytoplasm of the tenocyte118. Increased mRNA stability has been associated with 
tendinopathy, which is believed to result from increased α1(V) chain and type V collagen production, 
which results in decreased collagen fibril diameter and packing density, and potentially altered 
mechanical properties of the tendon110. In agreement with the COL5A1 rs12722 SNP findings, these 
two additionally analysed COL5A1 3’-UTR polymorphisms were not associated with ACL ruptures in 
males (Chapter 2). Although the trends were as proposed, the association of these additional 
polymorphisms with ACL ruptures in females was however inconclusive because of the small sample 













Type XI collagen shares structural homology with type V collagen28, which together with types II and 
IX collagen, forms heterotypic fibrils in cartilage 29,44. Both type V and type XI collagens regulate 
collagen fibril diameter28. This regulation occurs via their protruding N-terminal domains, which limit 
the appositional lateral growth of collagen fibrils by blocking further accretion of type I and type II 
collagen molecules respectively28. In addition, both collagens play a role in the interaction of 
collagens with proteoglycans of the ECM28. Until recently, the expression of type XI collagen was 
thought to be confined to cartilage. However, it has now been demonstrated that type XI collagen is 
expressed in many non-cartilaginous tissues28,30,45,47,48,146, as well as in the fibrocartilaginous zone of 
the mature ACL30.  
 
Type XI collagen is a quantitatively minor fibrillar collagen comprising three polypeptide chains; 
α1(XI), α2(XI) and α3(XI), encoded by the COL11A1, COL11A2 and COL2A1 genes respectively191. The 
α3 (XI) chain was revealed to be an overglycosylated form of the α1(II)-collagen chain, lacking an N-
terminal cysteine-rich domain191. Mutations in COL2A1, COL11A1 and COL11A2 have all been 
implicated in various inherited connective tissue disorders121–124,192,193, and polymorphisms within 
these genes have previously been associated with musculoskeletal injuries or connective tissue 
disorders128–130,134,136,137,139,141,142. 
 
The COL11A1 gene has previously been investigated for associations with early-onset arthritis126, 
osteoarthritis127, lumbar disc pathologies131,132 cleft palate128 and cancer133. However, it has only 
been significantly associated with lumbar disc desiccation and bulging128, LDH129, and limbus 
vertebra in gymnasts130. The COL11A2 gene has been investigated for associations with 
osteoarthritis126,127, rheumatoid arthritis134, osteochondrodysplasias 135, OPLL 136–139, lumbar128,140,141 
and intevertebral 142,143 disc disease, and cleft palate 131,132. However the only diseases which showed 
significant association included: lumbar disc desiccation, bulging and height narrowing128, 
rheumatoid arthritis 134 and OPLL137. 
Functional polymorphisms identified by these earlier studies include the rs3753841 (T/C) and 
rs1676486 (C/T) SNPs of COL11A1 and the rs1799907 (A/T) SNP of COL11A2. Specifically, the C allele 
of rs3753841 was associated with LDH129 and the T-allele of the rs1676486 was associated with 
LDH129 and limbus vertebra in gymnasts130. Additionally, the T allele of COL11A2 rs1799907 was 
associated with risk of lumbar disc desiccation128, lumbar spine stenosis141 and OPLL136–139.  
The primary aim of this study was therefore to investigate the association of the COL11A1 rs3753841 













with ACL ruptures in a South African Caucasian population. A secondary aim of this study was to 
investigate whether the COL11A1 and COL11A2 polymorphisms interact with the previously 
investigated rs71746744 (-/AGGGG) polymorphism within the COL5A1 3’-UTR to modulate the risk of 
ACL rupture. Although the previous Chapter did not show an independent association with 
rs71746744 and risk of ACL rupture, deletion of a 57 bp region in the COL5A1 3’-UTR containing the 
rs71746744 STRP abolishes the differences in mRNA stability between tendinopathic and 
asymptomatic individuals118. The rs71746744 variant was therefore selected based on its proposed 















3.2.1 Study Design and Participants 
Two hundred and fifteen (160 males and 55 females) participants with surgically confirmed ACL 
ruptures and 216 (133 males and 83 females) apparently healthy, unrelated, physically active control 
(CON) participants were recruited for this case-control genetic association study as previously 
described in Section 2.2.2 of Chapter 2. Prior to participation in this study, all participants gave 
written informed consent (Appendix B, B1.2) and completed the questionnaires (Appendix B, B1.4) 
as detailed in the previous Chapter. The 120 (91 males and 29 females) participants who had 
ruptured their ACL via confirmed non-contact (NON) mechanisms were analysed as a separate 
subgroup in this study.  
Approval for the study was obtained from the Research Ethics Committee of the Faculty of Health 
Sciences within the University of Cape Town (reference number 164/2006) (Appendix B, B1.1). 
3.2.2 Polymorphism Selection 
Two genes, COL11A1 and COL11A2, encoding for the α1(XI) and α2(XI) subunits of type XI collagen 
respectively, were chosen for this analysis. Functional polymorphisms that had previously been 
associated with musculoskeletal conditions were chosen. 
COL11A1  
The COL11A1 gene has been mapped to human chromosome 1p21. The rs3753841 (T/C) SNP is a 
T>C single nucleotide base change in exon 52 of the COL11A1 gene that results in a non-synonymous 
amino acid change from a leucine to a proline at position 1323 of the pro α1(XI) protein (Figure 3.1). 
This polymorphism has been investigated in a number of conditions, and has been significantly 
associated with susceptibility to LDH129.  
The rs1676486 SNP is a T>C single nucleotide base change in exon 62 of the COL11A1 gene that 
results in a non-synonymous amino acid change from a proline to a serine at amino acid position 
1535 (Figure 3.1). In addition to the potential affects from the amino acid change, Mio et al showed 
that the T allele of rs1676486 had significantly lower expression than the C allele, which appears to 
be due to increased mRNA degradation of the T allele transcript129. This variant has been associated 

















Figure 3.1 Schematic drawing of the COL11A1 gene, showing the position of the selected rs3753841 and 
rs1676486 SNPs. The COL11A1 gene is located on the reverse strand of chromosome 1 and is 232 030 base 
pairs in length. The entire COL11A1 transcript is depicted, with exons represented as vertical lines, and introns 
represented by the adjoining lines. A close-up of the region containing exons 49-62 is shown below, with the 
position of the SNPs depicted in boxes underneath. The SNP accession number together with its respective 
base change and resulting amino acid change are indicated in boxes below their location. The sequence and 
position of the SNPs in COL11A1 is relative to the ENST00000370096 ensembl transcript. The processed 
transcript is 7286 bp in length, comprises 67 exons, and encodes a 1806 amino acid protein. 
Notation in this study is (major allele/ minor allele).  
Although T (leucine) is the major allele of rs3753841 in a Caucasian population, the ancestral allele is C 
(proline). The ancestral allele of rs1676486 is C (proline), which is also the major allele.  
 
COL11A2  
The COL11A2 gene has been mapped to human chromosome 6p21.3. The IVS6-4 (rs1799907) 
polymorphism in COL11A2 is a T-A base change located in intron 5, 4 base pairs upstream of the 
start of exon 6, that results in alternative slicing (Figure 3.2). The rs1799907 SNP has been 
significantly associated with lumbar disc desiccation, bulging and height narrowing 128 rheumatoid 













Figure 3.2 Schematic drawing of the COL11A2 gene showing the position of the rs1799907 SNP. The COL11A2
gene is located on the reverse strand of chromosome 6 and there are 12 COL11A2 transcripts. The entire
COL11A2 transcript is depicted with exons represented as vertical lines, and introns represented by the
adjoining lines. A close-up of the region containing exons 5-6 and intron 5 is shown below, with the position of
the SNP depicted in a box beneath. The SNP accession number together with its respective base change and
resulting amino acid change is indicated below. The position of the SNP is relative to the ENST00000448717
ensembl transcript. The gene is 29 819 bp in length. The processed transcript is 6209 bp long, comprising 64
exons that encode a 1650 amino acid protein.
COL5A1 
This sample population in this study has previously been genotyped for a number of polymorphisms 
within the 3’-UTR of the COL5A1 gene, which has been mapped to human chromosome 9q34101,102. 
In addition to AT, the rs12722 SNP has been associated with ACL rupture in females103, ROM115,116 
and endurance running performance117. There are seven tightly linked polymorphisms within this 
region: rs13946, rs12722, rs3196378, rs71746744, rs16399, rs1134170 and rs3128575, which are 
thought to alter mRNA stability118. The rs71746744 polymorphism was selected to investigate gene-
gene interaction effects between COL11A1 and COL11A2 variants because deletion of a 57 bp region 
containing rs71746744, was shown to abolish the difference in mRNA stability between 













3.2.3 Genotyping  
Genotyping was performed using fluorescence-based Taqman  PCR assays (Applied Biosystems, 
Foster City, CA, USA). Allele specific probes and flanking primer sets (sequences available from 
manufacturer on request) were used along with a pre-made PCR mastermix containing ampliTaq® 
DNA polymerase Gold (Applied Biosystems, Foster City, CA, USA) in a final reaction volume of 8 µl. 
The PCR reactions were run on StepOnePlus qRT-PCR machine (Applied Biosystems) using the 
manufacturers recommended cycling conditions (Chapter 2, Section 2.2.4). A small number of 
samples failed to amplify (Chapter 2, Section 2.2.5).  
3.2.4 Statistical Analysis 
Quanto version 1.2.4. was used to determine the statistical power of the study for a given sample 
size and allele frequency 180. Assuming a minor allele frequency of 0.41, 0.21 and 0.34 for rs3753841, 
rs1676486 and rs1799907 respectively, a sample size of approximately 215 cases and equal number 
of controls would be adequate to detect a genetic effect size of at least 1.5, 1.6 and 1.5 respectively, 
at a power of 80% and a significance level of 5%. GenePop was used to determine whether the SNPs 
were in HWE (http://genepop.curtin.edu.au/genepop_op1.html). Data were analysed using 
STATISTICA Version 10.0 (Stat- Soft, Tulsa, OK, USA) and GraphPad Prism version 5.0d for Mac OS X 
(GraphPad Software, San Diego, CA, USA) programs. Continuous variables, such as weight, age, 
height and BMI were compared between the CON and ACL groups and NON subgroups using one-
way ANOVA and values were covaried for sex where necessary. Pearson’s chi-squared tests, or 
Fischer’s tests when required, were used to determine whether there were any significant 
differences in allele frequencies or other categorical variables between the CON and ACL groups and 
NON subgroups. Females and males were analysed separately and together to look for sex-specific 
associations. Chaplin case-control haplotype inference package (Epstein Software) was used to infer 
haplotypes and pseudohaplotypes181,182. LD between the COL11A1 rs3753841 and rs1676486 SNPs 
was calculated using Cubex software (http://www.oege.org/cgi-bin/cubex.py)183. In all cases, 















3.3.1 Participant Characteristics 
The participants in the CON and ACL groups, as well as the NON subgroup, were matched for age 
and country of birth (Table 3.1). There were significantly more males in the ACL group (74.4%, 
p=0.004) and the NON subgroup (75.8%, p=0.008) compared to the CON group (61.4%). The 
participants were matched for height after adjusting for sex. However the ACL group and NON 
subgroup remained significantly heavier (ACL, adjusted p=0.005; NON, adjusted p=0.015) than the 
CON group, with a correspondingly higher BMI (ACL, adjusted p<0.001; NON, adjusted p=0.002) 
when adjusted for sex. 
The ACL participants were recruited on average 4.5 ± 8.8 years after the initial injury and had gained 
2.1 ± 12.4 kg on average after the rupture. There were no genotype effects on any of the descriptive 
measures of the participants (Appendix A, Table A2.1). 
 
Table 3.1 Characteristics of the participants within the asymptomatic control group (CON), anterior cruciate 
ligament rupture group (ACL) and the ACL subgroup with a non-contact mechanism of injury (NON).  
 CON ACL p-value ‡ NON p-value § 
Age (years) 28.7±11.2 (210) 27.1±11.0 (187) 0.167 26.8±10.5 (114) 0.130 
Sex (% male) 61.6 (216) 74.4 (215) 0.004 75.8 (120) 0.008 
Height (cm) 175.±9 (210) 178±9 (194) 0.368 a 178±9 (116) 0.168a 
Weight (kg) 74.2±15.1 (211) 80.7 ±16.8 (194) 0.005 a 80.4±15.8 (117) 0.015a 
BMI (kg/m
2
) 23.8±4.2 (210) 26.2±9.2 (196) <0.001 a 25.5±4.5 (116) 0.002 a 
Country of birth 
(% South African) 
86.5 (207) 83.2 (196) 0.354 82.9 (117) 0.385 
Participants who were genotyped for at least one of rs3753841, rs1676486 or rs1799907 SNPs were included 
in the analysis. Most variables are expressed as mean ± standard deviation (n= number of participants for 
which valid data was available). Sex and country of birth are expressed as a percentage. Age, height and 
weight are self-reported values at the time of the first ACL rupture for the ACL group and NON subgroup, and 
at recruitment for the CON group. Significant p-values are indicated by bold typeface.  
‡ CON vs ACL  
§ CON vs NON 
a 














3.3.2 Genotype and Allele Frequency Distributions 
3.3.2.1 COL11A1 rs3753841 (T/C)  
There was a significant difference (p=0.028) in the COL11A1 rs3753841 genotype distribution when 
the ACL (n=215) group was compared to the CON (n=216) group (Table 3.2). The TC genotype was 
significantly (p=0.009, OR=1.7, 95% CI=1.1 to 2.5) over-represented in the CON group (54.2%) when 
compared to the ACL group (41.4%). Although the genotype distribution of the NON (n=120) 
subgroup was similar to the ACL group, there was no significant difference (p=0.162) in the 
rs3753841 genotype distribution between the CON group and NON subgroup. Similarly there were 
no significant differences in the allele frequency distributions when the ACL group (p=0.718) or the 
NON subgroup (p=0.503) were compared to the CON group (Table 3.2). 
 
When the male and female participants were analysed separately, there were no significant 
differences in the rs3753841 genotype (male p=0.139 and female p=0.175) or allele (male p=0.606 
and female p=1.000) frequency distributions when the male (n=160) or female (n=55) ACL groups 
were compared to their respective CON groups (male, n=133; female n=82) (Table 3.2). Similarly 
there were also no significant differences in the rs3753841 genotype (male p=0.303 and female 
p=0.508) or allele (male p=0.493 and female p=1.000) frequency distributions when the male (n=91) 
or female (n=29) NON subgroup was compared to their respective CON groups (Table 3.2). The 
genotype and allele frequency distributions of the male and female groups were nevertheless similar 
to their combined frequency distribution. Except for the ACL group (p=0.046), all the other groups 
and subgroups were in HWE.  
 
3.3.2.2 COL11A1 rs1676486 (C/T) 
There were no significant COL11A1 rs1676486 genotype (p=0.212) or allele (p=0.282) frequency 
differences between the ACL (n=215) and CON (n=216) groups for the combined participants (Table 
3.3). Similarly, there were no significant differences in the rs1676486 genotype (male p=0.250 and 
female p=0.440) or allele distributions (male p=0.161 and female p=1.000) when the male (n=160) 
and female (n=55) ACL groups were compared to the appropriate CON groups (male, n=133; female, 
n=82) (Table 3.3). The genotype and allele frequency distributions of the male and female groups 















Table 3.2 Genotype and allele frequency distribution of COL11A1 rs3753841 (T/C) in the asymptomatic 
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Values are expressed as a frequency (%) with the number of subjects (n) in parentheses. N is the total number 
of successfully genotyped participants in each group. HWE is the p-value for the exact tests for HWE. 
Significant p-values are indicated by bold typeface.  
 
 
When analysing the NON subgroups there were also no significant differences in the distribution of 
the rs1676486 genotype or allele frequency within all participants (p=0.528 and p=0.513 
respectively), male (p=0.631 and p=0.416 respectively) or female (p=0.554 and p=1.000 respectively) 
NON subgroups compared to their respective CON groups (Table 3.3). Although not significant, there 
was a tendency for the TT genotype to be over represented in the female NON subgroup (10.3%, 3 
of 83), compared to the female CON group (2.4%, 2 of 29). Except for the female NON subgroup 















Table 3.3 Genotype and allele frequency distribution of COL11A1 rs1676486 (C/T) in the asymptomatic 
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Values are expressed as a frequency (%) with the number of subjects (n) in parentheses. N is the total number 
of successfully genotyped participants in each group. HWE is the p-value for the exact tests for HWE. 
Significant p-values are indicated by bold typeface. 
 
 
3.3.2.3 COL11A2 rs1799907 (A/T) 
There were no significant differences in the COL11A2 rs1799907 genotype (p=0.261) or allele 
(p=0.737) frequency distributions between ACL (n=215) and CON (n=216) groups (Table 3.4). 
Similarly there were also no significant differences in the genotype (p=0.286) or allele (p=0.799) 
frequency distributions when the NON (n=120) subgroup was compared to the CON group (Table 
3.4). There were no significant differences in the rs1799907 genotype (male p=0.344 and female 
p=0.592) or allele (male p=0.448 and female p=0.701) frequency distributions when the male 
(n=160) or female ACL (n=55) groups were analysed separately and compared to their respective 













Table 3.4 Genotype and allele frequency distribution of COL11A2 rs1799907 (A/T) in the asymptomatic 
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Values are expressed as a frequency (%) with the number of subjects (n) in parentheses. N is the total number
of successfully genotyped participants in each group. HWE is the p-value for the exact tests for HWE.
Significant p-values are indicated by bold typeface.
Similarly, when males and females were analysed separately, there were no significant differences in 
the rs1799907 genotype (male p=0.287 and female p=0.557) or allele (male p=0.388 and female 
p=0.429) frequency distributions when the male (n=91) or female (n=29) NON subgroups were 
compared to their respective CON groups (Table 3.4). The genotype and allele frequency 
distributions of the male and female groups were nevertheless similar to the combined groups. 














Figure 3.3 Inferred haplotype frequencies for COL11A1 rs3753841 and rs1676486 for (A) combined (B) male 
and (C) female participants. Asymptomatic controls (CON) are depicted by solid black bars, anterior cruciate 
ligament (ACL) rupture groups are depicted by white bars and the non-contact (NON) subgroup is depicted by 
solid grey bars. The number of participants in each group is in parenthesis (n). Any significant differences (p 
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3.3.3 Haplotype Analysis of COL11A1 rs3753841 and COL11A1 rs1676486 
The COL11A1 rs3753841 and rs1676486 polymorphisms were in high LD for the CON group 
(D’=1.000; r2=0.393), ACL group (D’=0.923, r2=0.291) and combined groups (D’=0.963, r2=0.341). 
Because previous studies have shown that the genetic variants that predispose to ACL risk may differ 
depending on sex103,108, inferred haplotypes were constructed separately for the male and female 
CON and ACL groups (Appendix A: Table A2.2.1), as well as NON subgroups (Appendix A: Table 
A2.2.2). 
Three of the possible four haplotypes (TC, CC and CT), were inferred with a frequency greater than 
1% from the two COL11A1 polymorphisms (Figure 3.3) Although the inferred haplotype frequency 
distribution between the combined groups were similar to the male and female groups, the 
COL11A1 CT inferred haplotype was only significantly under-represented in (i) the combined ACL 
group (17.5%, 37 of 215) compared to the combined CON group (21.3%, 46 of 217) (p=0.044) (Figure 
3.3A), and (ii) in the female NON subgroup (14.9%, 4 of 29) compared to the female CON group 
(18.1%, 14 of 83) (p=0.015) (Figure 3.3C). 
3.3.4 Pseudohaplotype Analysis of COL11A1 and COL11A2  
Since the COL11A1 (chromosome 1p21) and COL11A2 (chromosome 6p21.3) genes encode for type 
XI collagen α-chains, inferred pseudohaplotypes were constructed from COL11A1 rs3753841, 
COL11A1 rs1676486 and COL11A2 rs1799907. Once again, inferred haplotypes were constructed 
separately for the male and female CON and ACL groups (Appendix A: Table A2.3.1), as well as NON 
subgroups (Appendix A: Table A2.3.2). 
Six pseudohaplotypes (TCA, TCT, CCA, CCA, CTT, CTA and CTT) of the possible eight were inferred 
with a frequency greater than 1% from the two COL11A1 and one COL11A2 SNPs (Figure 3.4). The 
CTA inferred pseudohaplotype was significantly (ACL vs CON, p=0.010 and NON vs CON, p=0.037) 
over-represented in the CON group (14.7%, 31 of 217) compared to the ACL group (9.5%, 20 of 215) 
and NON subgroup (10.3%, 12 of 120) (Figure 3.4A). 
Similarly, in the male participants, the CTA inferred pseudohaplotype was also significantly (ACL vs 
CON, p=0.015 and NON vs CON, p=0.044) over-represented in the CON (15.9%, 21 of 134) group 
compared to the ACL group (10.4%, 16 of 160) and NON subgroup (11.6%, 10 of 91) (Figure 3.4B). 
There was no significant difference in inferred pseudohaplotype frequency distribution in the ACL 
group or NON subgroup when the females were analysed separately (Figure 3.4C). The inferred 
pseudohaplotype frequency distributions between the male and female CON group, ACL group and 














Figure 3.4 Inferred pseudohaplotype frequencies for COL11A1 rs3753841 and rs1676486 and COL11A2 
rs1799907 polymorphisms in (A) combined (B) male and (C) female participants. Asymptomatic controls (CON) 
are depicted by solid black bars, anterior cruciate ligament (ACL) rupture groups are depicted by white bars 
and the non-contact (NON) subgroup is depicted by solid grey bars. Any significant differences (p <0.05) 
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3.3.5 Pseudohaplotype Analysis of COL11A1, COL11A2 and COL5A1 
Due to the possibility for interactions between type V and type XI collagen, gene-gene interactions 
were investigated between polymorphisms within COL11A1, COL11A2 and COL5A1. The COL5A1 
rs71746744 STRP was selected for this analysis because deletion of a 57 bp region in the COL5A1 3’-
UTR containing the rs71746744 STRP abolishes the differences in mRNA stability between 
tendinopathic and asymptomatic individuals118. The rs12722 SNP in the COL5A1 3’-UTR has 
previously been associated with ACL rupture in females103, therefore inferred pseudohaplotypes 
were once again constructed separately for the male and female CON and ACL groups (Appendix A: 
Table A2.4.1), as well as NON subgroups (Appendix A: Table A2.4.2).  
Eleven of the sixteen pseudohaplotypes were inferred with a frequency greater than 1% from the
COL11A1 rs3753841 (T/C), COL11A1 rs1676486 (C/T), COL11A2 rs1799907 (A/T) and COL5A1
rs71446744 (AGGG/-) polymorphisms (Figure 3.5). None of the expected inferred pseudohaplotypes
were significantly different between the CON and ACL groups and NON subgroups when combined 
(Figure 3.5A), male (Figure 3.5B) or female (Figure 3.5C) participants were analysed. In the combined 
male and female analysis the following two inferred pseudohaplotypes were significantly different
between groups: (i) TCT(AGGG) was significantly over-represented (p=0.030) in the CON (16.2%, 35
of 217) group compared to the NON (8.1%, 9 of 120) subgroup, and (ii) CTA(AGGG) was significantly
over-represented (p=0.021) in the CON (12.9%, 28 of 217) group compared to the ACL (9.2%, 19 of
215) group. There was a trend (p=0.051) for the TCA(AGGG) inferred pseudohaplotype to be under-
represented in the CON group (Figure 3.5A).
When only the male participants were analysed the following three inferred pseudohaplotypes were
significantly different between groups: (i) TCT(AGGG) was significantly over-represented (p=0.018) in
the CON (16.1%, 21 of 134) group compared to the ACL (9.0%, 14 of 160) group, (ii) TCT(-) was
significantly over-represented in the ACL (10.1% 16 of 160) group and NON (14.6%, 13 of 91)
subgroup compared to the CON (2.6%, 3 of 134) group (CON vs ACL, p=0.031; CON vs NON,
p=0.008), and (iii) CTA(AGGG) was significantly over-represented (p=0.029) in the CON (13.6%, 18 of 
134) group compared to the ACL (9.8%, 15 of 160) group (Figure 3.5B). There were however no
significant differences in the inferred pseudohaplotype distribution between the groups when only 













Figure 3.5 Inferred pseudohaplotype frequencies for COL11A1 rs3753841 and rs1676486, COL11A2 rs1799907 
and COL5A1 rs71746744 in (A) all (B) male and (C) female participants. Asymptomatic controls (CON) are 
depicted by solid black bars, anterior cruciate ligament (ACL) rupture groups are depicted by white bars and 
the non-contact (NON) subgroup is depicted by solid grey bars. Any significant differences (p <0.05) between 
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Familial heritability studies have suggested that genetic factors play an important role in 
susceptibility to ACL rupture90,92. The rs12722 (C/T) SNP in the COL5A1 gene, which encodes the 
α1(V) chain of type V collagen, has previously been associated with ACL ruptures in females103. 
Although there were trends in the females, no significant association was found between the 
rs71746744 (AGGG/-) STRP or rs1134170 (T/A) SNP and ACL rupture (Chapter 2), despite their close 
proximity to the rs12722 SNP in the COL5A1 3’-UTR.  
Type V and type XI collagen are structurally and functionally similar minor fibrillar collagens28 that
initiate collagen fibril nucleation during early fibrillogenesis and regulate fibril diameter23,26,28,42,43. 
The major type V collagen isoform [α1(V)2α2(V)] is encoded by the COL5A1 and COL5A2 genes
respectively, and type XI collagen is encoded by the COL11A1, COL11A2 and COL2A1 genes28. Until 
recently, the expression of these two proteins in tissues was thought to be mutually exclusive; with 
type V collagen expressed with type I collagen in tendon, ligament and skin28, and type XI collagen
expressed with type II collagen in cartilage29,43. However, evidence now suggests that these collagens 
have overlapping expression during the development of some tissues, and that the α1 chains are
interchangeable and capable of forming heterotrimers in some cases147–149,194. Type XI collagen is
expressed in addition to type V collagen at the bone-ligament interface of the ACL30. The COL11A1
rs3753841 and rs1676486 and COL11A2 rs1799907 polymorphisms were therefore investigated for 
an association with ACL rupture. In addition, the previously investigated rs71746744 AGGG/- STRP in
the COL5A1 3’-UTR (Chapter 2) was investigated for an interaction effect with COL11A1 and
COL11A2.
The first main finding of this study was that there was a significant difference in the genotype
frequency distribution of the COL11A1 rs3753841 (T/C) polymorphism between asymptomatic
controls (CON) and individuals with ACL rupture. Specifically, heterozygosity for the rs3753841 T/C
polymorphism was associated with protection (p=0.009, OR=1.67, 95% CI= 1.14-2.45). The
association of genetic heterozygosity with protection from disease phenotypes is not
unprecedented, although it may be more difficult to interpret biologically195. There is no obvious
biological explanation for the association of the TC genotype of rs3753841 with ACL injuries. This
association might merely indicate other variants within the COL11A1 gene and chromosomal region
may be associated with ACL ruptures. Further work is required to investigate this possibility. The 














The genotype and allele frequencies for the ACL and CON groups for all three SNPs were similar to 
the genotype and allele frequencies reported for a European population in the National Centre for 
Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov/snp/). There was a 
departure from HWE for the COL11A1 rs3753841 and rs1676486 markers in the ACL and CON 
groups. Departures from HWE suggest that perhaps the sample size of this study is too small or the 
individuals investigated in this study do not represent a randomly mating population185. The ACL 
group was selected based on clinical criteria and geographical ancestry and the CON group was 
selected to match the age, geographical ancestry and physical activity of the ACL group. The 
observed departure from HWE may thus be explained by the fact that the recruitment of the ACL 
and CON groups was highly selective. 
The second major finding of this study was that the COL11A1 CT inferred haplotype, constructed 
from the non-synonymous rs3753841 and rs1676486 SNPs, was under-represented in the ACL group, 
suggesting a protective effect. As previously mentioned the COL11A1 rs3753841 (T/C) SNP results in 
an amino acid change from a leucine to a proline at position 1323 (L1323P) of the α1(XI) chain that is 
predicted to be deleterious, while the rs1676486 SNP results in a change from proline to a serine at 
position 1535 (P1535S) that is very near to a predicted disulphide bond at amino acid position 1532. 
The resultant α1 (XI) chain from the CT haplotype therefore differs in structure in at least two amino 
acid residues from the wild type TC allele. This change in the amino acid sequence of the α(I)XI chain 
may have an effect on the structure and function of type XI collagen. Further work is required to test 
this hypothesis. COL11A1 mRNA stability has also been shown to be altered by the rs1676486 SNP129. 
The possible role of this SNP in regulating type XI collagen production will be discussed in greater 
detail in the following chapters of this dissertation.  
In order to investigate the interaction between the two COL11A1 SNPs and the rs1799907 SNP in 
COL11A2, Inferred pseudohaplotypes were constructed. The COL11A1-COL11A2 CTA inferred 
pseudohaplotype was significantly over-represented in the CON group compared to the ACL group. 
Therefore, in combination, the C, T and A alleles of rs3753841, rs1676486 and rs1799907 
respectively, appear to be protective. The COL11A2 rs1799907 (T/A) SNP occurs in intron 5, and 
results in alternative splicing of the COL11A2 gene, resulting in protein products of slightly different 
length. In the conventional type XI isoform, [α1(XI) α2(XI) α1(II)], the α1(XI) and α2(XI) chains 
combine in a 1:1 ratio. It is possible that the alternatively spliced variant from either the A or the T 
allele of rs1799907 interacts better with either the C or T allele of rs3753841137.  
The third major finding of this study was that the rs71746744 STRP in COL5A1 does not appear to 












modulate ACL rupture risk in the hypothesised manner. A complex picture emerged when the 
inferred pseudohaplotypes were constructed from COL11A1 rs3753841 and rs1676486, COL11A2 
rs1799907 and COL5A1 rs71746744. Three major inferred pseudohaplotype, namely TCT(-), 
CTA(AGGG) and CTA(AGGG), were significantly different between the CON and ACL groups and NON 
subgroups in the combined and male groups. The biological significance of these associations is not 
apparently clear. It is also possible that these are merely false positive findings due to the relative 
small sample size of this study. Further work in larger cohorts is required to investigate the 
association of these inferred haplotypes with ACL ruptures.  
Although there was no evidence for any sex-specific effects of the type XI collagen genes in
modulating the risk of ACL ruptures in this study, the small female sample size is a limitation of the
current study. In particular this study was under powered to conclusively determine whether there
were any type XI and type V collagen gene interactions in the modulation of ACL ruptures in females.
In conclusion, the functional COL11A1 rs3753841 and rs1676486 polymorphisms, as well as the
COL11A2 rs1799907 polymorphism appear to play a role in susceptibility to ACL rupture. Specifically,
the CTA inferred pseudohaplotype constructed from these SNPs appears to be protective; however













Chapter 4: The COL11A1 and COL11A2 Genes and  
Chronic Achilles Tendinopathy 
4.1 Introduction 
The Achilles tendon is the largest and strongest tendon within the human body and originates at the 
gastrocnemius and soleus muscles of the calf, and inserts at the calcaneus bone (heel) 1. There are a 
number of injuries that affect the Achilles tendon or surrounding tissues, such as bursitis, 
achillodinia, peritendinitis, tendinosis, tendinitis and rupture196. The focus of this specific study is on 
injuries within the midsubstance of the tendon structure, specifically chronically painful overuse 
Achilles tendon injuries. Since all the participants included in this dissertation with a painful overuse 
Achilles tendon injury were diagnosed clinically, the term chronic Achilles tendinopathy (AT) will be 
utilized, as it makes no assumptions about the underlying pathology. 
AT constitutes between 6 to 18% of reported tendon injuries79 and is among the most common 
sporting injuries, especially within a growing and active generation of older individuals5. In fact, the 
prevalence of AT and Achilles tendon ruptures appears to be increasing worldwide197,198. With time, 
AT often worsens, and involvement of the previously healthy contralateral tendon is common199. 
Unfortunately, AT can become a chronic condition, requiring management, and in severe cases 
requiring surgery200–202. 
Although Achilles tendinopathies are well studied at the clinical level, they remain poorly 
understood at the molecular level14,15,78,200,203,204. Histopathological findings typically reveal a 
degenerative rather than inflammatory process77,205,206, and the tendinopathic tissue is often 
characterized by collagen fibril degeneration and microtears, decreased fibril diameter, tenoctye 
dedifferentiation, hypo-or acellularity and increased glycoaminoglycan content77,205.  
AT is a multifactorial disorder, resulting from the numerous interactions of extrinsic and intrinsic risk 
factors (Chapter 1, Section 1.5.1). The genetic profile of an individual has recently been identified as 
one of the important intrinsic risk factors4,5,93,95,167. Previous studies have reported independent 
associations of several genes with AT (Chapter 1, Table 1.1)5. The genetic predisposition to AT is 
therefore polygenic, resulting from the interaction of risk alleles in a number of genes that make 
small cumulative contributions to the overall risk3,4,95. One of the most extensively investigated 












COL5A1 gene is also associated with ACL rupture in females103 and other exercise-associated 
phenotypes115–117,178. 
Type V collagen plays an important role in collagen fibril nucleation, and fibril diameter regulation 
during fibrillogenesis (Chapter 1, Section 1.3.2.1). As mentioned in Chapter 2, there are seven tightly 
linked polymorphisms in the COL5A1 3’-UTR; five of which (rs12722 (C/T), rs3196378 (C/A), 
rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 (A/T)) are thought to alter the secondary 
structure of the mRNA transcript104, and cause the observed changes in mRNA stability between 
tendinopathic and asymptomatic individuals118. The increase in COL5A1 mRNA stability in 
tendinopathic individuals may increase the amount of α1(V) protein that gets translated, thus 
decreasing the fibril diameter, and potentially altering biomechanical properties of the tissue110.  
As discussed in the previous chapter (Chapter 3), type XI collagen shares structural homology with
type V collagen28, which together with types II and IX collagen forms heterotypic fibrils in cartilage
29,44. Like type V collagen, type XI collagen is also a vital collagen fibril nucleator and regulator of 
collagen fibril diameter42,43. Recently, a synergistic relationship between COL5A1 and COL11A1 was
demonstrated in developing tendon in mice146, and the expression of COL11A1 has been detected in
developing human tendon 48,145. 
In the previous chapter (Chapter 3), two non-synonymous SNPs (rs3753841 T/C and rs1676486 C/T)
in the COL11A1 gene and an intronic SNP (rs1799907 A/T) in the COL11A2 gene were investigated
for an association with ACL rupture. Heterozygosity for the rs3753841 (T/C) polymorphism was 
associated with protection from ACL rupture. In addition, the CTA inferred pseudohaplotype
consisting of the C, T, a d A alleles of rs3753841, rs1676486 and rs1799907 respectively was
associated with protection from ACL rupture. Although the COL11A1 and COL11A2 polymorphisms
were investigated for interactions with the rs71746744 -/AGGG STRP in the 3’-UTR of the COL5A1
gene, the findings were inconclusive due to the small female sample size of the study (Chapter 3).
The aim of this study was to investigate whether the rs3753841 (T/C) and rs1676486 (C/T) 
polymorphisms in COL11A1 and the rs1799907 (A/T) polymorphism in COL11A2 are associated with 
AT in a South African and Australian population. Due to the potential for the functional COL11A1, 
COL11A2 and COL5A1 SNPs to interact during tendon fibrillogenesis, a secondary aim of this study 
was to investigate whether the COL11A1 and COL11A2 variants interact with the rs71746744 (-














4.2.1 Study Design 
A case-control genetic association study was conducted on individuals of self-reported European 
ancestry recruited from South Africa (SA) and Australia (AUS). This study forms part of a broader 
study to determine the genetic risk factors that contribute to AT. Approval for the study was 
obtained from the Research Ethics Committee of the Faculty of Health Sciences within the University 
of Cape Town (reference number 172/2005) (Appendix B, B2.1) and Human Ethics Committees of La 
Trobe and Deakin Universities, Melbourne, Australia.  
4.2.2 Participants 
South African Participants 
A total of 264 unrelated, physically active participants from South Africa, consisting of 160 
asymptomatic controls (SA CON group) and 104 individuals diagnosed with chronic Achilles 
tendinopathy (SA TEN group) were included in this study. The participants with clinically diagnosed 
Achilles tendinopathy were recruited from the Sports Medicine practice at the Sports Science 
Institute of South Africa and other collaborating clinical practices in Cape Town and Johannesburg, 
South Africa. The SA TEN diagnoses were reviewed and confirmed by a Sports Physician, using an 
inclusion and exclusion criteria and a checklist (Appendix B, B2.2). The SA CON participants reported 
no history of tendon pathology and were recruited from various recreational sporting clubs.  
The SA CON group were recruited such that the sex and country of birth were similar to that of the 
SA TEN group. In addition, the age of the SA CON group was matched to that of the age of initial 
injury onset in the SA TEN group in order to avoid the possible confounding effects of age. As 
previously noted of this population, the majority of participants in the TEN group had participated in 
long-distance running100. Therefore the CON group was matched for the number of years of 
participation in running activities. Although the TEN participants completed significantly less running 
training (hr/week) than the CON group during the past 2 years, the TEN group had participated for 
significantly more years in high-impact sports. There was no significant difference in the hours of 
training in high-impact sports during the past 2 years between the two groups. 
Australian Participants 
A total of 254 participants from Australia, consisting of 176 asymptomatic controls (AUS CON group) 
and 78 patients with chronic Achilles tendinopathy (AUS TEN group) were included in this study. The 












University in Melbourne Australia102. A Sports Physiotherapist confirmed the AUS TEN diagnoses, 
using criteria similar to that of the SA study. The participants were recruited such that their country 
of birth was matched between the AUS CON and AUS TEN groups, and the age of recruitment of the 
AUS CON group matched that of initial onset of injury of the AUS TEN group.  
In accordance with the Declaration of Helsinki, all participants signed informed consent forms 
(Appendix B, B2.3). SA participants were given information regarding the study (Appendix B, B2.4), 
gave their written informed consent and completed questionnaires concerning their medical history 
and involvement in physical activity (Appendix B, B2.5). AUS participants received similar forms and 
information to those used in the SA study, however unfortunately the physical activity of the AUS 
participants was not documented.  
4.2.3 DNA Extraction 
For the SA participants, approximately 4.5 ml of venous blood was collected via venipuncture of a 
forearm vein into EDTA vacutainer tubes and stored at 4 °C until total DNA extraction. Total DNA was
extracted from blood using a method described by Lahiri and Nurnberger (1991)179 and modified by
Mokone et al100 (See Appendix C1 for details). The DNA was stored at -20 °C until PCR analysis. For
the AUS participants, approximately 4.5 ml of venous blood was collected and DNA was extracted
using a sequence extraction technique (FlexiGene DNA Kit, Qiagen P/L, Valencia, California, USA) as
per the manufacturer’s instructions. 
4.2.4 Genotyping 
The rs3753841 (T/C) and rs1676486 (C/T) polymorphisms in COL11A1 (Chapter 3, Figure 3.1) and the
rs1799907 (A/T) polymorphism in COL11A2 (Chapter 3, Figure 3.2) were genotyped for this study.
The rs71746744 (-/AGGG) STRP (Chapter 2, Figure 2.1) had previously been genotyped, and was
included in this study for interaction effects. Genotyping was performed using fluorescence-based
Taqman PCR assays (Applied Biosystems, Foster City, CA, USA). Allele specific probes and flanking
primer sets (sequences available from manufacturer on request) were used along with a pre-made
PCR mastermix containing ampliTaq® DNA polymerase Gold (Applied Biosystems, Foster City, CA,
USA) in a final reaction volume of 8 µl. The PCR reactions were run on StepOnePlus qRT-PCR
machine (Applied Biosystems) using the manufacturers recommended cycling conditions (previously
described in Section 2.2.4). Genotypes were determined by end-point fluorescence and analyzed
using the StepOne Software Version 2.2.2 (Applied Biosystems) (example provided in Figure 2.2). A 












4.2.5 Statistical Analysis 
Quanto version 1.2.4. was used to determine the statistical power of the study for a given sample
size, allele frequency and odds ratio180. Assuming a minimum allele frequency of 0.42, 0.22 and 0.31
in the pooled CON group for rs3753841, rs1676486 and rs1799907 respectively, a sample size of 
approximately 150 cases would be adequate to detect a allelic odds ratio of at least 1.6, 1.7 and 1.6
respectively, at a power of 80% and a significance level of 5%. GenePop was used to determine
whether the SNPs were in HWE (http://genepop.curtin.edu.au/genepop_op1.html). Statistical
analysis was conducted using STATISTICA 10 (StatSoft Inc., Tulsa, OK, USA). Continuous variables,
such as weight, age, height and BMI, were compared using one-way ANOVA, co-varying for sex and
age of recruitment where required. Pearson’s chi-squared tests, or Fischer’s exact tests when
required, were used to determine whether there were any significant differences in allele
frequencies or other categorical variables between the CON and TEN groups. LD between the
COL11A1 rs3753841 and rs1676486 SNPs was calculated using Cubex software
(http://www.oege.org/cgi-bin/cubex.py)183. Combined genotype frequencies were analyzed using
the Monte Carlo test (CLUMP program, version 2.0)207.The odds ratios and 95% confidence intervals
were determined using GraphPad Prism version 5.0d (GraphPad Software, San Diego, California,
USA). Chaplin case-control haplotype inference package (Epstein Software) was used to infer
haplotypes (and pseudohaplotypes)181,182. In all cases, statistical significance was accepted when














4.3.1 Participant Characteristics 
The AUS CON and AUS TEN groups were similarly matched for age (p=0.487), and country of birth
(p=0.792) (Table 4.1). There was a significant difference in the sex composition of the AUS CON
(40.3% males) and AUS TEN (71.8% males) groups, with a larger proportion of females in the AUS 
CON group (p=0.010). After adjusting for sex, the groups were matched for height (p=0.101). The
mean difference between age of injury and age of recruitment of the AUS TEN group was 9.0 ± 10.1
years. There was therefore a significant difference between the age at recruitment of the AUS TEN
(49.6 ± 12.8 years) and the AUS CON (39.4 ± 12.3 years) groups (p<0.001). After adjusting for both
age at recruitment and sex, the AUS CON and AUS TEN groups were matched for weight (p=0.343)
and BMI (p=0.384) (Table 4.1).  
The SA CON and SA TEN groups were matched for height (p=0.395), sex (p=0.553) and country of
birth (p=0.941) (Table 4.1). However, there were significant diff rences in age (p=0.007), as well as
weight (p=0.003) and BMI (p=0.003), with the SA TEN group being older and heavier than the SA
CON group. The mean difference between age of injury and age of recruitment of the SA TEN group
was 8.3 ± 9.8 years. There was therefore also a significant difference between the age at recruitment
of the SA TEN (48.4 ± 11.4 years) and the SA CON (36.4 ± 10.8 years) groups (p<0.001). When weight
and BMI were adjusted for age of recruitment, weight (p=0.150) and BMI (p=0.125) were no longer 
significantly different. There were no significant genotype effects on participant characteristics














Table 4.1 Characteristics of the AUS TEN and SA TEN groups and their respective AUS CON and SA CON 
groups 
 

































































ND ND ND  73.6 (159) 74.0 (100) 0.941  
Participants were included in the analysis if they were genotyped at least once for rs3753841, rs1676486 or 
rs1799907. Variables are expressed as mean ± standard deviation, except for sex and country of birth, which 
are represented as a percentage (%). Number of participants for which data was available is in parenthesis (n). 
Age of CON groups = age of recruitment; age of TEN groups = age of initial onset of symptoms. Weight, height 
and BMI values are those reported at recruitment. Significant differences (p<0.05) are highlighted in bold 
typeset. BMI, body mass index, ND, not determined. ‡ Covaried for sex. # Covaried for age of recruitment. § 




4.3.2 Genotype and Allele Frequency Distributions 
4.3.2.1 COL11A1 rs3753841 (T/C)  
There were no significant differences in genotype (p=0.235) or allele (p=0.429) frequency 
distribution between AUS TEN (n=56) and AUS CON (n=104) participants for COL11A1 rs3753841 
(Table 4.2). Similarly, there were no significant differences between SA CON (n=150) and SA TEN (96) 
groups for genotype (p=0.321) and allele (p=0.143) frequency distributions (Table 4.2). Since the 
genotype frequency distributions for both cohorts were similar (p=0.226), they were combined for 
further analysis (CON, n=254; TEN, n=152). As illustrated in Figure 4.1A, there was no significant 
difference in the genotype (p=0.102) frequency distribution between CON and TEN groups of the 
combined AUS and SA cohorts. There was however a tendency (p=0.087) for the T- allele to be over-
represented in the TEN group (Figure 4.1B). Except for the AUS TEN (p=050) group, all the other 














Table 4.2 Genotype and allele frequency distribution of the functional SNPs rs3753841 and rs1676486 in 
COL11A1 and the rs1799907 SNP in COL11A2, in the AUS TEN, AUS CON, SA TEN and SA CON groups.  
  rs3753841 genotype   rs3753841 allele  
 N TT TC CC 
P-
value 
HWE T-allele C-allele 
P- 
value  
Australia 160         
AUS CON 104 29.8 (31) 49.0 (51) 21.2 (22)  0.904 54.3 (113) 45.7 (95)  
AUS TEN 56 41.1 (23) 35.7 (20) 23.2 (13) 0.235 0.050 58.9 (66) 41.1 (46) 0.429 
South 
Africa  
246         
SA CON 150 37.3 (56) 46.7 (70) 16.0 (24)  0.786 60.7 (182) 39.3 (118)  
SA TEN 96 46.9 (45) 40.6 (39) 12.5 (12) 0.321 0.441 67.2 (129) 32.8 (63) 0.143 
          
  rs1676486 genotype   rs1676486 allele  
 N CC CT TT 
P-
value 
HWE C-allele T- allele 
P-
value  
Australia 205         
AUS CON 138 62.3 (86) 31.2 (43) 6.5 (9)  0.264 77.9 (215) 22.1 (61)  
AUS TEN 67 67.2 (45) 29.8 (20) 3.0 (2) 0.537 0.901 82.1 (110) 17.9 (24) 0.326 
South 
Africa  
229         
SA CON 139 64.0 (89) 29.5 (41) 6.5 (9)  0.165 78.8 (219) 21.2 (59)  
SA TEN 90 68.9 (62) 26.7 (24) 4.4 (4) 0.688 0.405 82.2 (148) 17.8 (32) 0.367 
          
  rs1799907 genotype   rs1799907 allele  
 N AA AT TT 
P-
value 
HWE A-allele T-allele 
P- 
value 
Australia 192         
AUS CON 126 52.4 (66) 34.9 (44) 12.7 (16)  0.055 69.8 (176) 30.2 (76)  
SA TEN 66 39.4 (26) 45.4 (30) 15.2 (10) 0.227 0.782 62.1 (82) 37.9 (50) 0.126 
South 
Africa  
261         
SA CON 158 46.8 (74) 41.8 (66) 11.4 (18)  0.576 67.7 (214) 32.3 (102)  
SA TEN 103 40.8 (42) 46.6 (48) 12.6 (13) 0.629 0.901 64.1 (132) 35.9 (74) 0.389 
          
Values are percentages (%), with sample number of participants (n) displayed in parenthesis. N is the total 
number of successfully genotyped participants in each group. HWE is the p-value for the exact tests for HWE. 

















Figure 4.1 Genotype and allele frequency distributions of the combined Australian and South African CON and 
TEN participants for COL11A1 rs3753841 (T/C), COL11A1 rs1676486 (C/T) and COL11A2 rs1799907 (A/T). 
Frequencies are expressed as percentages. The CON group is represented by the black bars, and the TEN 
groups are represented by white bars. The number of participants (n) is in parenthesis, followed by the p-
value. (A) rs3753841 genotype distribution, CON, HWE=0.729, TEN, HWE= 0.054. (B) rs3753841 allele 
frequency distribution (C) rs1676486 genotype distribution, CON, HWE=0.076, TEN HWE=0.584. (D) rs1676486 
allele frequency distribution, (E) rs1799907 genotype frequency distribution CON, HWE=0.092, TEN 














4.3.2.2 COL11A1 rs1676486 (C/T) 
There were no significant differences in genotype (p=0.537) or allele (p=0.326) frequency 
distribution between AUS TEN (n=67) and AUS CON (n=138) participants for COL11A1 rs1676486 
(Table 4.2). Similarly, there were no significant differences between SA CON (139) and SA TEN (90) 
groups for genotype (p=0.688) and allele (p=0.367) frequency distributions (Table 4.2). Since the 
genotype frequency distributions for both cohorts were similar (p=0.943), they were combined for 
further analysis (CON, n=277; TEN, n=157). There were no significant differences between the 
genotype (p=0.412) and allele (p=0.178) frequency distributions of the CON and TEN groups when 
the AUS and SA cohorts were combined (Figure 4.1C and Figure 4.1D). All groups were in HWE.  
4.3.2.3 COL11A2 rs1799907 (A/T) 
There were no significant differences in genotype (p=0.227) or allele (p=0.126) frequency
distribution for COL11A2 rs1799907 between AUS TEN (n=66) and AUS CON (n=126) participants
(Table 4.2). Similarly there were no significant differences in genotype (p=0.629) or allele (p=0.389)
frequency between SA CON (n=158) and SA TEN (n=103) groups (Table 4.2). Since the genotype
frequency distributions for both cohorts were similar (p=0.327), they were combined for further
analysis (CON, n=284; TEN, n=169). There was no significant difference between the genotype
(p=0.172) frequency distribution between CON and TEN groups when the AUS and SA cohorts were 
combined (Figure 4.1E). There was however a tendency (p=0.099) for the minor T allele to be over-
represented in the TEN group (Figure 4.1F). All groups were in HWE.
4.3.3 Genotype Interactions Between COL11A1 and COL11A2
LD between the COL11A1 rs3753841 and rs1676486 polymorphisms was similar for the CON group
(D’ =0.903; r2 =0.342), TEN group (D’=0.962, r2=0.328) and combined groups (D’=0.923, r2=0.338) and
was shown to be tightly linked. Since the three SNPs investigated in this study could theoretically
interact with one another to regulate or affect type XI collagen production, gene-gene interactions
were investigated (Table 4.3). 
There was no significant difference (Monte Carlo test) between genotype frequency distributions 
when the combined COL11A1 rs3753841 and rs1676486 SNPs for the pooled South African and 
Australian TEN and CON groups were analysed. There was however a tendency towards significance 
in the COL11A1 rs3753841 and COL11A2 rs1799907 interaction (T1, p=0.051) and COL11A1 
rs1676486 and COL11A2 rs1799907 interaction (T1, p=0.060), therefore specific biologically 
meaningful genotype interactions were analysed further. The TT-TT genotype combination of 













the CON group (3.2%) (p=0.019, OR=3.1, 95% CI=1.2-7.9). The interaction of the COL11A1 rs1676486 
CC genotype together with a COL11A2 rs1799907 AT or TT genotype was also significantly over-
represented in the TEN group (47.9%) compared to the CON group (31.7%) (p=0.002, OR= 2.0, 95% 
CI= 1.3-3.1).  
 
Table 4.3 Two-way combined genotype frequencies distributions for COL11A1 rs3753841, rs1676486 and 
COL11A2 rs1799907 
COL11A1 rs3753841 and COL11A1 rs1676486 
rs3753841 rs1676486 CON (n=233) TEN (n=141) TEN/CON 
TT CC 33.5 (78) 42.6 (60) 1.27 
TT CT 1.3 (3) 0.7 (1) 0.55 
TT TT 0.0 (0) 0.0 (0) 1.00 
CT CC 23.9 (54) 23.4 (33) 0.98 
CT CT 22.8 (53) 15.6 (22) 0.69 
CT TT 0.9 (2) 0.0 (0) ND 
CC CC 4.3 (10) 2.8 (4) 0.66 
CC CT 7.7 (18) 11.4 (16) 1.47 
CC TT 6.4 (15) 3.6 (5) 0.55 
COL11A1 rs3753841 and COL11A2 rs1799907 
rs3753841 rs1799907 CON (n=216 ) TEN (n=140) TEN/CON 
TT AA 17.1 (37) 17.1 (24) 1.00 
TT AT 15.7 (34) 20.0 (28) 0.76 
TT TT 3.2 (7) 9.3 (13) 2.87
a 
CT AA 24.1 (52) 13.6 (19) 0.56 
CT AT 16.7 (36) 20.7 (29) 1.24 
CT TT 6.0 (13) 2.9 (4) 0.48 
CC AA 6.5 (14) 8.6 (12) 1.32 
CC AT 7.9 (17) 6.4 (9) 0.82 
CC TT 2.8 (6) 1.4 (2) 0.51 
COL11A1 rs1676486 and COL11A2 rs1799907 
rs1676486 rs1799907 CON (n=230) TEN (n=144) TEN/CON 
CC AA 31.7 (73) 22.2 (32) 0.70 
CC AT 25.2 (58) 36.1 (52) 1.43
b 
CC TT 6.5 (15) 11.8 (17) 1.81
b 
CT AA 15.7 (36) 14.6 (21) 0.93 
CT AT 10.0 (23) 9.7 (14) 0.97 
CT TT 4.8 (11) 2.1 (3) 0.44 
TT AA 1.3 (3) 1.4 (2) 0.77 
TT AT 3.9 (9) 1.4 (2) *0.36 
TT TT 0.9 (2) 0.7 (0) 0.79 
MonteCarlo tests performed with 2000 simulations.  
Monte Carlo Test: rs3753841 and rs1676486, P-values for: T1=0.226, T2=0.145, T3=0.078, T4=0.141  
Monte Carlo Test: rs3753841 and rs1799907, P-values for: T1=0.051, T2=0.038, T3=0.015, T4=0.073 
Monte Carlo Test:  rs1676486 and rs1799907, P-values for: T1=0.060, T2=0.046, T3=0.022, T4=0.052  
ND, no data. Significant associations (p<0.05) are indicated in bold typeset.  
 
a p=0.019, OR=3.1, 95 % CI=1.2-7.9 
b














4.3.4 Inferred Haplotype and Pseudohaplotypes Analysis of COL11A1 and COL11A2 
Since significant gene-gene interactions were observed between the COL11A1 and COL11A2 genes in 
the previous section (Section 4.3.3), inferred haplotypes and pseudohaplotypes were constructed 
between the SNPs to confirm these findings (Appendix A, Table A3.2). 
4.3.4.1 COL11A1 rs3753841 and COL11A1 rs1676486 
Three haplotypes (TC, CC and CT), of the possible four, were inferred with a frequency greater than 
1.2% from the COL11A1 SNPs rs3753841 and rs1676486 (Figure 4.2A). The major COL11A1 TC 
inferred haplotype was significantly over-represented in the TEN group (63.3%, n=106) compared to 
the CON group (57.8%, n=172) (p=0.029). 
4.3.4.2 COL11A1 rs3753841 and COL11A2 rs1799907 
All four possible pseudohaplotypes were inferred with a frequency greater than 1% from the 
COL11A1 rs3753841 and COL11A2 rs1799907 SNPs (Figure 4.2B). In agreement with the interactions 
reported in Table 4.3, the TT inferred pseudohaplotype was significantly over-represented in the TEN 
group (26.9%, n=48) compared to the CON group (16.9%, n=84) (p=0.005). 
4.3.4.3 COL11A1 rs1676486 and COL11A2 rs1799907 
Similarly all four possible pseudohaplotypes were inferred with a frequency greater than 1% from 
the COL11A1 rs1676486 and COL11A2 rs1799907 SNPs (Figure 4.2C). In agreement with the 
interactions reported in Table 4.3, the CT inferred pseudohaplotype was significantly over-
represented in the TEN group (32.5%, n=59) compared to the CON group (23.1%, n=76) (p=0.010). 
The CA, and TT inferred pseudohaplotype were on the other-hand under-represented in the TEN 
group (CA, 49.5%, n=90; TT, 4.0%, n=7) compared to the CON group (CA, 55.2%, n=182; TT, 8.2%, 
n=27) (CA, p=0.038; TT, p=0.027).  
4.3.4.4 COL11A1 rs3753841 and COL11A1 rs1676486 and COL11A2 rs1799907 
Six pseudohaplotypes (TCA, TCT, CCA, CCA, CTT, CTA and CTT), of the possible eight, were inferred 
with a frequency greater than 1.2% from the two COL11A1 and one COL11A2 SNPs (Figure 4.2D). As 
expected from the top three panels of Figure 4.2, (TC_, T_T and _CT), The TCT pseudohaplotype was 
significantly (p=0.005) over-represented in the TEN group (26.2%, n=47) compared to the CON group 














Figure 4.2 Inferred haplotypes and pseudohaplotypes for COL11A1 rs3753841 and rs1676486 and COL11A2 
rs1799907. The AUS and SA Achilles tendinopathy (TEN, clear bars) and control (CON, black solid bars) 
participants were pooled for this analysis. A) COL11A1 rs3753841 and rs1676486, B) COL11A1 rs3753841 and 
COL11A2 rs1799907, C) COL11A1 rs1676486 and COL11A2 rs1799907, D) COL11A1 rs3753841 and rs1676486 













4.3.5 Genotype Interactions Between COL11A1, COL11A2 and COL5A1 
Since type V and type XI collagen both regulate fibrillogenesis, the COL11A1 and COL11A2 SNPs 
investigated in this study were investigated for gene-gene interactions with the previously 
investigated COL5A1 rs71746744 (AGGG/-) STRP104 (Table 4.4). There were significant differences 
(Monte Carlo test) in two-way genotype frequency distributions between COL5A1 rs71746744 and 
COL11A1 rs3753841 (T1, p=0.001), and COL5A1 rs71746744 and rs1676486 (T1, p=0.002) when the 
pooled Australian and South African TEN and CON groups were analysed. Interestingly there was no 
significant difference in two-way genotype frequency for COL5A1 rs71746744 and COL11A2 
rs1799907 between the TEN and CON groups (T1, p=0.291). 
 
Since the previous suggestions of the chapter suggested that the COL11A1 rs3753841 T and the 
COL11A1 rs1676486 C alleles were associated with AT, the interactions of these alleles with the 
COL5A1 rs71746744 AGGG/AGGG genotype were further investigated (Table 4.4). The AGGG/AGGG-
TT genotype combination of rs71746744 and rs3753841 was significantly over-represented in the 
TEN group (27.3 %) compared to the CON group (11.4 %) (p=0.005, OR=2.9, 95 % CI=1.4-5.9). 
Similarly the COL5A1 rs71746744 AGGG/AGGG genotype combined with the C allele (CC or CT 
genotypes) of COL11A1 rs1676486 was also significantly over-represented in the TEN group (64.1 %) 
compared to the CON group (38.5 %) (p<0.001, OR=2.9, 95 % CI=1.6-5.0). 
4.3.6 Pseudohaplotype Analysis of COL11A1, COL11A2 and COL5A1 
Since significant gene-gene interactions were observed between the types XI and V collagen genes in 
the previous section, inferred haplotypes and pseudohaplotypes were constructed between the 
SNPs to confirm these findings (Appendix A, Table A3.3). 
4.3.6.1 COL11A1 rs3753841 and COL5A1 rs71746744 
All four possible pseudohaplotypes were inferred with a frequency greater than 1% from the 
COL11A1 rs3753841 and COL5A1 rs71746744 polymorphisms (Figure 4.3A). In agreement with the 
interactions reported in Table 4.4, the T/AGGG inferred pseudohaplotype was significantly over-
represented in the TEN group (49.3%, n=80) compared to the CON group (37.2%, n=104) (p=0.004) 
(Figure 4.3A). The T/- and C/- inferred pseudohaplotype were on the other hand significantly under-
represented in the TEN group (C/-, 6.4%, n=10; T/-, 14.7%, n=24) compared to the CON group (C/-, 













Table 4.4 Two-way combined genotype frequencies distributions for COL5A1rs71746744 and COL11A1 
rs3753841, rs1676486 and COL11A2 rs1799907 
COL5A1 rs71746744 and COL11A1 rs3753841 
rs71746744 rs3753841 CON (n=158) TEN (n=77) TEN/CON 
AGGG/AGGG TT 11.4 (18) 27.3 (21) 2.39
a
AGGG/AGGG CT 22.2 (35) 23.4 (18) 0.95 
AGGG/AGGG CC 7.6 (12) 14.3 (11) 1.88 
-/AGGG TT 17.7 (28) 18.2 (14) 1.03 
-/AGGG CT 20.9 (33) 13.0 (10) 0.62 
-/AGGG CC 9.5 (15) 0 (0) ND 
-/- TT 3.8 (6) 0 (0) ND 
-/- CT 5.7 (9) 1.3 (1) 0.22 
-/- CC 1.3 (2) 2.6 (2) 2.00 
COL5A1 rs71746744 and COL11A2 rs1676486 
rs71746744 rs1676486 CON (n=177) TEN (n=78) TEN/CON 
AGGG/AGGG CC 24.9 (44) 39.7 (31) 1.59
b
AGGG/AGGG CT 13.6 (24) 24.4 (19) 1.79
b
AGGG/AGGG TT 3.4 (6) 1.3 (1) 0.38 
-/AGGG CC 26.6 (47) 26.9 (21) 1.01 
-/AGGG CT 17.5 (31) 3.9 (3) 0.22 
-/AGGG TT 2.8 (5) 0 (0) ND 
-/- CC 9.6 (17) 1.3 (1) 0.13 
-/- CT 1.1 (2) 2.6 (2) 2.36 
-/- TT 0.6 (1) 0 (0) ND 
COL5A1 rs71746744 and COL11A2 rs1799907
rs71746744 rs1799907 CON (n=162) TEN (n=83) TEN/CON 
AGGG/AGGG AA 19.1 (31) 27.7 (23) 1.45 
AGGG/AGGG AT 19.1 (31) 28.9 (24) 1.51 
AGGG/AGGG TT 6.2 (10) 4.8 (4) 0.77 
-/AGGG AA 24.7 (40) 18.1 (15) 0.73 
-/AGGG AT 18.5 (30) 13.3 (11) 0.72 
-/AGGG TT 2.5 (4) 2.4 (2) 0.96 
-/- AA 3.7 (6) 1.2 (1) 0.32 
-/- AT 3.7 (6) 3.6 (3) 0.97 
-/- TT 2.5 (4) 0 (0) ND 
MonteCarlo tests performed with 2000 simulations. 
Monte Carlo Test: rs71746744 and rs3753841, P-values for: T1=0.001, T2<0.001, T3=0.011, T4=0.006 
Monte Carlo Test: rs71746744and rs1676486, P-values for: T1=0.002, T2=0.001, T3=0.013, T4<0.001 
Monte Carlo Test: rs71746744 and rs1799907, P-values for: T1=0.291, T2=0.191, T3=0.300, T4=0.176 
ND, no data. Significant associations (p<0.05) are indicated in bold typeset. 
a p=0.005, OR=2.9, 95 % CI=1.4-5.9 
b













4.3.6.2 COL11A1 rs1676486 and COL5A1 rs71746744 
All four possible pseudohaplotypes were inferred with a frequency greater than 1% from the 
COL11A1 rs1676486 and COL5A1 rs71746744 polymorphisms (Figure 4.3B). As expected the C/AGGG 
inferred pseudohaplotype was significantly over-represented in the TEN (63.5 %, n=106) group 
compared to the CON (49.8%, n=142) group (p<0.001) (Figure 4.3B). The C/- and T/- inferred 
pseudohaplotypes were on the other hand significantly under-represented in the TEN group (C/-, 
18.6%, n=31; T/-, 2.3%, n=3) compared to the CON group (C/-, 28.4%, n=81; T/-, 5.1 %, n=14) (C/-, 
p=0.016; T/-, p=0.042).  
4.3.6.3 COL11A2 rs1799907 and COL5A1 rs71746744 
All four possible pseudohaplotypes were inferred with a frequency greater than 1% from the 
COL11A2 rs1799907 and COL5A1 rs71746744 polymorphisms (Figure 4.3C). The T/AGGG inferred 
pseudohaplotype was significantly over-represented in the TEN group (29.6%, n=51) compared to 
the CON group (21.3%, n=65)( p=0.016). The A/AGGG inferred pseudohaplotype was significantly 
under-represented in the TEN group (13.7%, n=23) compared to the CON group (23.5%, n=72) 
(p=0.002) (Figure 4.3C).  
4.3.6.4 COL11A1 rs3753841 and rs1676486 and COL11A2 rs1799907 and COL5A1 rs71746744 
Eleven of the possible 16 pseudohaplotypes were inferred with a frequency greater than 2% from 
the combined COL11A1, COL11A2 and COL5A1 polymorphisms (Figure 4.3D). As expected from 
Figure 4.3A-C, the TCT(AGGG) pseudohaplotype was significantly over-represented (p<0.001) in the 
TEN group (25.2%, n=46) compared to the CON group (9.1%, n=30). In addition, the CTA(-) (p=0.037) 
and CCA(-) (p=0.043) inferred pseudohaplotypes were significantly over-represented in the CON 
group (CTA(-), 5.3%, n=17; CCA(-), 5.3%, n=18) compared to the TEN group (CTA(-), 2.2%, n=4, CCA(-), 















Figure 4.3 Inferred pseudohaplotypes for COL5A1 rs71746744 and COL11A1 rs3753841, rs1676486 and 
COL11A2 rs1799907 for the pooled Australian and South African control (CON, black solid bars) and Achilles 
tendinopathy (TEN, clear bars) groups. A) COL11A1 rs3753841 and COL5A1 rs71746744. B) COL11A1 
rs1676486 and COL5A1 rs71746744. C) COL11A2 rs1799907 and COL5A1 rs71746744. D) COL11A1 rs3753841 
and COL11A1 rs1676486 and COL11A2 rs1799907 and COL5A1 rs71746744. Significant values (P<0.05) are 















The first main finding of this study was that none of the three newly investigated polymorphisms 
within the COL11A1 (rs3753841 and rs1676486) and COL11A2 (rs1799907) genes were 
independently associated with AT in the AUS, SA or combined populations. The minor allele 
frequency of rs3753841 (0.42) rs1676486 (0.22) and rs1799907 (0.20) in the CON group agrees 
closely with reported minor allele frequencies (0.36, 0.20 and 0.30) respectively, for individuals of 
European ancestry available on the NCBI database dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP, accessed 12/02/2013).  
Departure from HWE was noted in some of the groups, suggesting that perhaps the AUS individuals 
in this cohort do not represent a randomly mating population, or that the sample size of this study is 
too small184,185. The AUS TEN group was selected based on clinical criteria and geographical ancestry 
and the AUS CON group was selected to match the age, geographical ancestry and physical activity 
of the AUS TEN group. The observed departure from HWE may thus be explained by the fact that the 
recruitment of the CON and TEN groups was highly selective. 
The second main finding of this study was that, although there were no independents associations, 
gene-gene interactions between the COL11A1 and COL11A2 genes were associated with AT. 
Specially, the T and C alleles of the COL11A1 rs3753841 and rs1676486 SNPs, respectively, as well as 
the T allele of the COL11A2 rs1799907 SNP, were associated with increased risk of AT. Consistent 
results were obtained when investigating combined genotype interactions, haplotype or 
pseudohaplotype analysis.  
As previously mentioned in Chapter 1 (Section 1.6.2) and Chapter 3 (Section 3.4), the non-
synonymous COL11A1 rs3753841 (T/C) and rs1676486 (C/T) SNPs result in L1323P and P1535S 
amino acid substitutions respectively. The P1535S substitution occurs very near to a predicted 
disulphide bond at position 1532129 and could potentially lead to a conformational change in the 
type XI heterotrimer. Alternatively, the combined effect of the two amino acid changes could alter 
the folding of the α1 chain, or affect the ability of the α1(XI) chain to form the type XI collagen trimer 
or interact with other collagens or ECM molecules.  
 
However the effect of the COL11A1 rs1676486 SNP may be due to quantitative rather than 
qualitative differences in type XI collagen. Previous investigations into the biological significance of 
the COL11A1 SNPs have focussed on rs1676486, where the T-allele of rs1676486 was shown to 













Furthermore, the T allele of COL11A2 rs1799907 (IVS6-4, T/A), which was also implicated in the 
pseudohaplotypes, produces a distinct isoform of the α2(XI) chain in which several amino acids in 
the amino terminal acidic domain are deleted. This acidic domain provides potential sites for the 
interaction of type XI collagen with other molecules and may prevent further deposition of collagen 
molecules in the fibril137. It is therefore reasonable to hypothesise that the risk associated 
pseudohaplotype has a biological consequence. Although expressed in the developing tendon, 
further research is however required to determine the functional significance of the type XI collagen 
gene polymorphisms in tendinopathy. 
 
Intriguingly, while the minor C-allele of COL11A1 rs3753841 and the minor T-allele of COL11A1 
rs1676486 was over-represented in patients with LDH, the current study described in this chapter 
found that the T-allele of rs3753841 and the C-allele of rs1676486 were associated with risk of AT. A 
similar phenomenon has been observed previously for the Sp1 binding site polymorphism 
(rs1800012) in COL1A1; in which the TT genotype was associated with protection against ACL 
rupture in three independent populations105–107, but also resulted in increased risk for 
osteoporosis208–210 and lumbar disc disease211,212. These findings suggest that both the alternative 
alleles within a gene can be associated with increased risk of different multifactorial disorders. 
 
The third finding of this study was the additive contribution of the AGGG allele of the COL5A1 -
/AGGG polymorphism, together with the TCT inferred pseudohaplotype of the COL11A1 and 
COL11A2 genes, to an increased risk of AT. This gene-gene association is perhaps not surprising 
taking into account the mounting evidence that the structural and functional homology between the 
α1(XI) and α1(V) chains encoded by COL11A1 and COL5A1 respectively, facilitate an 
interchangeability between the two polypeptides, resulting in heterotrimer [α1(XI)2α2(V)] 
formation147–149,194. It is possible that the reported interaction in this study between the COL5A1 and 
COL11A1 polymorphisms indicate the role of a minor fibrillar collagen consisting of type V/XI α-
chains in tendinopathy. Alternatively the traditional type XI collagen heterotrimer may be able to 
functionally replace or compensate for type V collagen in tendons. The possible role of type XI 
collagen in pathology of the mature tendon needs to be investigated. 
 
As previously mentioned, the rapidly degraded T-allele of COL11A1 rs1676486 was more common in 
the asymptomatic control population, and the wild-type, more stable C-allele was more common in 
the tendinopathic population. AT has been associated with increased COL5A1 mRNA stability118 and 













interaction between this allele and COL5A1 is due to the effect they have on (i) mRNA stability, (ii) 
potential effects on type V and XI protein levels, (iii) their subsequent effects on collagen fibril 
diameter and (iv) altered biomechanical properties of the collagen fibril at the tissue level. It is 
therefore reasonable to conceive that individuals who have these functional alleles as reflected from 
the pseudohaplotypes could possibly be producing a functionally altered type XI and type V collagen, 
which collectively are responsible for the altered biomechanical property of the tendon collagen 
fibrils.  
 
As previously mentioned, although type XI collagen is classified as a cartilage protein, it is produced 
in the developing tendon28,48,145,146. To our knowledge there is no evidence that the protein is 
produced in mature tendons. It is therefore possible that the proposed biological consequences of 
the reported association in this study could be due to altered protein profiling in: (i) the mature, 
diseased and/or healing tendon, (ii) the fibrocartilaginous regions of the mature tendon and (iii) 
tendon development. Irrespective of the mechanism(s), further research is required to replicate 
these findings in larger independent populations and to explore the functional mechanisms 
underlying the complex genetic associations with the type XI collagen encoding genes and their 
interactions with the type V collagen encoding gene.  
 
In conclusion, the functional variants within the type XI collagen genes investigated in this study 
were not independently associated with AT. This study does however provide evidence suggesting 
that the genes that encode for the structural and functionally related type XI (COL11A1 and 
COL11A2) and type V (COL5A1) collagen interact with one another to collectively modulate the risk 
for AT. Although expressed in the developing tendon, the role of type XI collagen in the pathology of 














Chapter 5: Conclusions 
Both ACL rupture and AT are multifactorial conditions that result from the complex interaction of
intrinsic and extrinsic risk factors2. Recently, genetic factors have been identified as important
intrinsic risk factors in both these conditions90,92,93. However, the two conditions differ in their
aetiology: ACL rupture is an acute injury that results from the sudden application of excessive
internal or external forces that exceed the strength of the tissue75,153,189; while AT is a largely
degenerative condition that results from overuse with a failure of the tendon to repair and
adapt14,15,77,78,200,203. Because the aetiology of these conditions differ, it is likely that the molecular
mechanisms that underlie these conditions also differ and the genetic variants that predispose to
these conditions may therefore be unique. However, as the molecular components and structure of
ligaments and tendons are very similar, genetic variants that affect these structures, and therefore
the integrity of these tissues, are more likely to be implicated in both. Thus, investigating the genes
that are important molecular or regulatory components of both ligaments and tendons might
identify genetic variants that predispose individuals to both ACL ruptures and AT. Moreover, this
molecular approach may also identify the similarities nd differences in the aetiology of ACL
ruptures and AT. 
The CC genotype of the rs12722 (C/T) polymorphism in the COL5A1 3’-UTR was previously associated
with reduced risk of AT101,102 and reduced risk of ACL ruptures in females 103. Subsequently, three
polymorphisms, namely rs71746744 (-/AGGG), rs16399 (ATCT/-) and rs1134170 (A/T), also within
the COL5A1 3’-UTR, have independently been associated with AT104. Specifically the AGGG/AGGG, -/-
and TT genotypes of these three polymorphisms were associated with increased risk of AT104. 
Furthermore, the COL5A1 3′ -UTR contains several putative cis-acting elements including a
functional Hsa-miR-608 binding site 102,104. Two forms of the mature Hsa-miR-608, which are
produced from the polymorphic (rs4919510, C/G) SNP in the MIR608 gene on chromosome 10q24, 
can potentially bind this miRNA binding site104. Recently the CC genotype of MIR608 rs4919510 was
shown to be associated with increased risk of AT104. Therefore, the first objective of this dissertation
was to determine whether the rs71746744 (-/AGGG) and rs1134170 (A/T) polymorphisms in the
COL5A1 gene and the rs4919510 (C/G) polymorphism in the MIR608 gene were associated with ACL
rupture in a South African Caucasian study sample (Chapter 2).
The COL5A1 gene codes for a component of type V collagen; a protein that regulates the fibril 
diameter and density of collagen fibrils in a number of connective tissues including tendon19–













and inversely associated with elasticity (Chapter 1, Section 1.4). Type XI collagen is involved in a 
similar biological process and shares functional homology with type V collagen28. Type XI collagen is 
expressed in developing tendons48,145,146 and is encoded by the COL11A1, COL11A2 and COL2A1 
genes. These genes are also implicated in several musculoskeletal disorders that affect connective 
tissue structure and biomechanical properties121,123,146,192,193,214. Since the COL11A1 and COL11A2 
genes have not previously been investigated for an association with acute ACL ruptures and/or AT, 
the second (Chapter 3) and third (Chapter 4) objectives were therefore to determine whether the 
rs3753841 and rs1676486 polymorphisms in the COL11A1 gene, and the rs1799907 polymorphism in 
the COL11A2 gene are associated with ACL rupture (Chapter 3) or AT (Chapter 4) in a Caucasian 
population. A secondary aim of these studies was to determine whether these specific COL11A1 and 
COL11A2 polymorphisms collectively interact with the rs71746744 polymorphism in the COL5A1 
gene to modulate the risk of sustaining an ACL rupture (Chapter 3) or AT injury (Chapter 4).  
5.1 Novel Findings of this Dissertation 
This dissertation identified the following significant associations: 
 None of the COL5A1 (rs71746744 and rs1134170) and MIR608 (rs4919510) polymorphisms 
investigated in this dissertation were independently associated with ACL rupture risk. A novel 
finding of this dissertation was that the inferred -/A haplotype constructed from the COL5A1 3’-
UTR rs71746744 (-/AGGG) and rs1134170 (A/T) polymorphisms was however significantly under-
represented in all ACL participants (25.1%, p<0.001) and in the male (25.0%, p=0.001) ACL 
rupture group compared to their respective control groups (all 27.9%, male 27.6%). This 
suggests a “weak” protective effect of these variants against ACL rupture (Chapter 2). Although 
the female frequency distribution was similar to that of the combined male and female and male 
only groups, it was not significant due to its small sample size. The significantly associated 
inferred pseudohaplotypes constructed from the two COL5A1 polymorphisms and the MIR608 
rs4919510 (C/G) polymorphism were difficult to interpret. Additional work with larger samples 
sizes is required to investigate these interactions.  
 
 The TC genotype of the COL11A1 rs3753841 polymorphism was significantly under-represented 
within the ACL (41.4%) rupture group, compared to the CON (54.2%) group (p=0.009, OR=1.6, 
95% CI=1.1 to 2.5) (Chapter 3), suggesting that this genotype is protective. The biological 
mechanism of this protection is unknown. None of the other type XI collagen gene 
polymorphisms, COL11A1 rs1676486 and COL11A2 rs1799907, were independently associated 













COL11A1 CT haplotype constructed from rs3753841 and rs1676486 was significantly under-
represented (p=0.044) in the ACL group (17.4%) compared to the CON group (21.3%), suggesting 
a protective effect. In addition, the inferred CTA pseudohaplotype constructed from the two 
COL11A1 polymorphisms and COL11A2 rs1799907 (A/T) was also significantly under-represented 
(p=0.010) in the ACL group (9.5%) compared to the CON (14.7%) group, suggesting a protective 
effect against ACL rupture (Chapter 3). 
 
 The major novel finding of this dissertation was that the TCT inferred pseudohaplotype 
constructed from COL11A1 rs3753841, COL11A1 rs1676486 and COL11A2 rs1799907 was 
significantly over-represented (p=0.006) in the TEN (25.9%) group compared to the CON (17.1%) 
group. The TCT(AGGG) inferred pseudohaplotype constructed using these type XI collagen 
polymorphisms and the functional COL5A1 rs71746744 (-/AGGG) polymorphism was also 
significantly over-represented (p<0.001) in the TEN (25.2%) group compared to the CON (9.1%) 
group, suggesting a “strong” effect (Chapter 4). In addition, the CTA(-) haplotype was 
significantly over-represented (p=0.037) in the CON (5.3%) compared to the TEN (2.2%) group. 
 
In summary, five of the six polymorphisms investigated in this study were implicated in modulating 
the risk of ACL ruptures; either through an independent association (COL11A1 rs3753841) and/or an 
inferred haplotype or pseudohaplotype (COL5A1 rs71746744, COL5A1 rs1134170, COL11A1 
rs1676486 and COL11A2 rs1799907) association. Furthermore, all three polymorphisms investigated 
in the AT study (COL11A1 rs3753841, COL11A1 rs1676486 and COL11A2 rs1799907) were implicated 
in modulating the risk of AT through an inferred pseudohaplotype association. The COL5A1 
rs71746744, COL5A1 rs1134170 and MIR608 rs4919510 polymorphisms have previously been 
implicated in the risk of AT104. There was consistency and agreement (Table 5.1) between the 
genotype and/or alleles associated with risk of both ACL rupture and AT. This dissertation therefore 
highlights similarities in the aetiology of acute ACL ruptures and AT. The potential biological 














Table 5.1 A Summary of reported findings of the COL5A1, MIR608, COL11A1 and COL11A2 
polymorphisms implicated in the risk of ACL rupture and Achilles tendinopathy 
 ACL Rupture Achilles tendinopathy 
 Protection Protection Risk 
COL5A1 rs71746744 (-/AGGG) - allele - allele AGGG/AGGG genotype 1 
COL5A1 rs1134170 (A/T) A allele  TT genotype 1 
MIR608 rs4919510 (C/G) Not associated  CC genotype 1 
COL11A1 rs3753841 (C/T) 
CT genotype 
C allele 
C allele T allele 
COL11A1 rs1676486 (T/C) T allele T allele C allele 
COL11A2 rs1799907 (A/T) A allele A allele T allele 
1
 Abrahams, Y., Laguette, M.-J., Prince, S. and Collins, M. (2013), Polymorphisms within theCOL5A1 3′ -UTR that 
alters mRNA Structure and the MIR608 Gene are associated with Achilles Tendinopathy. Annals of Human 
Genetics. doi:10.1111/ahg.12013 
 
5.2 Potential Biological Significance of the COL5A1, COL11A1 and COL11A2 
Associations and Interactions 
5.2.1 COL5A1 
This dissertation investigated the COL5A1 rs71746744 (-/AGGG) and rs1134170 (A/T) polymorphisms 
for an association with ACL rupture (Chapter 2). As previously mentioned (Section 1.6.1), the COL5A1 
gene encodes the α1 chain of type V collagen, a minor fibrillar collagen that is vital for nucleation of 
collagen fibrils and the regulation of collagen fibril diameter23,26. With the exception of Ehlers Danlos 
syndrome, where a 50% reduction in the production of type V collagen causes the production of 
large irregular cauliflower shaped fibrils with reduced tensile strength21, the greater the 
concentration of type V collagen in a tissue, the smaller the collagen fibril diameter23,26, and smaller 
diameter collagen fibrils are associated with lower tensile strength73. Thus polymorphisms which 
alter the amount of type V collagen produced will alter the structure of the collagen fibrils, with 
consequent effects on the biomechanical properties of the tissue110,215.  
 
As previously discussed, the common rs12722 (C/T) SNP in the COL5A1 3’-UTR has previously been 
associated with AT101,102 and ACL rupture in females103. It has also been associated with ROM115,116, 
general joint laxity and knee hyperextension (genu recuvarum)190, and endurance running 
performance117; suggesting a role for this region in multiple sports injury and exercise-related 













rs13946 (C/T), rs12722 (C/T), rs3196378 (C/A), rs71746744 (del/AGGG), rs16399 (ACTC/del), 
rs1134170 (A/T) and rs3128575 (T/C). Two allelic forms of the COL5A1 3-UTR have been identified: 
the C form, which corresponds to the wild-type sequence, was identified in most of the clones 
generated from asymptomatic controls, and contains the polymorphisms in the sequence C-C-C-
(AGGG)1-(ATCT)2-A-T, while the T form was the predominant form identified in the AT patients, and 
contains the polymorphisms in the sequence T-T-A-(AGGG)2-(ATCT)1-T-C
118. The T-form was found to 
have increased mRNA stability compared to the C-form118 and the AGGG/AGGG, del/del and TT 
genotypes of rs71746744, rs16399 and rs1134170 respectively, were each independently associated 
with AT in a South African and Australian study population104. 
 
When two of these COL5A1 3’-UTR variants, rs71746744 (del/AGGG) and rs1134170 (A/T) were 
investigated, neither of the polymorphisms were independently associated with ACL rupture 
(Chapter 2). It is probable that the hypothesised association of these variants with ACL ruptures in 
females could not be determined due to the small sample size of the female participants and the 
relatively high frequency of the proposed associated alleles of these polymorphisms (rs71746744 
AGGG, 0.71; rs1134170 T, 0.72). The previous association of the rs12722 SNP with female ACL 
ruptures103 was more informative in a smaller sample size due to the relatively low frequency (0.43) 
of the minor C allele. Further work with a larger sample size is thus required to test the association 
of these polymorphisms with ACL rupture in females. In agreement with the previously published 
study of the rs12722 SNP and ACL rupture, these additional 3’-UTR polymorphisms were not 
associated with ACL ruptures in males103.  
However, in agreement with the hypothesis, when inferred haplotypes were constructed from these 
two COL5A1 3’-UTR polymorphisms, the -/A haplotype was under-represented in the combined and 
male ACL rupture groups compared to their respective control groups. Although not significant due 
to a small sample size, the inferred haplotype distributions were similar in the females. The finding 
that males with the COL5A1 -/A haplotype were protected from ACL rupture is a novel finding, as a 
previous study on the COL5A1 rs12722 SNP found no association in males103. This is however not 
surprising as haplotype analyses potentially have a greater power to statistically implicate a genetic 
interval in an association study compared to the power of individual polymorphisms at the same 
loci216,217. This dissertation is therefore the first to suggest that COL5A1 may be a ‘weak’ modulator 
of ACL rupture risk in males. This would be in agreement with the proposed function of the COL5A1 
3’-UTR polymorphisms on injury risk discussed in the next paragraph. Further work is however 












A molecular mechanism for the role of the COL5A1 3’-UTR polymorphisms on injury risk has been 
proposed (Figure 5.1). Polymorphisms such rs71746744 and rs1134170 in the COL5A1 3’-UTR (and 
others) collectively determine the secondary structure of the COL5A1 3’UTR mRNA transcript. The 
different combinations result in two allelic forms with gross structural differences that are thought 
to influence the stability of the mRNA transcript by altering a miRNA binding site or some other 
mRNA stability protein104. 
Figure 5.1 A hypothetical schematic diagram illustrating the proposed mechanism of how polymorphisms 
within the COL5A1 3’-UTR potentially affect fibrillogenesis in the anterior cruciate ligament (ACL). (1) The 
COL5A1 rs71746744 (-/AGGG) and COL5A1 rs1134170 (A/T) polymorphisms are part of an inferred haplotype 
that is associated with ACL rupture. (2) The COL5A1 rs71746744 (-) allele and the COL5A1 rs1134170 A allele 
are both believed to associated with increased mRNA degradation, due to changes in the secondary structure 
of the mRNA. Increased mRNA degradation is indicated in the left panel, while decreased mRNA degradation is 
indicated in the right panel. (3) The altered mRNA stability associated with these polymorphisms is believed to 
result in altered α1(V) chain and type V collagen production (decreased in left panel and increased in the right 
panel). (4) Types V collagen regulates collagen fibril assembly and diameter (fibrillogenesis) and thus the 
mechanical properties of ligaments. (5) There is an inverse relationship between the types V collagen content 
of the fibril and its diameter. Thinner more densely packed collagen fibrils are produced due to the increased 
production of types V collagen by the more stable AGGG/T inferred haplotype (Right Panel). Figure modified 
from Ribbans, W. J., and M. Collins. (2013)Pathology of the tendo Achillis: Do our genes contribute?, The bone 















It is hypothesised that the -/A haplotype has lower mRNA stability than the AGGG/T haplotype. The 
decreased mRNA stability of the -/A haplotype is predicted to decrease the rate of protein 
translation, resulting in decreased concentrations of type V collagen. Decreased type V collagen 
production would subsequently affect collagen fibril diameter, creating larger collagen fibrils with 
increased tensile strength and decreased elasticity. The increased tensile strength of the collagen 
fibrils, coupled with the decreased joint flexibility may protect against rupture of the ACL.  
5.2.2 MIR608 
Hsa-miR-608 was shown to bind to the COL5A1 3’-UTR and the CC genotype of the rs4919510 (C/G) 
SNP within the MIR608 gene was shown to independently associate with risk of AT104. Therefore the 
rs4919510 (C/G) polymorphism in the MIR608 gene was also investigated for interactions with the 
COL5A1 SNPs. The MIR608 rs4919510 SNP was not independently associated with ACL rupture, 
however the AGGG/T/C combination of COL5A1 rs71746744 (-/AGGG), rs1134170 (A/T) and MIR608 
rs4919510 (C/G) was over-represented in the female ACL group compared to the CON group, which 
is consistent for the risk alleles in AT104. Other inferred pseudohaplotypes which do not fit into our 
current working hypothesis were also identified. These could be a type I error due to the small 
female sample size. Additional work is required to investigate these polymorphisms in larger sample 
sizes. 
5.2.3 COL11A1 and COL11A2 
Polymorphisms in the COL11A1 and COL11A2 genes were investigated for associations with risk of 
developing ACL rupture (Chapter 3) and AT (Chapter 4). As previously mentioned in Section 1.6.2, 
type XI collagen is a qua titatively minor fibrillar collagen comprising three polypeptide chains, 
α1(XI), α2(XI) and α1(II), encoded by the COL11A1, COL11A2 and COL2A1 genes respectively. Type XI 
collagen plays a similar role to type V collagen in tendons and ligaments, in that it regulates collagen 
fibril diameter in cartilage43, which mostly consists of type II collagen29. Despite the fact that type XI 
plays a similar role to type V collagen in regulating collagen fibril diameter28, and is expressed in 
developing tendon48,145,146,213, this is the first study to our knowledge that investigated the COL11A1 
and COL11A2 for associations with tendon or ligament injuries.  
Similar to the findings noted for the COL5A1 polymorphism analyses conducted in Chapter 2, the 
COL11A1 and COL11A2 SNPs were not independently associated with ACL rupture risk. However, 
when inferred haplotypes or inferred pseudohaplotypes were constructed, the C, T and A alleles of 













against ACL rupture, and the complementary T, C and T alleles were associated with risk of AT. This 
finding suggests a common molecular mechanism is involved in both AT and ACL rupture. 
The ancestral allele of the rs3753841 (T/C) polymorphism in exon 52 of the COL11A1 gene is a 
cytosine (C) nucleotide; however the major allele (highest frequency) in the Caucasian populations is 
a thymine (T) nucleotide. The notation for polymorphisms investigated in this dissertation has been 
(major allele/minor allele). The change from the ancestral C allele to the T allele results in an amino 
acid change from a proline (codon: CCT) to a leucine (codon: CTT) at position 1323; a substitution 
that has been predicted to be deleterious by SIFT (Sorting Intolerant From Tolerant)218. The SIFT 
algorithm assesses the effects of single amino acid changes on protein function based on the 
assumption that sequence homology will be conserved for important amino acid positions218. The 
ancestral (or minor) C-allele has previously been associated with LDH129; however in this dissertation 
the major T allele, which corresponds to the deleterious amino acid change, was associated with risk 
for AT and the C allele was associated with protection from ACL rupture. The deleterious T allele may 
increase risk via changes in the structure of the α1(XI) chain, which may affect the assembly of the 
type XI collagen trimer, or alternatively may affect the ability of the type XI molecule to interact with 
other collagens or ECM components. Further work is however required to investigate this 
hypothesis.  
The rs1676486 (C/T) polymorphism in exon 62 results in a non-synonymous amino acid change from 
a proline (codon: CCT) to a serine (codon: TCT) at position 1535. The P1535S occurs very near to a 
predicted disulphide bond at position 1532129 and could potentially lead to a conformational change 
in the protein. Further work is however required to investigate any functional consequences of this 
amino acid substitution. The T-allele of this variant has been associated with LDH129 and limbus 
vertebra in gymnasts130.  
The TC haplotype of rs3753841 and rs1676486 was associated with AT risk and the CT haplotype was 
associated with protection from ACL rupture. The haplotypes were therefore more informative in 
capturing the ACL risk profile than either of the individual polymorphisms. As previously mentioned 
in Chapter 3 (Section 3.4) and Chapter 4 (Section 4.4), this haplotype association could be due to a 
cumulative effect of the two non-synonymous amino acid changes on protein folding or on the 
ability of the α1(XI) chain to form the type XI collagen trimer or interact with other collagens or ECM 
molecules. This genetic interval defined by the associated haplotype therefore requires further 
exploration to identify the risk associated sequence motif within this gene region so that one can 













Intriguingly, while the minor C allele of COL11A1 rs3753841 and the minor T allele of COL11A1 
rs1676486 were over-represented in patients with LDH, the current study implicated the alternate 
alleles in the risk-associated pseudohaplotype. Similarly, the functional rare TT genotype of the 
COL1A1 Sp1 binding site polymorphism was reported to be associated with risk for several 
multifactorial disorders, including osteoporosis208–210,212 and lumber disc disease211,212, but was 
associated with protection against ACL ruptures in three independent populations105–107. These 
findings suggest that both the alternative alleles within a gene can be associated with increased risk 
of different multifactorial disorders.  
Although both COL11A1 polymorphisms cause amino acid substitutions, as mentioned in Chapter 3 
and 4, the effect of the COL11A1 rs1676486 SNP may be due to quantitative rather than qualitative 
differences in type XI collagen. The T allele of rs1676486 was shown to produce unstable COL11A1 
mRNA transcripts that are degraded faster than the C allele129. It has been hypothesised that the 
4856–4865 nucleotides (caaaaaatct) in COL11A1 mRNA closely match the consensus for a mRNA 
stability motif, “g/tanaaaag/tcc/t” approximately 200 bp away129. The sequence variation may 
therefore affect the mRNA stability motif and disrupt the cis- lement critical for mRNA stability. 
Alternatively, the sequence variation might induce a conformational change in the mRNA that could 
decrease mRNA stability or increase the sensitivity of the transcript to RNases129.  
 
There is some evidence that the change in mRNA stability caused by the rs1676486 SNP does affect 
protein levels129. In a study on LDH, the less stable rs1676486 T allele was associated with increased 
risk, and although protein levels were not measured in the study, there was an inverse relationship 
between COL11A1 expression and severity of disc degeneration. This led the authors to hypothesise 
that the decrease in the COL11A1 transcript associated with the T-allele led to the decrease in type 
XI collagen protein levels 129.  
 
Moreover, since the C allele of rs1676486 was associated with AT, this suggests that increased type 
XI collagen levels are associated with increased injury risk. This is comparable to the proposed 
mechanisms of increased COL5A1 mRNA stability leading to increased type V collagen and increased 
risk of AT (Figure 5.1). This will be further explored in the section on interactions between COL5A1 
and COL11A1.  
 
The COL11A2 rs1799907 (A/T) SNP occurs in intron 5, and results in alternative splicing of the 
COL11A2 gene, resulting in protein products of slightly different length137. The T allele of COL11A2 













(Chapter 4), and the A-allele was associated protection from ACL rupture when combined with the 
CT haplotype of COL11A1 (Chapter 3). In contrast to the investigated COL11A1 SNPs, where the risk 
and protection alleles were reversed compared to previous studies129,130, the association of the T 
allele of COL11A2 rs1799907 with risk agrees with previous studies that associated the T allele with 
lumbar disc desiccation128, lumbar spine stenosis141 and OPLL136–139.  
The rs1799907 polymorphism may exert its physiological effect via the alteration it causes in the 
highly acidic variable domain encoded by exons 6-8 at the amino terminal of the α2(XI) chain137. This 
variable region provides potential sites for the interaction of type XI collagen with other molecules 
and may prevent further deposition of collagen fibrils145. Exon 7, which is often skipped in the T 
allele, and included in the A allele, contains 8 acidic residues of the 21 amino acids, none of which 
are basic, suggesting that this region in particular is involved in cross-linking to each other or other 
molecules137. Therefore the A allele may exert is protective effect because it is better able to interact 
with components of the ECM.  
An explanation for how the T allele of rs1799907 interacts with the T or C allele of rs3753841 or 
rs1676486 is not known, but the missing exons could potentially alter the way that the type XI 
collagen fibril forms, and the amino acid substitutions could have small effects on the proα(XI) chain. 
In the conventional type XI isoform, [α1(XI) α2(XI) α1(II)], the α1(XI) and α2(XI) chains combine in a 
1:1 ratio. It is possible that the alternatively spliced variant from either the A or the T allele of 
rs1799907 interacts better with either the C or T allele of rs3753841.  
The significant associations of the COL11A1 and COL11A2 inferred haplotypes and pseudohaplotypes 
with AT and ACL rupture risk suggest that type XI collagen plays a role in the aetiology of both 
conditions. It is therefore reasonable to hypothesise that the associated pseudohaplotype has a 
biological consequence. It should be noted that the observed statistical association was greater in 
the AT study than ACL rupture investigation. Both COL11A1 and COL11A2 are expressed in the 
developing tendon48,145,146, however, further research is required to determine the functional 
significance of these type XI collagen gene polymorphisms in mature tendon and ligament, as this 
will facilitate our understanding of their biological significance in tendinopathy and ligament rupture 
injuries. 
5.2.4 COL5A1, COL11A1 and COL11A2 
Many biological systems have built-in redundancy whereby two or more genes perform the same or 
similar functions, and inactivation of one of these genes has little or no effect on the biological 













function of regulating collagen fibril diameter28. In addition, type V and type XI collagens are 
regulated in a similar manner194 and can form type V/XI heterotimers28,147–149,214.  
Recently, phenotypic evidence for biological redundancy between type V and type XI collagen in the 
development of certain tissues was suggested146,214. A study on developing tendon in mice revealed 
that the COL11A1 gene can compensate for COL5A1 haploinsufficiency146. Deletion of the COL11A1 
gene in addition to COL5A1 +/- haploinsufficiency resulted in a far more severe phenotype, with 
larger, more irregularly shaped fibrils and lower tensile strength, than that of the COL5A1+/- knock-
out mice alone. Thus, the COL5A1 +/- haplotype was most severe when compensation by COL11A1 
was prevented. The COL11A1 gene can therefore functionally “replace” the COL5A1 gene functions 
in certain circumstances.  
 
A second example of biological redundancy between type V and XI collagens comes from a study on 
cho mice which harbour a deletion of the COL11A1 gene220. Fernandes et al (2007) showed that lack 
of the α1(XI) chain, which is vital to the formation of type XI collagen, did not result in a total lack of 
fibril formation214. Rather, in the absence of α1(XI) chains, the cho mice synthesized alternate type XI 
chain assemblies consisting of α1(V)α2(XI)α1(II)214. The ability of the α1(V) chain to ‘stand in’ for the 
α1(XI) chain in cho mice is further evidence of biological redundancy between the COL5A1 and 
COL11A1 genes.  
Because the proα1(XI) and proα1(V) chains of type V and type XI collagen may be interchangeable, 
the previous association of the COL5A1 gene with AT101,102 served as a major motivation for 
investigating the COL11A1 gene. An aim of this dissertation was therefore to investigate if there was 
any modulating effect between these two type XI collagen genes on injury risk; and in particular, to 
identify if there was a y potential interactions between the previously associated COL5A1 
polymorphisms and the newly investigated COL11A1 and COL11A2 SNPs on injury risk. 
In ACL rupture, the interactions between COL11A1 rs3753841, rs1676486, and COL11A2 rs1799907 
and COL5A1 rs71746744 did not make biological sense. However, based on previous work103, the 
COL5A1 rs71746744 was proposed to be associated with ACL rupture in females (Chapter 2). The 
results from this dissertation also suggested that the COL5A1 3’-UTR variants may “weakly” 
modulate the risk of ACL ruptures in males. Larger sample sizes are therefore required to investigate 
type XI collagen polymorphism interactions with COL5A1 3’-UTR polymorphisms in modulating risk 












In AT however, the combination of the AGGG allele of rs71746744 and the TCT inferred 
pseudohaplotype constructed from COL11A1 rs3753841, rs1676486 and COL11A2 rs1799907 was 
“strongly” associated with increased risk of injury. The possible biological significance of this 
combination of alleles will be discussed in greater detail, together with the development of a model 
and hypothesis in Section 5.3.  
5.3 An Interaction Between Type V/XI Collagen, Collagen Fibril Diameter and 
Musculoskeletal Soft Tissue Injuries: A Hypothesis 
Recently, Collins and Posthumus proposed a novel hypothesis for how the COL5A1 gene may be
associated with musculoskeletal injuries and exercise-related phenotypes via alterations in
architecture of collagen fibrils with consequent effects on the fibril’s biomechanical properties110. 
Genetic variants in the COL5A1 3’-UTR are thought to alter the mRNA stability of COL5A1 , changing
the amount of transcript available to be translated into protein110. The α1(V) chain of type V collagen
is the rate-limiting step of type V collagen synthesis, and therefore an increase in the α1(V) chain
may result in an increase in type V collagen. The increase in type V collagen may result in smaller
diameter fibrils23,26. 
This dissertation adds to this model (Figure 5.2). As previously mentioned, the rapidly degraded
mRNA produced from the T allele of COL11A1 rs1676486 was more common in the asymptomatic
control population, and the wild-type, more stable mRNA produced from the C allele was more
common in the tendinopathic population. Thus we speculate that the rs1676486 C allele results in
higher expression of α1(XI), resulting in smaller, more densely packed fibrils when combined with 
the stable T-allelic form of COL5A1 (containing rs71746744 AGGG). Taking this into account, when
the COL5A1 AGGG and COL11A1 C risk associated alleles are inherited together, they potentially
result in a synergistic effect on total risk. We hypothesise that the more stable mRNA transcripts
may result in greater translation, higher protein levels and smaller diameter collagen fibrils, which
will consequently alter the biomechanical properties of the tendon and ligament tissue. It is also
tempting to speculate further from this model, that the rapidly degraded mRNA from the COL11A1
rs1676486 T allele is able to attenuate the effect of the more stable mRNA from the COL5A1 T-form,














It is possible that the reported interaction in this study between the COL5A1 and COL11A1 
polymorphisms indicate the role of a minor fibrillar collagen consisting of type V/XI α-chains in 
tendinopathy. Alternatively the traditional type XI collagen heterotrimer may be able to functionally 






Figure 5.2 A hypothetical schematic diagram illustrating the proposed mechanism of how polymorphisms 
within COL5A1 and COL11A1 potentially affect fibrillogenesis. (A) The COL5A1 rs71746744 (-/AGGG) and 
COL11A1 rs1676486 (C/T) polymorphisms are part of an inferred pseudohaplotype that is associated with AT. 
The COL5A1 rs71746744 (-) allele and the COL11A1 rs1676486 T allele are both believed to associated with 
increased mRNA degradation. Increased mRNA degradation is indicated in the left panel, while decreased 
mRNA degradation is indicated in the right panel. (B) The altered mRNA stability associated with these 
polymorphisms is believed to result in altered α1(V) and α1(XI) chain and types V and XI collagen production 
(decreased in left panel and increased in the right panel). (C) Types V and XI collagen regulates collagen fibril 
assembly and diameter (fibrillogenesis). Thus low concentrations of type V/XI collagen result in large diameter 
fibrils (left panel), and high concentrations results in small diameter fibrils (right panel). (D) The diameter and 
packing density of the collagen fibrils ultimately affect the mechanical properties of tendons. Therefore larger 
diameter fibrils have greater tensile strength and reduced elasticity (left panel), while small diameter fibrils 













An assumption of this model is that type V and type XI collagen are both expressed and able to 
interact in tendon and ligament tissue. As previously mentioned type XI is produced in the 
developing tendon11 12, however to our knowledge there is no evidence that the protein is produced 
in mature tendons. The proposed biological consequences of the reported association in this study 
could thus be the result of its expression and function during tendon development. Alternatively, 
this association may be due to altered protein profiling in (i) the expression of type XI collagen in the 
mature, diseased and/or healing tendon, or (ii) its expression only in the fibrocartilaginous regions of 
the mature tendon. Both of these alternatives should be further investigated by determining the 
levels of type XI or type V/XI heterotrimers in healthy and diseased mature tendon as well as in the 
midsubstance and insertion regions. 
 
In summary, the association of these allele combinations with musculoskeletal injury risk may be the 
biological consequence of their cumulative effect on mRNA stability, with potential effects on 
protein levels and collagen fibril diameter. Collagen fibril diameter will ultimately affect the 
mechanical properties of the tissue and hence influence an individual’s risk of sustaining a potential 
injury. 
5.4 Limitations 
The sample sizes of the groups within this dissertation were not sufficiently powered to detect small 
genetic effects, the female ACL rupture group in particular. Rather, the studies were powered to 
detect relatively large genetic effects of 1.5-1.7. This was a limitation, as polygenic multifactorial 
conditions such as ACL rupture and AT are generally caused by numerous variants, many with a small 
effect size94,221,222. However, this sample size was previously more than adequate to identify the 
independent association of several polymorphisms with musculoskeletal soft tissue injuries101–104. 
Many of the genes, such as COL11A1 and COL11A2, which are hypothesised to modulate or interact 
with previously strongly associated variants, such as COL5A1 3’-UTR polymorphisms, probably have a 
small effect size, and therefore much larger sample sizes would be needed in order to increase the 
power of future studies.  
Departure from HWE was present in the ACL and AT cohorts. As previously discussed, this may be 
due to the sample sizes being too small; however it may also be a sign that the sample does not 
represent a random mating population185. Since the cases for ACL rupture and AT were selected 
based on their clinical diagnosis, the departure may also be a true reflection of a difference in 













 Achilles Tendinopathy Cohort 
Although an effort was made to match the AUS and SA Achilles tendinopathy and control 
participants, this was not always possible. The SA cohort, consisting of SA TEN and SA CON groups, 
all completed physical activity questionnaires, and were grouped for similar levels of activity 100,101. 
The physical activity of the AUS CON and AUS TEN groups was unfortunately not captured, and 
therefore activity between the groups cannot be quantitatively compared. Care was taken however 
to recruit physically active individuals in both populations, and repeatable results were obtained 
between the two cohorts.  
There are several pathologies that affect the Achilles tendon and surrounding tissues76; however this 
study included only those participants that had been diagnosed with chronic Achilles tendinopathy. 
Diagnosis was made using clinical criteria and/or soft-tissue ultrasound as previously described 
101,102. The majority of participants injured the mid-portion of their tendon; however a portion of the 
participants were injured at the insertion site. Although care was taken to only include participants 
with a well-defined Achilles tendon injury101,102, we cannot exclude the possibility that the TEN group 
represented a number of related, but similar, pathologies; and it is possible that these different 
tendinopathies differ slightly in their genetic predisposition. However, the genetic associations 
reported in this study would most likely be strengthened if participants with a similar pathology with 
a different aetiology were excluded.  
Since type XI collagen is expressed mainly in the OTJ, the investigated SNPs may have a stronger 
association with insertional Achilles tendinopathy than midsubstance injury and are ideal candidates 
for investigating this subset of Achilles tendon injuries. Similarly, type XI collagen polymorphisms 
would make ideal candidates for association studies of other tendon pathologies, such as patellar 
tendinopathy, which is characterized by degeneration at the bone-tendon interface where type XI 
collagen is more likely to be expressed223.  
Another limitation is that the TEN and CON participants differed in several other potentially 
contributing physical characteristics. The TEN group for both the SA and AUS cohorts were 
significantly heavier than the CON participants and excess weight has previously been implicated in 
the development of AT224. Future studies should accurately document weight at injury, since many of 















 Anterior Cruciate Ligament Cohort 
In the ACL cohorts, it was difficult to recruit a large sample of female cases, even though the 
condition is more likely to affect females103,108. Many previous studies on ACL rupture risk have 
mainly identified significant genetic associations, specifically with COL5A1, in the female 
participants103,108. Therefore a larger sample of female participants needs to be recruited in future 
studies to investigate the association of type V and XI collagen genes with ACL rupture.  
5.5 Future Work 
As mentioned throughout this dissertation, the findings of this study could be improved upon by 
increased sample sizes. The barriers to including more participants in this dissertation were purely 
pragmatic: the number of participants was determined by the number of consenting participants 
that could be recruited from collaborating doctors during the time-frame of this dissertation. 
Unfortunately, the more susceptible female ACL rupture group partake in less high-risk sporting 
activities and therefore injure less frequently than males, and are more difficult to recruit.  
However, research into the genetic determinants of musculoskeletal injury is ongoing and the 
intention is to continue recruiting participants in order to detect small genetic effects in the future. 
In order to achieve this, additional collaborations are being made with local doctors and 
international collaborators. Polymorphisms that show the potential to be involved in the aetiology of 
musculoskeletal injury, such as those identified in this dissertation (COL5A1, rs71746744 and 
rs1134170; MIR608, rs4919510; COL11A1, rs3753841 and rs1676486 and COL11A2 rs1799907), will 
be re-analysed in a larger cohort in the future.  
In addition, information was collected on extrinsic risk factors from all recruited participants, and 
that data is captured for future analysis. Unfortunately, at this stage the sample size is still too small 
to study complex interactions. However, it is an aim of the research group to continue to refine our 
understanding of the interactions of extrinsic and intrinsic risk factors in future studies.  
To investigate the hypothesized effects of these polymorphisms on tendon and ligament structure 
and biomechanical properties, imaging work and biomechanical testing should be undertaken. In 
order to overcome the barriers of tendon and ligament heterogeneity and the confounding effects 
of age, physical activity and other extrinsic factors on tissue structure and tensile properties, the 
effect on fibril diameter and biomechanical properties may initially be best determined using a tissue 
engineering approach, in which the effect of polymorphisms of interest on fibril diameter and 












This dissertation has also revealed that COL11A1 and COL11A2 may play a far more important role in 
tendons and ligaments than previously suspected. The presence of type XI collagen as well as the 
proportions and combinations of type V and type XI collagen chains should therefore be 
investigated. The analysis many involve a combination of molecular biology techniques such as qRT-
PCR to detect gene expression, Western Blot analysis to detect the presence and proportions of the 
different type V and type XI α-chains and in situ hybridization and immunofluorescence microscopy 
to confirm their presence and location in tendons and ligaments.  
5.6 Clinical Significance 
The aetiology of musculoskeletal soft tissue injuries remains unclear, and the molecular mechanisms
that contribute to these conditions are likely to be intricate, involving the cumulative biological
effect of genes in many different biological pathways. 
The clinical significance of the identification of genes that predispose to tendon and ligament injuries
is three-fold: (1) it is valuable to predict in advance whether an individual has an increased risk of
injury as a result of repetitive loading during either sporting or occupational activity; (2)
understanding the molecular mechanism may be useful for determining which therapeutic
interventions may be effective in treatment of the injury, and (3), the genetic risk factors may be
important in defining the prognosis of the injury for the individual102. Therefore, although the
identification of an interaction between the genes encoding the minor type V/XI collagens has no
immediate clinical applications, it is important as it provides additional evidence that inter-individual
variations in collagen fibril assembly might be an important molecular mechanism in the aetiology of
musculoskeletal soft tissue injuries.
5.7 Final Remarks
In conclusion, this dissertation further explored previous findings that implicated the COL5A1 gene in 
musculoskeletal soft tissue injuries. In addition, we found that genetic variants in COL11A1, COL11A2 
and COL5A1 can interact to increase or modulate risk. Because of functional redundancy between 
type V and type XI collagen, it is useful to examine variants in the genes encoding both proteins, as 




























1. Järvinen, T. A., Kannus, P., Paavola, M., Järvinen, T.L., Józsa, L. & Järvinen, M. Achilles tendon 
injuries. Curr. Opin. Rheumatol. 13, 150–155 (2001). 
2. Meeuwisse, W. H. Assessing Causation in Sport Injury: A Multifactorial Model. Clin. J. Sport 
Med. 4, 166–170 (1994). 
3. Collins, M. & Raleigh, S. M. Genetic Risk Factors for Musculoskeletal Soft Tissue Injuries Med. 
Sport Sci. (Collins, M.) 54, 136–149 (KARGER, 2009). 
4. Collins, M. Genetic risk factors for soft-tissue injuries 101: a practical summary to help 
clinicians understand the role of genetics and ‘personalised medicine’. Br. J. Sports Med. 44, 
915–917 (2009). 
5. Ribbans, W. J. & Collins, M. Pathology of the tendo Achillis: Do our genes contribute? Bone Jt. J. 
95-B, 305–313 (2013). 
6. Amis, A. A. & Dawkins, G. P. Functional Anatomy of the Anterior Cruciate Ligament Fibre 
Bundle Actions Related to Ligament Replacements and Injuries. J. Bone Jt. Surg. 73-B, 260–267 
(1991). 
7. Duthon, V. B., Barea, C., Abrassart, S., Fasel, J. H., Fritschy, D., & Ménétrey, J. Anatomy of the 
anterior cruciate ligament. Knee Surg. Sports Traumatol. Arthrosc. 14, 204–213 (2006). 
8. Kannus, P. Structure of the tendon connective tissue. Scand. J. Med. Sci. Sports 10, 312–320 
(2000). 
9. Frank, C. B. Ligament structure, physiology and function. J. Musculoskelet. Neuronal Interact. 4, 
199 (2004). 
10. Kirkendall, D. T. & Garrett, W. E. Function and biomechanics of tendons. Scand. J. Med. Sci. 
Sports 7, 62–66 (1997). 
11. O’Brien, M. Structure and metabolism of tendons. Scand. J. Med. Sci. Sports 7, 55–61 (1997). 
12. Kastelic, J., Galeski, A. & Baer, E. The multicomposite structure of tendon. Connect. Tissue Res. 
6, 11–23 (1978). 
13. Andrades, J. A., Claros, S., -Palomo, P. , J. M., Zamora‐Navas, P., Guerado, 
E., , M., Araque, M. C. & Becerra, J. in Regen. Med. Tissue Eng. - Cells Biomater. 
(Eberli, D.) (2011). ISBN: 978-953-307-663-8, InTech, DOI: 10.5772/20889. at 
http://www.intechopen.com/books/regenerative-medicine-and-tissue-engineering-cells-and-
biomaterials/skeletal-regeneration-by-mesenchymal-stem-cells-what-else 
14. Riley, G. Tendinopathy--from basic science to treatment. Nat. Clin. Pract. Rheumatol. 4, 82–89 
(2008). 














16. Eastwood, M., McGrouther, D. A. & Brown, R. A. Fibroblast responses to mechanical forces. 
Proc. Inst. Mech. Eng. [H] 212, 85–92 (1998). 
17. Kadler, K. E., Baldock, C., Bella, J. & Boot-Handford, R. P. Collagens at a glance. J. Cell Sci. 120, 
1955 –1958 (2007). 
18. Gordon, M. K. & Hahn, R. A. Collagens. Cell Tissue Res. 339, 247–257 (2009). 
19. Wenstrup, R. J., Florer, J. B., Cole, W. G., Willing, M. C. & Birk, D. E. Reduced type I collagen 
utilization: a pathogenic mechanism in COL5A1 haplo-insufficient Ehlers-Danlos syndrome. J. 
Cell. Biochem. 92, 113–124 (2004). 
20. Wenstrup, R. J., Florer, J. B., Brunskill, E. W., Bell, S. M., Chervoneva, I. & Birk, D.E. Type V 
Collagen Controls the Initiation of Collagen Fibril Assembly. J. Biol. Chem. 279, 53331–53337 
(2004). 
21. Wenstrup, R. J. Florer, J. B., Davidson, J. M., Phillips, C. L., Pfeiffer, B.J., Menezes, D. W., 
Chervoneva, I. & Birk, D. E. Murine Model of the Ehlers-Danlos Syndrome: COL5A1 
haploinsufficieny disrupts collagen fibril assembly at multiple stages. J. Biol. Chem. 281, 12888–
12895 (2006). 
22. Fitch, J. M., Gross, J., Mayne, R., Johnson-Wint, B. & Linsenmayer, T. F. Organization of collagen 
types I and V in the embryonic chicken cornea: monoclonal antibody studies. Proc. Natl. Acad. 
Sci. 81, 2791 (1984). 
23. Birk, D. E., Fitch, J. M., Babiarz, J. P., Doane, K. J. & Linsenmayer, T. F. Collagen fibrillogenesis in 
vitro: interaction of types I and V collagen regulates fibril diameter. J. Cell Sci. 95 ( Pt 4), 649–
657 (1990). 
24. Linsenmayer, T. F., Gibney, E., Igoe, F., Gordon, M. K., Fitch, J. M., Fessler, L. I. & Birk, D.E. Type 
V collagen: molecular structure and fibrillar organization of the chicken alpha 1 (V) NH2-
terminal domain, a putative regulator of corneal fibrillogenesis. J. Cell Biol. 121, 1181 (1993). 
25. Marchant, J. K., Hahn, R. A., Linsenmayer, T. F. & Birk, D. E. Reduction of type V collagen using a 
dominant-negative strategy alters the regulation of fibrillogenesis and results in the loss of 
corneal-specific fibril morphology. J. Cell Biol. 135, 1415 (1996). 
26. Birk, D. E. Type V collagen: heterotypic type I/V collagen interactions in the regulation of fibril 
assembly. Micron 32, 223–237 (2001). 
27. Chanut-Delalande, H. Fichard, A., Bernocco, S., Garrone, R., Hulmes, D. J. & Ruggiero, F. Control 
of heterotypic fibril formation by collagen V is determined by chain stoichiometry. J. Biol. 
Chem. 276, 24352 (2001). 
28. Fichard, A., Kleman, J. P. & Ruggiero, F. Another look at collagen V and XI molecules. Matrix 
Biol. J. Int. Soc. Matrix Biol. 14, 515–531 (1995). 
29. Mendler, M., Eich-Bender, S. G., Vaughan, L., Winterhalter, K. H. & Bruckner, P. Cartilage 
contains mixed fibrils of collagen types II, IX, and XI. J. Cell Biol. 108, 191–197 (1989). 
30. Sagarriga Visconti, C., Kavalkovich, K., Wu, J., & Niyibizi, C. Biochemical Analysis of Collagens at 
the Ligament–Bone Interface Reveals Presence of Cartilage-Specific Collagens. Arch. Biochem. 













31. Gelse, K., Pöschl, E. & Aigner, T. Collagens--structure, function, and biosynthesis. Adv. Drug 
Deliv. Rev. 55, 1531–1546 (2003). 
32. Zhang, G., Young, B. B., Ezura, Y., Favata, M., Soslowsky, L.J., Chakravarti, S. & Birk, D. E. 
Development of tendon structure and function: regulation of collagen fibrillogenesis. J 
Musculoskelet Neuronal Interact 5, 5–21 (2005). 
33. Banos, C. C., Thomas, A. H. & Kuo, C. K. Collagen fibrillogenesis in tendon development: 
Current models and regulation of fibril assembly. Birth Defects Res. Part C Embryo Today Rev. 
84, 228–244 (2008). 
34. Engel, J. & Prockop, D. J. The zipper-like folding of collagen triple helices and the effects of 
mutations that disrupt the zipper. Annu. Rev. Biophys. Biophys. Chem. 20, 137–152 (1991). 
35. Doege, K. J. & Fessler, J. H. Folding of carboxyl domain and assembly of procollagen I. J. Biol. 
Chem. 261, 8924–8935 (1986). 
36. Van der Rest, M. & Dublet, B. Type XII and type XIV collagens: interfibrillar constituents of 
dense connective tissues. Semin. Cell Dev. Biol. 7, 639–648 (1996). 
37. Canty, E. G., Lu, Y., Meadows, R. S., Shaw, M. K., Holmes, D. F. & Kadler, K. E. Coalignment of 
plasma membrane channels and protrusions (fibripositors) specifies the parallelism of tendon. 
J. Cell Biol. 165, 553–563 (2004). 
38. Birk, D. E. & Trelstad, R. L. Extracellular compartments in tendon morphogenesis: collagen 
fibril, bundle, and macroaggregate formation. J. Cell Biol. 103, 231–240 (1986). 
39. Kalamajski, S. & Oldberg, Å. The role of small leucine-rich proteoglycans in collagen 
fibrillogenesis. Matrix Biol. 29, 248–253 (2010). 
40. Romanic, A. M., Adachi, E., Kadler, K. E., Hojima, Y. & Prockop, D. J. Copolymerization of 
pNcollagen III and collagen I. pNcollagen III decreases the rate of incorporation of collagen I 
into fibrils, the amount of collagen I incorporated, and the diameter of the fibrils formed. J. 
Biol. Chem. 266, 12703–12709 (1991). 
41. Linsenmayer, T. F., Fitch, J. M., Schmid, T. M. Zak, N. B., Gibney, E., Sanderson, R. D. & Mayne, 
R. Monoclonal antibodies against chicken type V collagen: production, specificity, and use for 
immunocytochemical localization in embryonic cornea and other organs. J. Cell Biol. 96, 124 
(1983). 
42. Holmes, D. F. & Kadler, K. E. The 10+4 microfibril structure of thin cartilage fibrils. Proc. Natl. 
Acad. Sci. 103, 17249–17254 (2006). 
43. Keene, D. R., Oxford, J. T. & Morris, N. P. Ultrastructural localization of collagen types II, IX, and 
XI in the growth plate of human rib and fetal bovine epiphyseal cartilage: type XI collagen is 
restricted to thin fibrils. J. Histochem. Cytochem. 43, 967–979 (1995). 
44. Burgeson, R. E. & Hollister, D. W. Collagen heterogeneity in human cartilage: identification of 
several new collagen chains. Biochem. Biophys. Res. Commun. 87, 1124–1131 (1979). 
45. Bernard, M. Yoshioka, H., Rodriguez, E., Van der Rest, M., Kimura, T., Ninomiya, Y., Olsen, B. R. 













XI belongs to the fibrillar class of collagens and reveals that the expression of the gene is not 
restricted to cartilagenous tissue. J. Biol. Chem. 263, 17159–17166 (1988). 
46. Imamura, Y., Scott, I. C. & Greenspan, D. S. The pro-alpha3(V) collagen chain. Complete primary 
structure, expression domains in adult and developing tissues, and comparison to the 
structures and expression domains of the other types V and XI procollagen chains. J. Biol. 
Chem. 275, 8749–8759 (2000). 
47. Sandberg, M. M., Hirvonen, H. E., Elima, K. J. & Vuorio, E. I. Co-expression of collagens II and XI 
and alternative splicing of exon 2 of collagen II in several developing human tissues. Biochem. J. 
294 ( Pt 2), 595–602 (1993). 
48. Lui, V. C., Kong, R. Y., Nicholls, J., Cheung, A. N. & Cheah, K. S. The mRNAs for the three chains 
of human collagen type XI are widely distributed but not necessarily co-expressed: implications 
for homotrimeric, heterotrimeric and heterotypic collagen molecules. Biochem. J. 311 ( Pt 2), 
511–516 (1995). 
49. Kania, A. M. Reichenberger, E., Baur, S. T., Karimbux, N. Y., Taylor, R. W., Olsen, B. R. & 
Nishimura, I. Structural variation of type XII collagen at its carboxyl-terminal NC1 domain 
generated by tissue-specific alternative splicing. J. Biol. Chem. 274, 22053–22059 (1999). 
50. Young, B. B., Zhang, G., Koch, M. & Birk, D. E. The roles of types XII and XIV collagen in 
fibrillogenesis and matrix assembly in the developing cornea. J. Cell. Biochem. 87, 208–220 
(2002). 
51. Ansorge, H. L., Meng, X., Zhang, G., Veit, G., Sun, M., Klement, J.F., Beason, D. P., Soslowsky, L. 
J., Koch, M. & Birk, D.E. Type XIV Collagen Regulates Fibrillogenesis: premature collagen fibril 
growth and tissue dysfunction in null mice. J. Biol. Chem. 284, 8427–8438 (2008). 
52. Nishiyama, T., McDonough, A. M., Bruns, R. R. & Burgeson, R. E. Type XII and XIV collagens 
mediate interactions between banded collagen fibers in vitro and may modulate extracellular 
matrix deformability. J. Biol. Chem. 269, 28193–28199 (1994). 
53. Hulmes, D. J. S., Kadler, K. E., Mould, A. P., Hojima, Y., Holmes, D. F., Cummings, C., Chapman, J. 
A. & Prockop, D. J. Pleomorphism in type I collagen fibrils produced by persistence of the 
procollagen N-propeptide. J. Mol. Biol. 210, 337–345 (1989). 
54. Font, B., Eichenberger, D., Rosenberg, L. M. & Van Der Rest, M. Characterization of the 
interactions of type XII collagen with two small proteoglycans from fetal bovine tendon, 
decorin and fibromodulin. Matrix Biol. 15, 341–348 (1996). 
55. Font, B., Aubert-Foucher, E., Goldschmidt, D., Eichenberger, D. & van der Rest, M. Binding of 
collagen XIV with the dermatan sulfate side chain of decorin. J. Biol. Chem. 268, 25015–25018 
(1993). 
56. Brown, J. C., Mann, K., Wiedemann, H. & Timpl, R. Structure and binding properties of collagen 
type XIV isolated from human placenta. J. Cell Biol. 120, 557–567 (1993). 
57. Varki A, Cummings RD, Esko JD, Freeze, H., Stanley, P. Bertozzi, C. R. Hart, G. W. & Etzler, M. E. 
Essentials of Glycobiology. (Cold Spring Harbor Laboratory Press, 2009).  
58. Cribb, A. M. & Scott, J. E. Tendon response to tensile stress: an ultrastructural investigation of 












59. Zhang, G., Ezura, Y., Chervoneva, I., Robinson, P. S., Beason, D. P., Carine, E. T., Soslowsky, L. J.,
Iozzo, R. V. & Birk, D. E. Decorin regulates assembly of collagen fibrils and acquisition of
biomechanical properties during tendon development. J. Cell. Biochem. 98, 1436–1449 (2006).
60. Danielson, K. G., Baribault, H., Holmes, D. F., Graham, H., Kadler, K. E. & Iozzo, R. V. Targeted
disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol.
136, 729–743 (1997).
61. Lechner, B. E., Lim, J. H., Mercado, M. L. & Fallon, J. R. Developmental regulation of biglycan
expression in muscle and tendon. Muscle Nerve 34, 347–355 (2006).
62. Corsi, A., Xu, T., Chen, X. D., Boyde, A., Liang, J., Mankani, M., Sommer, B., Iozzo, R. V.,
Eichstetter, I., Robey, P. G., Bianco, P. & Young, M. F. Phenotypic effects of biglycan deficiency
are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic
Ehlers-Danlos-like changes in bone and other connective tissues. J. Bone Miner. Res. 17, 1180–
1189 (2002).
63. Ameye, L., Aria, D., Jepsen, K., Oldberg, A., Xu, T. & Young, M. F. Abnormal collagen fibrils in
tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification,
and osteoarthritis. Faseb J. 16, 673–680 (2002).
64. Svensson, L., Närlid, I. & Oldberg, A. Fibromodulin and lumican bind to the same region on
collagen type I fibrils. Febs Lett. 470, 178–182 (2000).
65. Jepsen, K. J., Wu, F., Peragallo, J. H., Paul, J., Roberts, L., Ezura, Y., Oldberg, A., Birk, D. E. &
Chakravarti, S. A Syndrome of Joint Laxity and Impaired Tendon Integrity in Lumican- and
Fibromodulin-deficient Mice. J. Biol. Chem. 277, 35532–35540 (2002).
66. Ezura, Y., Chakravarti, S., Oldberg, A., Chervoneva, I. & Birk, D. E. Differential expression of
lumican and fibromodulin regulate collagen fibrillogenesis in developing mouse tendons. J. Cell
Biol. 151, 779–788 (2000).
67. Svensson, L., Aszódi, A., Reinholt, F. P., Fässler, R., Heinegård, D. & Oldberg, A. Fibromodulin-
null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in
tendon. J. Biol. Chem. 274, 9636–9647 (1999).
68. Chakravarti, S., Magnuson, T., Lass, J. H., Jepsen, K. J., LaMantia, C. & Carroll, H. Lumican
Regulates Collagen Fibril Assembly: Skin Fragility and Corneal Opacity in the Absence of
Lumican. J. Cell Biol. 141, 1277–1286 (1998).
69. Ottani, V., Raspanti, M. & Ruggeri, A. Collagen structure and functional implications. Micron.
1993 32, 251–260 (2001).
70. Woo, S. L., Debski, R. E., Zeminski, J., Abramowitch, S. D., Saw, S. S. & Fenwick, J. A. Injury and
repair of ligaments and tendons. Annu. Rev. Biomed. Eng. 2, 83–118 (2000).
71. Silver, F. H., Freeman, J. W. & Seehra, G. P. Collagen self-assembly and the development of
tendon mechanical properties. J. Biomech. 36, 1529–1553 (2003).













73. Parry, D. A. D., Barnes, G. R. G. & Craig, A. S. A comparison of the size distribution of collagen 
fibrils in connective tissues as a function of age and a possible relation between fibril size 
distribution and mechanical properties. Proc. R. Soc. Lond. B Biol. Sci. 203, 305 (1978). 
74. Rees, J. D. Current concepts in the management of tendon disorders. Rheumatology 45, 508–
521 (2006). 
75. Griffin, L. Y., Albohm, M. J., Arendt, E. A., Bahr, R., Beynnon, B. D., Demaio, M., Dick, R. W., 
Engebretsen, L., Garrett, W. E. Jr., Hannafin, J. A., Hewett, T. E., Huston, L. J., Ireland, M. L. 
Johnson, R. J., Lephart, S., Mandelbaum, B. R., Mann, B. J., Marks, P. H., Marshall, S. W., 
Myklebust, G., Noyes, F. R., Powers, C., Shields, C. Jr., Shultz, S. J., Silvers, H., Slauterbeck, J., 
Taylor, D. C., Teitz, C. C., Wojtys, E. M. & Yu, B. Understanding and preventing noncontact 
anterior cruciate ligament injuries: a review of the Hunt Valley II meeting, January 2005. Am. J. 
Sports Med. 34, 1512–1532 (2006). 
76. Järvinen, T. A. H., Kannus, P., Maffulli, N. & Khan, K. M. Achilles Tendon Disorders: Etiology and 
Epidemiology. Foot Ankle Clin. 10, 255–266 (2005). 
77. Järvinen, M., Józsa, L., Kannus, P., Järvinen, T. L., Kvist, M. & Leadbetter, W. Histopathological 
findings in chronic tendon disorders. Scand. J. Med. Sci. Sports 7, 86–95 (2007). 
78. Fredberg, U. & Stengaard-Pedersen, K. Chronic tendinopathy tissue pathology, pain 
mechanisms, and etiology with a special focus on inflammation. Scand. J. Med. Sci. Sports 18, 
3–15 (2008). 
79. Mazzone, M. F. & McCue, T. Common conditions of the Achilles tendon. Am. Fam. Physician 
65, 1805–1810 (2002). 
80. Posthumus, M., lins, M., September, A. & Schwellnus, M. The Intrinsic Risk Factors for ACL 
Ruptures: An Evidence-Based Review. Phys. Sportsmed. 39, 62–73 (2011). 
81. Kousta, E., Papathanasiou, A. & Skordis, N. Sex determination and disorders of sex 
development according to the revised nomenclature and classification in 46 XX individuals. 
Horm. Athens Greece 9, 218–131 (2010). 
82. Peeters, M. W., Thomis, M. A., Loos, R. J., Derom, C. A., Fagard, R., Claessens, A. L., Vlietinck, R. 
F. & Beunen, G. P. Heritability of somatotype components: a multivariate analysis. Int. J. Obes. 
31, 1295–1301 (2007). 
83. Yang, J., Benyamin, B., McEvoy, B. P., Gordon, S., Henders, A. K., Nyholt, D. R., Madden, P. A., 
Heath, A. C., Martin, N. G., Montgomery, G. W., Goddard, M. E. & Visscher, P. M. Common 
SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42, 565–569 
(2010). 
84. Battié, M. C., Levalahti, E., Videman, T., Burton, K. & Kaprio, J. Heritability of lumbar flexibility 
and the role of disc degeneration and body weight. J. Appl. Physiol. Bethesda Md 1985 104, 
379–385 (2008). 
85. Maes, H. H. M., Beunen, G. P., Vlietinck, R. F., Neale, M. C., Thomis, M., Vanden Eynde, B., 
Lysens, R., Simons, J., Derom, C. & Derom, R.. Inheritance of physical fitness in 10-yr-old twins 












86. Falconer, D. S. The inheritance of liability to certain diseases, estimated from the incidence
among relatives. Ann. Hum. Genet. 29, 51–76 (1965).
87. Gennari, L., Merlotti, D., De Paola, V., Calabrò, A., Becherini, L., Martini, G. & Nuti, R. Estrogen
Receptor Gene Polymorphisms and the Genetics of Osteoporosis: A HuGE Review. Am. J.
Epidemiol. 161, 307–320 (2005).
88. Dunning, A. M., Dowsett, M., Healey, C. S., Tee, L., Luben, R. N., Folkerd, E., Novik, K. L.,
Kelemen, L., Ogata, S., Pharoah, P. D., Easton, D. F., Day, N. E. & Ponder, B. A. Polymorphisms
Associated With Circulating Sex Hormone Levels in Postmenopausal Women. Jnci J. Natl.
Cancer Inst. 96, 936–945 (2004).
89. Tucker, R. & Collins, M. What makes champions? A review of the relative contribution of genes
and training to sporting success. Br. J. Sports Med. 46, 555–561 (2012).
90. Flynn, R. K., Pedersen, C. L., Birmingham, T. B., Kirkley, A., Jackowski, D. & Fowler, P. J. The
Familial Predisposition Toward Tearing the Anterior Cruciate Ligament: A Case Control Study. 
Am. J. Sports Med. 33, 23–28 (2005).
91. Goshima, K., Kitaoka, K., Nakase, J., Takahashi, R. & Tsuchiya, H. Clinical evidence of a familial
predisposition to anterior cruciate ligament injury. Br. J. Sports Med. 45, 350 (2011).
92. Harner, C. D., Paulos, L. E., Greenwald, A. E., Rosenberg, T. D. & Cooley, V. C. Detailed analysis
of patients with bilateral anterior cruciate ligament injuries. Am. J. Sports Med. 22, 37–43
(1994).
93. Kraemer, R., Wuerfel, W., Lorenzen, J., Busche, M., Vogt, P. M. & Knobloch, K. Analysis of
hereditary and medical risk factors in Achilles tendinopathy and Achilles tendon ruptures: a
matched pair analysis. Arch. Orthop. Trauma Surg. 132, 847–853 (2012).
94. Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy,
M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., Cho, J. H., Guttmacher, A. E., Kong, A., 
Kruglyak, L., Mardis, E., Rotimi, C. N., Slatkin, M., Valle, D., Whittemore, A. S., Boehnke, M.,
Clark, A. G., Eichler, E. E., Gibson, G., Haines, J. L., Mackay, T. F., McCarroll, S. A. & Visscher,
P.M. Finding the missing heritability of complex diseases. Nature 461, 747–753 (2009).
95. Posthumus, M., Saunders, C., September, A. V. & Collins, M. The polygenic profiles in
participants with Achilles tendinopathy and controls. Br. J. Sports Med. 45, 369–369 (2011).
96. September, A. V., Nell, E. M., O'Connell, K., Cook, J., Handley, C. J., van der Merwe, L.,
Schwellnus, M. & Collins, M. A pathway-based approach investigating the genes encoding
interleukin-1β, interleukin-6 and the interleukin-1 receptor antagonist provides new insight
into the genetic susceptibility of Achilles tendinopathy. Br. J. Sports Med. 45, 1040–1047
(2011).
97. Posthumus, M. Collins, M., van der Merwe, L., O'Cuinneagain, D., van der Merwe, W., Ribbans,
W. J., Schwellnus, M. P., Raleigh, S. M. Matrix metalloproteinase genes on chromosome 11q22
and the risk of anterior cruciate ligament (ACL) rupture. Scand. J. Med. Sci. Sports 22, 523–533
(2012).
98. Raleigh, S. M., van der Merwe, L., Ribbans, W. J., Smith, R. K., Schwellnus, M. P. & Collins, M.
Variants within the MMP3 gene are associated with Achilles tendinopathy: possible interaction












99. Nell, E. M., van der Merwe, L., Cook, J., Handley, C. J., Collins, M., & September, A. V. The
apoptosis pathway and the genetic predisposition to Achilles tendinopathy. J. Orthop. Res. 30,
1719–1724 (2012).
100. Mokone, G. G., Gajjar, M., September, A. V., Schwellnus, M. P., Greenberg, J, Noakes, T. D. &
Collins, M. The Guanine-Thymine Dinucleotide Repeat Polymorphism Within the Tenascin-C
Gene Is Associated With Achilles Tendon Injuries. Am. J. Sports Med. 33, 1016–1021 (2005).
101. Mokone, G. G., Schwellnus, M. P., Noakes, T. D. & Collins, M. The COL5A1 gene and Achilles
tendon pathology. Scand. J. Med. Sci. Sports 16, 19–26 (2006).
102. September, A. V., Cook, J., Handley, C. J., van der Merwe, L., Schwellnus, M. P. & Collins, M.
Variants within the COL5A1 gene are associated with Achilles tendinopathy in two populations.
Br. J. Sports Med. 43, 357–365 (2009).
103. Posthumus, M., September, A. V., O'Cuinneagain, D., van der Merwe, W., Schwellnus, M. P. &
Collins, M. The COL5A1 gene is associated with increased risk of anterior cruciate ligament
ruptures in female participants. Am. J. Sports Med. 37, 2234–2240 (2009).
104. Abrahams, Y., Laguette, M. J., Prince, S. & Collins, M. Polymorphisms within the COL5A1 3′ -
UTR that alters mRNA structure and the MIR608 Gene are associated with Achilles
tendinopathy. Ann. Hum. Genet. (2013). doi:10.1111/ahg.12013
105. Khoschnau, S., Melhus, H., Jacobson, A., Rahme, H., Bengtsson, H., Ribom, E., Grundberg, E., 
Mallmin, H. & Michaëlsson, K. Type I Collagen 1 Sp1 Polymorphism and the risk of cruciate
ligament ruptures or shoulder dislocations. Am. J. Sports Med. 36, 2432–2436 (2008).
106. Posthumus, M., September, A. V., Keegan, M., O'Cuinneagain, D., Van der Merwe, W.,
Schwellnus, M. P. & Collins, M. Genetic risk factors for anterior cruciate ligament ruptures:
COL1A1 gene variant. Br. J. Sports Med. 43, 352–356 (2009).
107. Ficek, K., Cieszczyk, P., Kaczmarczyk, M., Maciejewska-Karłowska, A., Sawczuk, M., Cholewinski,
J., Leonska-Duniec, A., Stepien-Slodkowska, M., Zarebska, A., Stepto, N. K., Bishop, D. J. &
Eynon, N. Gene variants within the COL1A1 gene are associated with reduced anterior cruciate
ligament injury in professional soccer players. J. Sci. Med. Sport (2012). 
doi:10.1016/j.jsams.2012.10.004
108. Posthumus, M., September, A. V., O'Cuinneagain, D., van der Merwe, W., Schwellnus, M. P. &
Collins, M. The association between the COL12A1 gene and anterior cruciate ligament
ruptures. Br. J. Sports Med. 44, 1160–1165 (2009).
109. Posthumus, M., Collins, M., Cook, J., Handley, C. J., Ribbans, W. J., Smith, R. K., Schwellnus, M.
P. & Raleigh, S. M. Components of the transforming growth factor-beta family and the
pathogenesis of human Achilles tendon pathology- a genetic association study. Rheumatol. 49,
2090–2097 (2010).
110. Collins, M. & Posthumus, M. Type V Collagen Genotype and Exercise-Related Phenotype
Relationships: A Novel Hypothesis. Exerc. Sport Sci. Rev. 39, 191-198 (2011).
111. Malfait, F., Wenstrup, R. J. & De Paepe, A. Clinical and genetic aspects of Ehlers-Danlos












112. Mitchell, A. L., Schwarze, U., Jennings, J. F. & Byers, P. H. Molecular mechanisms of classical
Ehlers-Danlos syndrome (EDS). Hum. Mutat. 30, 995–1002 (2009).
113. Caridi, G., Pezzolo, A., Bertelli, R., Gimelli, G., Di Donato, A., Candiano, G. & Ghiggeri, G. M.
Mapping of the human COL5A1 gene to chromosome 9q34.3. Hum. Genet. 90, 174–176 (1992).
114. Takahara, K., Hoffman, G. G. & Greenspan, D. S. Complete structural organization of the human
alpha 1 (V) collagen gene (COL5A1): divergence from the conserved organization of other
characterized fibrillar collagen genes. Genomics 29, 588–597 (1995).
115. Collins, M., Mokone, G. G., September, A. V., van der Merwe, L. & Schwellnus, M. P. The
COL5A1 genotype is associated with range of motion measurements. Scand. J. Med. Sci. Sports
19, 803–810 (2009).
116. Brown, J. C., Miller, C. J., Schwellnus, M. P. & Collins, M. Range of motion measurements
diverge with increasing age for COL5A1 genotypes. Scand. J. Med. Sci. Sports e266-e272 (2011).
117. Posthumus, M., Schwellnus, M. P. & Collins, M. The COL5A1 Gene: A novel marker of
endurance running performance. Med. Sci. Sports Exerc. 43, 584–589 (2011).
118. Laguette, M. J., Abrahams, Y., Prince, S. & Collins, M. Sequence variants within the 3′ -UTR of
the COL5A1 gene alters mRNA stability: Implications for musculoskeletal soft tissue injuries.
Matrix Biol. 30, 338–345 (2011).
119. Conne, B., Stutz, A. & Vassalli, J. D. The 3’ untranslated region of messenger RNA: A molecular 
`hotspot’ for pathology? Nat Med 6, 637–641 (2000).
120. Fabian, M. R., Sonenberg, N. & Filipowicz, W. Regulation of mRNA translation and stability by
microRNAs. Annu. Rev. Biochem. 79, 351–379 (2010).
121. Snead, M. P. & Yates, J. R. Clinical and Molecular genetics of Stickler syndrome. J. Med. Genet.
36, 353–359 (1999).
122. Shanske, A. L., Bogdanow, A., Shprintzen, R. J. & Marion, R. W. The Marshall syndrome: report
of a new family and review of the literature. Am. J. Med. Genet. 70, 52–57 (1997).
123. Giedion, A., Brandner, M., Lecannellier, J., Muhar, U., Prader, A., Sulzer, J., Zweymüller, E. Oto-
spondylo-megaepiphyseal dysplasia (OSMED). Helv. Paediatr. Acta 37, 361–380 (1982).
124. Weissenbacher, G. & Zweymueller, E. [Simultaneous occurrance of the Pierre Robin syndrome
and fetal chondrodysplasia]. Monatsschrift für kinderheilkd. 112, 315–317 (1964).
125. Spranger, J. The type XI collagenopathies. Pediatr. Radiol. 28, 745–750 (1998).
126. Jakkula, E., Melkoniemi, M., Kiviranta, I., Lohiniva, J., Räinä, S. S., Perälä, M., Warman, M. L.,
Ahonen, K., Kröger, H., Göring, H. H. & Ala-Kokko, L. The role of sequence variations within the
genes encoding collagen II, IX and XI in non-syndromic, early-onset osteoarthritis. Osteoarthr.
Cartil. Oars Osteoarthr. Res. Soc. 13, 497–507 (2005).
127. Ikeda, T., Mabuchi, A., Fukuda, A., Kawakami, A., Ryo, Y., Yamamoto, S., Miyoshi, K., Haga, N.,
Hiraoka, H., Takatori, Y., Kawaguchi, H., Nakamura, K. & Ikegawa, S. Association analysis of
single nucleotide polymorphisms in cartilage-specific collagen genes with knee and hip












128. Videman, T., Saarela, J., Kaprio, J., Näkki, A., Levälahti, E., Gill, K., Peltonen, L. & Battié, M. C.
Associations of 25 structural, degradative, and inflammatory candidate genes with lumbar disc
desiccation, bulging, and height narrowing. Arthritis Rheum. 60, 470–481 (2009).
129. Mio, F., Chiba, K., Hirose, Y., Kawaguchi, Y., Mikami, Y., Oya, T., Mori, M., Kamata, M.,
Matsumoto, M., Ozaki, K., Tanaka, T., Takahashi, A., Kubo, T., Kimura, T., Toyama, Y. &
Ikegawa, S. A Functional Polymorphism in COL11A1, Which Encodes the α1 Chain of Type XI
Collagen, is Associated with Susceptibility to Lumbar Disc Herniation. Am. J. Hum. Genet. 81,
1271–1277 (2007).
130. Koyama, K., Nakazato, K., Min, S., Gushiken, K., Hatakeda, Y., Seo, K. & Hiranuma, K. COL11A1
gene is associated with limbus vertebra in gymnasts. Int. J. Sports Med. 33, 586–590 (2012).
131. Jugessur, A., Shi, M., Gjessing, H. K., Lie, R. T., Wilcox, A. J., Weinberg, C. R., Christensen, K.,
Boyles, A. L., Daack-Hirsch, S., Nguyen, T. T., Christiansen, L., Lidral, A. C. & Murray, J. C.
Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations
in two population-based cleft studies from Scandinavia. Plos One 5, e11493 (2010).
132. Nikopensius, T., Jagomägi, T., Krjutskov, K., Tammekivi, V., Saag, M., Prane, I., Piekuse, L.,
Akota, I., Barkane, B., Krumina, A., Ambrozaityte, L., Matuleviciene, A., Kucinskiene, Z. A., Lace,
B., Kucinskas, V., Metspalu, A. Genetic variants in COL2A1, COL11A2, and IRF6 contribute risk
to nonsyndromic cleft palate. Birt. Defects Res. A. Clin. Mol. Teratol. 88, 748–756 (2010).
133. Park, H. J., Choe, B. K., Kim, S. K., Park, H. K., Kim, J. W., Chung, J. H., Hong, I. K., Chung, D. H. &
Kwon, K. H. Association between collagen type XI α1 gene polymorphisms and papillary thyroid
cancer in a Korean population. Exp. Ther. Med. 2, 1111-1116 (2011). 
134. Lee, H. S., Lee, A. T., Criswell, L. A., Seldin, M. F., Amos, C. I., Carulli, J. P., Navarrete, C.,
Remmers, E. F., Kastner, D. L., Plenge, R. M., Li, W. & Gregersen, P. K. Several regions in the 
major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid
arthritis, independent of the DRB1 locus. Mol. Med. 14, 293–300 (2008).
135. Vikkula, M., Mariman, E. C., Lui, V. C., Zhidkova, N. I., Tiller, G. E., Goldring, M. B., van Beersum
S. E., de Waal Malefijt, M. C., van den Hoogen, F. H. & Ropers, H. H. Autosomal dominant and
recessive osteochondrodysplasias associated with the COL11A2 locus. Cell 80, 431–437 (1995).
136. Maeda, S., Koga, H., Matsunaga, S., Numasawa, T., Ikari, K., Furushima, K., Harata, S., Takeda,
J., Sakou, T., Komiya, S. & Inoue, I. Gender-specific haplotype association of collagen alpha 2 
(XI) gene in ossification of the posterior longitudinal ligament of the spine. J. Hum. Genet. 46,
1–4 (2001).
137. Maeda, S., Ishidou, Y., Koga, H., Taketomi, E., Ikari, K., Komiya, S., Takeda, J., Sakou, T. & Inoue
I. Functional Impact of Human Collagen α2(XI) Gene Polymorphism in Pathogenesis of
Ossification of the Posterior Longitudinal Ligament of the Spine. J. Bone Miner. Res. 16, 948–
957 (2001).
138. Horikoshi, T., Maeda, K., Kawaguchi, Y., Chiba, K., Mori, K., Koshizuka, Y., Hirabayashi, S.,
Sugimori, K., Matsumoto, M., Kawaguchi, H., Takahashi, M., Inoue, H., Kimura, T., Matsusue, Y.,
Inoue, I., Baba, H., Nakamura, K. & Ikegawa, S. A large-scale genetic association study of













139. Koga, H., Sakou, T., Taketomi, E., Hayashi, K., Numasawa, T., Harata, S., Yone, K., Matsunaga, S.,
Otterud, B., Inoue,I. & Leppert, M. Genetic mapping of ossification of the posterior longitudinal
ligament of the spine. Am. J. Hum. Genet. 62, 1460–1467 (1998).
140. Karppinen, J., Daavittila, I., Solovieva, S., Kuisma, M., Taimela, S., Natri, A., . Haapea, M.,
Korpelainen, R., Niinimäki, J., Tervonen, O., Ala-Kokko, L., & Männikkö, M. Genetic factors are
associated with modic changes in endplates of lumbar vertebral bodies. Spine 33, 1236–1241
(2008).
141. N Noponen-Hietala, E Kyllonen & M Mannikko. Sequence variations in the collagen IX and XI
genes are associated with degenerative lumbar spinal stenosis. Ann. Rheum. Dis. 62, 1208–
1214 (2003).
142. Solovieva, S., Lohiniva, J., Leino-Arjas, P., Raininko, R., Luoma, K., Ala-Kokko, L., & Riihimäki, H.
Intervertebral disc degeneration in relation to the COL9A3 and the IL-1ss gene polymorphisms.
Eur. Spine J. 15, 613–619 (2006).
143. Virtanen, I. M., Karppinen, J., Taimela, S., Ott, J., Barral, S., Kaikkonen, K., Heikkilä, O.,
Mutanen, P., Noponen, N., Männikkö, M., Tervonen, O., Natri, A. & Ala-Kokko, L. Occupational
and genetic risk factors associated with intervertebral disc disease. Spine 32, 1129–1134
(2007).
144. Eskola, P. J., Kjaer, P., Daavittila, I. M., Solovieva, S., Okuloff, A., Sorensen, J. S., Wedderkopp, 
N., Ala-Kokko, L., Männikkö, M. & Karppinen, J. I. Genetic risk factors of disc degeneration
among 12-14-year-old Danish children: a population study. Int. J. Mol. Epidemiol. Genet. 1,
158–165 (2010).
145. Zhidkova, N. I., Justice, S. K. & Mayne, R. Alternative mRNA processing occurs in the variable
region of the pro-alpha 1(XI) and pro-alpha 2(XI) collagen chains. J. Biol. Chem. 270, 9486–9493
(1995).
146. Wenstrup, R. J., Smith, S. M., Florer, J. B., Zhang, G., Beason, D. P., Seegmiller, R. E., Soslowsky,
L. J. & Birk, D. E. Regulation of Collagen Fibril Nucleation and Initial Fibril Assembly Involves
Coordinate Interactions with Collagens V and XI in Developing Tendon. J. Biol. Chem. 286,
20455–20465 (2011).
147. Kleman, J.-P., Hartmann, D. J., Ramirez, F. & Rest, M. The human rhabdomyosarcoma cell line
A204 lays down a highly insoluble matrix composed mainly of alpha1 type-XI and alpha2 type-V
collagen chains. Eur. J. Biochem. 210, 329–335 (1992).
148. Mayne, R., Brewton, R. G., Mayne, P. M. & Baker, J. R. Isolation and characterization of the
chains of type V/type XI collagen present in bovine vitreous. J. Biol. Chem. 268, 9381–9386
(1993).
149. Niyibizi, C. & Eyre, D. R. Identification of the cartilage alpha 1(XI) chain in type V collagen from
bovine bone. Febs Lett. 242, 314–318 (1989).
150. Zantop, T., Petersen, W., Sekiya, J. K., Musahl, V. & Fu, F. H. Anterior cruciate ligament
anatomy and function relating to anatomical reconstruction. Knee Surg. Sports Traumatol.












151. Bicer, E. K., Lustig, S., Servien, E., Selmi, T. A. S. & Neyret, P. Current knowledge in the anatomy
of the human anterior cruciate ligament. Knee Surg. Sports Traumatol. Arthrosc. 18, 1075–
1084 (2009).
152. Kopf, S., Musahl, V., Tashman, S., Szczodry, M., Shen, W., & Fu, F. H. A systematic review of the
femoral origin and tibial insertion morphology of the ACL. Knee Surg. Sports Traumatol.
Arthrosc. 17, 213–219 (2009).
153. Marshall, S.W., Padua, D., McGrath, M. Incidence of ACL injuries. In: Hewett TE, Schultz SJ,
Griffin LY (eds.) American Orthopaedic Society for Sports Medicine. Understanding and
preventing noncontact ACL injuries. (Human Kinetics, 2007).
154. Marshall, S. W. Recommendations for defining and classifying anterior cruciate ligament
injuries in epidemiologic studies. J. Athl. Train. 45, 516–518 (2010).
155. Ettlinger, C. F., Johnson, R. J. & Shealy, J. E. A Method to Help Reduce the Risk of Serious Knee
Sprains Incurred in Alpine Skiing. Am. J. Sports Med. 23, 531–537 (1995).
156. Fischer, J. F., Leyvraz, P. F. & Bally, A. A dynamic analysis of knee ligament injuries in alpine 
skiing. Acta Orthop. Belg. 60, 194–203 (1994).
157. Geyer, M. & Wirth, C. J. [A new mechanism of injury of the anterior cruciate ligament].
Unfallchirurg 94, 69–72 (1991).
158. Hame, S. L., Oakes, D. A. & Markolf, K. L. Injury to the anterior cruciate ligament during alpine 
skiing: a biomechanical analysis of tibial torque and knee flexion angle. Am. J. Sports Med. 30,
537–540 (2002).
159. Gianotti, S. M., Marshall, S. W., Hume, P. A. & Bunt, L. Incidence of anterior cruciate ligament
injury and other knee ligament injuries: a national population-based study. J. Sci. Med. Sport
Sports Med. Aust. 12, 622–627 (2009).
160. Granan, L.-P., Bahr, R., Steindal, K., Furnes, O. & Engebretsen, L. Development of a national
cruciate ligament surgery registry: the Norwegian National Knee Ligament Registry. Am. J. 
Sports Med. 36, 308–315 (2008).
161. Barenius, B., Forssblad, M., Engström, B. & Eriksson, K. Functional recovery after anterior
cruciate ligament reconstruction, a study of health-related quality of life based on the Swedish
National Knee Ligament Register. Knee Surg. Sports Traumatol. Arthrosc. 21, 914-927 (2012).
162. De Loës, M., Dahlstedt, L. J. & Thomée, R. A 7-year study on risks and costs of knee injuries in
male and female youth participants in 12 sports. Scand. J. Med. Sci. Sports 10, 90–97 (2000).
163. Brooks, J. H. M. Epidemiology of injuries in English professional rugby union: part 1 match
injuries. Br. J. Sports Med. 39, 757–766 (2005).
164. Freedman, K. B., Glasgow, M. T., Glasgow, S. G. & Bernstein, J. Anterior cruciate ligament injury
and reconstruction among university students. Clin. Orthop. 208–212 (1998).
165. Øiestad, B. E., Holm, I., Engebretsen, L., Aune, A. K., Gunderson, R., & Risberg, M. A. The
prevalence of patellofemoral osteoarthritis 12 years after anterior cruciate ligament












166. Lohmander, L. S., Englund, P. M., Dahl, L. L. & Roos, E. M. The Long-term Consequence of
Anterior Cruciate Ligament and Meniscus Injuries: Osteoarthritis. Am. J. Sports Med. 35, 1756–
1769 (2007).
167. September, A. V., Schwellnus, M. P., Collins, M. & Gibson, W. Tendon and ligament injuries: the
genetic component * COMMENTARY. Br. J. Sports Med. 41, 241–246 (2007).
168. Raleigh, S. M., Posthumus, M., O’Cuinneagain, D., van der Merwe, W. & Collins, M. The GDF5
Gene and Anterior Cruciate Ligament Rupture. Int. J. Sports Med. 34, 364-367 (2013).
169. Toth, A. P. & Cordasco, F. A. Anterior cruciate ligament injuries in the female athlete. J. Gend.-
Specif. Med. 4, 25–34 (2001).
170. Agel, J., Arendt, E. A. & Bershadsky, B. Anterior cruciate ligament injury in national collegiate
athletic association basketball and soccer: a 13-year review. Am. J. Sports Med. 33, 524–530
(2005).
171. Colgan, D. F. & Manley, J. L. Mechanism and regulation of mRNA polyadenylation. Genes Dev.
11, 2755–2766 (1997).
172. Ross, J. mRNA stability in mammalian cells. Microbiol. Rev. 59, 423–450 (1995).
173. Mazumder, B., Seshadri, V. & Fox, P. L. Translational control by the 3′ -UTR: the ends specify
the means. Trends Biochem. Sci. 28, 91–98 (2003).
174. Xie, X., Lu, J., Kulbokas, E. J., Golub, T. R., Mootha, V., Lindblad-Toh, K., Lander, E. S., & Kellis, 
M. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison
of several mammals. Nature 434, 338–345 (2005).
175. Lau, N. C. & Lai, E. C. Diverse roles for RNA in gene regulation. Genome Biol. 6, 315 (2005).
176. Matzke, M. A. & Birchler, J. A. RNAi-mediated pathways in the nucleus. Nat. Rev. Genet. 6, 24–
35 (2005).
177. Sayed, D. & Abdellatif, M. MicroRNAs in development and disease. Physiol. Rev. 91, 827–887
(2011).
178. Brown, J. C., Miller, C.-J., Posthumus, M., Schwellnus, M. P. & Collins, M. The COL5A1 gene,
ultra-marathon running performance, and range of motion. Int. J. Sports Physiol. Perform. 6,
485–496 (2011).
179. Lahiri, D. K. & Nurnberger, J. I., Jr. A rapid non-enzymatic method for the preparation of HMW
DNA from blood for RFLP studies. Nucleic Acids Res. 19, 5444 (1991).
180. Gauderman, W. J. Sample Size Requirements for Association Studies of Gene-Gene Interaction.
Am. J. Epidemiol. 155, 478–484 (2002).
181. Epstein, M. P. & Satten, G. A. Inference on Haplotype Effects in Case-Control Studies Using
Unphased Genotype Data. Am. J. Hum. Genet. 73, 1316–1329 (2003).
182. Satten, G. A. & Epstein, M. P. Comparison of prospective and retrospective methods for













183. Gaunt, T. R., Rodríguez, S. & Day, I. N. Cubic exact solutions for the estimation of pairwise 
haplotype frequencies: implications for linkage disequilibrium analyses and a web tool ‘CubeX’. 
BMC Bioinformatics 8, 428 (2007). 
184. Turnpenny P, Ellard S. in Emerys Elem. Med. Genet. 123–136 (Elsevier Churchill Livingstone, 
2005). 
185. Gibson, W. T. Genetic association studies for complex traits: relevance for the sports medicine 
practitioner. Br. J. Sports Med. 43, 314–316 (2008). 
186. Gonçalves-Neto, J., Witzel, S. S., Teodoro, W. R., Carvalho-Junior, A. E., Fernandes, T. D., & 
Yoshinari, H. H. Changes in collagen matrix composition in human posterior tibial tendon 
dysfunction. Joint Bone Spine 69, 189–194 (2002). 
187. Loudon, J. K., Jenkins, W. & Loudon, K. L. The relationship between static posture and ACL 
injury in female athletes. J. Orthop. Sports Phys. Ther. 24, 91–97 (1996). 
188. Ramesh, R., Von Arx, O., Azzopardi, T., & Schranz, P. J. The risk of anterior cruciate ligament 
rupture with generalised joint laxity. J. Bone Jt. Surg. - Br. Vol. 87-B, 800–803 (2005). 
189. Boden, B. P., Dean, G. S., Feagin, J. A., Jr & Garrett, W. E., Jr. Mechanisms of anterior cruciate 
ligament injury. Orthopedics 23, 573–578 (2000). 
190. Bell, R. D., Shultz, S. J., Wideman, L. & Henrich, V. C. Collagen Gene Variants Previously 
Associated With Anterior Cruciate Ligament Injury Risk Are Also Associated With Joint Laxity. 
Sports Heal. Multidiscip. Approach 4, 312–318 (2012). 
191. Morris, N. P. & Bächinger, H. P. Type XI collagen is a heterotrimer with the composition (1 
alpha, 2 alpha, 3 alpha) retaining non-triple-helical domains. J. Biol. Chem. 262, 11345–11350 
(1987). 
192. Griffith, A. J., Sprunger, L. K., Sirko-Osadsa, D. A., Tiller, G. E., Meisler, M. H., & Warman, M. L. 
Marshall Syndrome Associated with a Splicing Defect at the COL11A1 Locus. Am. J. Hum. Genet. 
62, 816–823 (1998). 
193. Annunen, S., Körkkö, J., Czarny, M., Warman, M. L., Brunner, H. G., Kääriäinen, H., Mulliken, J. 
B., Tranebjaerg, L., Brooks, D. G., Cox, G. F., Cruysberg, J. R., Curtis, M. A., Davenport, S. L., 
Friedrich, C. A., Kaitila, I., Krawczynski, M. R., Latos-Bielenska, A., Mukai, S., Olsen, B. R., 
Shinno, N., Somer, M., Vikkula, M., Zlotogora, J., Prockop, D. J., & Ala-Kokko, L. Splicing 
Mutations of 54-bp Exons in the COL11A1 Gene Cause Marshall Syndrome, but Other 
Mutations Cause Overlapping Marshall/Stickler Phenotypes. Am. J. Hum. Genet. 65, 974–983 
(1999). 
194. Brown, K. E., Lawrence, R. & Sonenshein, G. E. Concerted modulation of alpha 1(XI) and alpha 
2(V) collagen mRNAs in bovine vascular smooth muscle cells. J. Biol. Chem. 266, 23268–23273 
(1991). 
195. Van Helden, P. Not too much and not too little. EMBO Rep. 13, 942 (2012). 
196. Benazzo, F., Mosconi, M., Pio, A. & Combi, F. Hindfoot Tendinopathies in Athletes in 
Tendinopathy Athletes (Woo, S. L.-Y., Renstrm, P. A. F. H. & Arnoczky, S. P.) (Blackwell 












197. Houshian, S., Tscherning, T. & Riegels-Nielsen, P. The epidemiology of Achilles tendon rupture
in a Danish county. Injury 29, 651–654 (1998).
198. Tumilty, S. Achilles tendon rupture: rising incidence in New Zealand follows international
trends. Phys. Ther. Rev. 12, 59–65 (2007).
199. Paavola, M., Kannus, P., Paakkala, T., Pasanen, M. & Järvinen, M. Long-term prognosis of
patients with achilles tendinopathy. An observational 8-year follow-up study. Am. J. Sports
Med. 28, 634–642 (2000).
200. Cook, J. L. & Purdam, C. R. Is tendon pathology a continuum? A pathology model to explain the
clinical presentation of load-induced tendinopathy. Br. J. Sports Med. 43, 409–416 (2008).
201. Paavola, M., Kannus, P., Orava, S., Pasanen, M., & Järvinen, M. Surgical treatment for chronic
Achilles tendinopathy: a prospective seven month follow up study. Br. J. Sports Med. 36, 178–
182 (2002).
202. Kader, D., Saxena, A., Movin, T., & Maffulli, N. Achilles tendinopathy: some aspects of basic
science and clinical management. Br. J. Sports Med. 36, 239–249 (2002).
203. Riley, G. Chronic tendon pathology: molecular basis and therapeutic implications. Expert Rev.
Mol. Med. 7, 1–25 (2005).
204. Fu, S.-C., Rolf, C., Cheuk, Y.-C., Lui, P. P. & Chan, K.-M. Deciphering the pathogenesis of
tendinopathy: a three-stages process. Sports Med. Arthrosc. Rehabil. Ther. Technol. Smartt 2,
30 (2010).
205. Aström, M. & Rausing, A. Chronic Achilles tendinopathy. A survey of surgical and
histopathologic findings. Clin. Orthop. 151–164 (1995).
206. Clancy, W. Failed healing responses. Sports-Induc. Inflamm. Clin. Basic Sci. Concepts Park Ridge 
Il Am. Orthop. Soc. Sports Med. (1989).
207. Sham, P. C. & Curtis, D. Monte Carlo tests for associations between disease and alleles at highly
polymorphic loci. Ann. Hum. Genet. 59, 97–105 (1995).
208. Jin, H., Evangelou, E., Ioannidis, J. P. A. & Ralston, S. H. Polymorphisms in the 5’ flank of
COL1A1 gene and osteoporosis: meta-analysis of published studies. Osteoporos. Int. 22, 911–
921 (2010).
209. Mann, V., Hobson, E. E., Li, B., Stewart, T. L., Grant, S. F., Robins, S. P., Aspden, R. M., & Ralston,
S. H. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by
affecting bone density and quality. J. Clin. Invest. 107, 899–907 (2001).
210. Mann, V. & Ralston, S. H. Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone
mineral density and osteoporotic fracture. Bone 32, 711–717 (2003).
211. Tilkeridis, C., Bei, T., Garantziotis, S., & Stratakis, C. A. Association of a COL1A1 polymorphism
with lumbar disc disease in young military recruits. J. Med. Genet. 42, e44–e44 (2005).
212. Pluijm, S. M. F., Van Essen, H. W., Bravenboer, N., Uitterlinden, A. G., Smit, J. H., Pols, H. A. P.,
& Lips, P. Collagen type I 1 Sp1 polymorphism, osteoporosis, and intervertebral disc












213. Fessler, L. I., Shigaki, N. & Fessler, J. H. Isolation of a new procollagen V chain from chick
embryo tendon. J. Biol. Chem. 260, 13286–13293 (1985).
214. Fernandes, R. J., Weis, M., Scott, M. A., Seegmiller, R. E. & Eyre, D. R. Collagen XI chain
misassembly in cartilage of the chondrodysplasia (cho) mouse. Matrix Biol. 26, 597–603 (2007).
215. Dressler, M. R., Butler, D. L., Wenstrup, R., Awad, H. A., Smith, F., & Boivin, G. P. A potential
mechanism for age-related declines in patellar tendon biomechanics. J. Orthop. Res. 20, 1315–
1322 (2002).
216. Ott, J. & Rabinowitz, D. The effect of marker heterozygosity on the power to detect linkage
disequilibrium. Genetics 147, 927–930 (1997).
217. Chapman, N. H. & Wijsman, E. M. Genome screens using linkage disequilibrium tests: optimal
marker characteristics and feasibility. Am. J. Hum. Genet. 63, 1872–1885 (1998).
218. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on
protein function using the SIFT algorithm. Nat. Protoc. 4, 1073–1081 (2009).
219. Nowak, M. A., Boerlijst, M. C., Cooke, J. & Smith, J. M. Evolution of genetic redundancy. Nature
388, 167–171 (1997).
220. Li, Y., Lacerda, D. A., Warman, M. L., Beier, D. R., Yoshioka, H., Ninomiya, Y., Oxford, J. T.,
Morris, N. P., Andrikopoulos, K., Ramirez, F., Wardell, B. B., Lifferth, G.D., Teuscher, C.,
Woodward, S.R., Taylor, B.A., Seegmiller, R.E., & Olsen, B. R. A fibrillar collagen gene, COL11A1, 
is essential for skeletal morphogenesis. Cell 80, 423–430 (1995).
221. So, H.-C., Gui, A. H. S., Cherny, S. S. & Sham, P. C. Evaluating the heritability explained by
known susceptibility variants: a survey of ten complex diseases. Genet. Epidemiol. 35, 310–317 
(2011).
222. Mittag, F., Büchel, F., Saad, M., Jahn, A., Schulte, C., Bochdanovits, Z., Simón-Sánchez, J., Nalls, 
M. A., Keller, M., Hernandez, D. G., Gibbs, J. R., Lesage, S., Brice, A., Heutink, P., Martinez, M.,
Wood, N. W., Hardy, J., Singleton, A. B., Zell, A., Gasser, T., & Sharma, M. Use of support vector
machines for disease risk prediction in genome-wide association studies: Concerns and
opportunities. Hum. Mutat. 33, 1708–1718 (2012).
223. Panni, A. S., Tartarone, M. & Maffulli, N. Patellar tendinopathy in athletes. Outcome of
nonoperative and operative management. Am. J. Sports Med. 28, 392–397 (2000).















Appendix A- Supplementary Tables 
A1 Chapter 2- Supplementary Tables 
Table A1.1 Genotype Effects on descriptive measures for COL5A1 rs71746744 (-/AGGG) and rs1134170 (A/T) 
and MIR608 rs4919510 (C/G) in a Caucasian South African population. 
 COL5A1 rs71746744 COL5A1 rs1134170 MIR608 rs4919510 
Age  0.578 0.479 0.252 
Height 0.215 0.218 0.528 
Weight 0.338 0.465 0.080 
BMI 0.292 0.222 0.591 
Gender 0.406 0.808 0.330 
P-values are tabulated.  
 
Table A1.2.1 Inferred haplotype Analysis of COL5A1 rs71746744 and rs1134170 in all participants, male 





CON ACL LR p-value Model 




AGGG/T 70.5 (152) 70.9 (152) 1.566 0.211 Dom 
AGGG/A 0.5(1) 0.5 (1) 0.001 0.921 Rec 
-/T 1.2 (2) 3.5 (7) 5.787 0.016 Dom 
-/A 27.9 (60) 25.1 (53) 11.483 <0.001 Rec 




AGGG/T 71.6 (95) 69.6 (111) 0.973 0.324 Rec 
AGGG/A 0.4 (0) 0.7 (1) 0.198 0.656 Dom 
-/T 0.4 (0) 4.7 (7) 13.234 <0.001 Dom 
-/A 27.6 (36) 25.0 (39) 10.306 0.001 Rec 




AGGG/T 68.6 (56) 74.6 (40) 2.367 0.124 Dom 
AGGG/A 0.6 (0) 0 (0) 1.032 0.310 Dom/Mult 
-/T 2.4 (2) 0 (0) 4.105 0.043 Dom/Mult 
-/A 28.3 (23) 25.4 (13) 1.560 0.206 Rec 
CON group and ACL rupture group are represented as a frequency (%), with the number of participants (n) in 
parenthesis. LR is the estimated risk. ND, not determined due to small sample size. Significant p-values 
(p<0.05) are indicated by bold type-face.  
Best fit model was determined by AIC values. Models: Rec= reccesive; Dom= dominant; Mult= multiplicative, 
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Table A1.2.2 Inferred haplotype Analysis of COL5A1 rs71746744 and rs1134170 in all participants, male 
participants and female participants for asymptomatic controls (CON) and non-contact ACL rupture 










AGGG/T 70.5 (152) 70.4 (84) 0.026 0.872 Dom 
AGGG/A 0.5 (1) 0.4 (1) 0.005 0.943 Rec/Dom/Mult 
-/T 1.2 (2) 4.2 (5) 6.360 0.012 Dom 





AGGG/T 71.6 (95) 69.2 (62) 0.296 0.586 Mult 
AGGG/A 0.4 (0) 0.6 (0) 0.074 0.785 Dom/Mult 
-/T 0.4 (0) 5.5 (5) 13.156 <0.001 Dom 





AGGG/T 68.6 (56) 74.1 (21) 1.516 0.218 Dom 
AGGG/A 0.6 (0) 0 (0) 0.609 0.435 Dom 
-/T 2.4 (2) 0 (0) 2.422 0.120 Dom/Mult 
-/A 28.3 (23) 25.9 (7) 0.991 0.319 Rec 
CON group and non-contact (NON) ACL rupture subgroup are represented as a frequency (%), with the number
of participants (n) in parenthesis. LR is the estimated risk. ND, not determined due to small sample size. 
Significant p-values (p<0.05) are indicated by bold type-face. 
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Table A1.3.1 Inferred pseudohaplotypes for the COL5A1 rs71746744 and rs1134170 and miR-608 rs4919510 
polymorphisms in the control (CON), and anterior cruciate ligament rupture (ACL) groups in all participants, 





CON ACL LR p-value Model 






AGGG/T/C 55.9 (121) 57.9 (124) 0.133 0.715 Rec 
AGGG/T/G 14.6 (31) 13.0 (27) 0.171 0.679 Rec 
AGGG/A/C 0.3 (0) 0.4 (0) 0.004 0.948 Rec 
AGGG/A/G 0.02 (0) 0.1 (0) 0.001 0.973 Rec/Dom/Mult 
-/T/C 0.8 (1) 2.8 (6) 5.114 0.024 Dom  
-/T/G 0.3 (0) 0.7 (1) 1.862 0.172 Dom  
-/A/C 24.0 (52) 18.4 (39) 8.315 0.004 Rec 
-/A/G 3.8 (8) 6.6 (14) 1.255 0.263 Dom 






 AGGG/T/C 57.1 (76) 56.0 (89) 2.604 0.106 Dom 
 AGGG/T/G 14.5 (19) 13.6 (21) 1.013 0.314 Rec 
 AGGG/A/C 0.4 (0) 0.6 (0) 0.067 0.796 Dom/Mult 
 AGGG/A/G 0 (0) 0.1 (0) <0.001 0.989 Rec 
-/T/C 0.4 (0) 3.8 (6) 10.396 0.001 Dom 
-/T/G 0 (0) 0.9 (1) 0.008 0.928 Rec 
-/A/C 24.9 (33) 17.9 (28) 6.984 0.008 Rec 
-/A/G 2.7 (3) 7.1 (11) 3.618 0.057 Dom 






 AGGG/T/C 54.1 (44) 63.4 (34) 4.617 0.032 Dom 
 AGGG/T/G 14.5 (12) 11.1 (6) 0.431 0.511 Mult 
 AGGG/A/C 0 (0) 0 (0) IF IF IF 
 AGGG/A/G 0.6 (0) 0 (0) 1.060 0.303 Mult 
-/T/C 1.6 (1) 0 (0) 3.282 0.070 Dom 
-/T/G 0.8 (0) 0 (0) 1.543 0.214 Dom 
-/A/C 22.6 (18) 19.9 (10) 1.501 0.221 Rec 
-/A/G 5.8 (4) 5.8 (3) 0.360 0.549 Rec 
CON group and ACL rupture group are represented as a frequency (%), with the number of participants (n) in 
parenthesis. LR is the estimated risk. ND, not determined due to small sample size. Significant p-values 
(p<0.05) are indicated by bold type-face.  
Best fit model was determined by AIC values. Models: rec= Reccesive; Dom= dominant; Mult= multiplicative, 
Gen= general.  
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TableA1.3.2 Inferred pseudohaplotypes for the COL5A1 rs71746744 and rs1134170 and miR-608 rs4919510 
polymorphisms in all participants, male participants and female participants for the asymptomatic control 












 AGGG/T/C 55.9 (121) 56.0 (67) 0.805 0.370 Dom 
 AGGG/T/G 14.6 (31) 14.4 (17) 0.869 0.351 Rec 
 AGGG/A/C 0.3 (0) 0.0 (0) 0.826 0.363 Dom/Mult 
 AGGG/A/G 0.0 (0) 0.4 (0) 0.197 0.657 Dom 
-/T/C 0.8 (1) 3.00 (3) 4.904 0.027 Dom 
-/T/G 0.3 (0) 1.2 (1) 2.510 0.113 Dom 
-/A/C 24.0 (52) 20.9 (25) 2.601 0.107 Rec 







 AGGG/T/C 57.1 (76) 53.5 (48) 4.234 0.040 Dom 
 AGGG/T/G 14.5 (19) 15.7 (14) 1.748 0.186 Rec 
 AGGG/A/C 0.4 (0) 0 .0(0) 0.730 0.393 Dom 
 AGGG/A/G 0.0 (0) 0.6 (0) <0.001 0.980 Rec 
-/T/C 0.4 (0) 4.0 (3) 9.140 0.002 Dom 
-/T/G 0 (0) 1.5 (1) IF IF IF 
-/A/C 24.9 (33) 20.0 (18) 2.607 0.106 Rec 







 AGGG/T/C 54.1 (44) 62.8 (18) 3.222 0.073 Dom 
 AGGG/T/G 14.5 (12) 11.3 (3) 1.093 0.296 Rec 
AGGG/A/C 0.0 (0) 0.0 (0) IF IF IF 
AGGG/A/G 0.6 (0) 0.0 (0) 0.632 0.427 Dom/Mult 
-/T/C 1.6 (1) 0.0 (0) 1.624 0.203 Dom/Mult 
-/T/G 0.8 (0) 0.0 (0) 0.947 0.330 Dom/Mult 
-/A/C 22.6 (18) 24.8 (7) 0.230 0.631 Rec 
-/A/G 5.8 (4) 1.1 (0) 1.882 0.170 Dom/Mult 
CON group and ACL rupture group are represented as a frequency (%), with the number of participants (n) in 
parenthesis. LR is the estimated risk. ND, not determined due to small sample size. Significant p-values 
(p<0.05) are indicated by bold type-face.  
Best fit model was determined by AIC values. Models: Rec= reccesive; Dom= dominant; Mult= multiplicative, 
Gen= general.  
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A2 Chapter 3- Supplementary Tables 
Table A2.1 Genotype Effects on descriptive measures for COL11A1 rs3753841 and rs1676486 and COL11A2 
rs1799907 in a Caucasian South African population. 
 COL11A1 rs3753841  COL11A1 rs1676486 COL11A2 rs1799907 
Age  0.904 0.782 0.018 
Height 0.403 0.450 0.290 
Weight 0.078 0.318 0.611 
BMI 0.961 0.548 0.053 
Gender 0.868 0.575 0.808 
P-values are tabulated.  
 
Table A2.2.1 Inferred haplotypes for the COL11A1 rs3753841 and rs1676486 polymorphisms in the control 






CON ACL LR p-value Model 




TC 59.1 (128) 59.4 (127) 1.235 0.266 Dom 
TT 0.0 (0) 0.9 (1) 0.038 0.846 Rec 
CC 19.6 (42) 22.3 (47) 1.392 0.238 Rec 
CT 21.3 (46) 17.4 (37) 4.044 0.044 Dom 




TC 57.8 (77) 59.2 (94) 0.745 0.388 Rec 
TT 0.0 (0) 0.8 (1) 1.495 0.221 Mult 
CC 18.8 (25) 22.0 (35) 2.339 0.126 Rec 
CT 23.3 (31) 18.00 (28) 3.589 0.058 Dom 




TC 61.1 (50) 59.8 (32) 1.084 0.298 Dom 
TT 0.0 (0) 1.1 (0) ND ND ND 
CC 20.8 (17) 23.0 (12) 0.391 0.532 Dom 
CT 18.1 (14) 16.1 (8) 1.084 0.298 Rec 
CON group and ACL rupture group are represented as a frequency (%), with the number of participants (n) in 
parenthesis. LR is the estimated risk. ND, not determined due to small sample size. Significant p-values 
(p<0.05) are indicated by bold type-face.  
Best fit model was determined by AIC values. Models: Rec= reccesive; Dom= dominant; Mult= multiplicative, 
Gen= general.  
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Table A2.2.2 Inferred haplotypes for the COL11A1 rs3753841 and rs1676486 polymorphisms in the control 
(CON) group, and non-contact (NON) anterior cruciate ligament rupture subgroup for all participants, male 










TC 59.1 (126) 60.2 (72) 0.335 0.563 Rec 
TT 0.0 (0) 1.5 (1) 0.007 0.931 Rec 
CC 19.5 (42) 20.7 (24) 0.062 0.803 Dom/mult 





TC 57.8 (77) 60.2 (54) 0.453 0.501 Rec 
TT 0.0 (0) 1.4 (1) 0.006 0.940 Rec 
CC 18.8 (25) 20.0 (18) 0.122 0.727 Rec 





TC 61.1 (50) 60.3 (17) 0.099 0.753 Dom 
TT 0.0 (0) 1.9 (0) ND ND ND 
CC 20.8 (17) 22.9 (6) 0.180 0.672 Dom 
CT 18.1 (14) 14.9 (4) 8.297 0.015 Gen 
CON group and NON ACL rupture subgroup are represented as a frequency (%), with the number of
participants (n) in parenthesis. LR is the estimated risk. ND, not determined due to small sample size.
Significant p-values (p<0.05) are indicated by bold type-face. 
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Table A2.3.1 Inferred pseudohaplotypes for the COL11A1 rs3753841 and rs1676486 and COL11A2 rs1799907 
polymorphisms in the control (CON), and anterior cruciate ligament rupture (ACL) groups for all participants, 












TCA 37.4 (81) 39.7 (85) 0.084 0.772 Mult 
TCT 21.7 (47) 19.7 (42) 0.597 0.440 Rec 
TTA 0.0 (0) 0.9 (1) 0.010 0.921 Rec 
TTT 0.0 (0) 0.0 (0) (0) ND ND ND 
CCA 13.9 (30) 14.9 (31) 0.280 0.597 Mult 
CCT 5.7 (12) 7.4 (15) 0.949 0.330 Dom 
CTA 14.7 (31) 9.5 (20) 6.697 0.010 Rec 







TCA 39.0 (52) 39.5 (63) 0.063 0.802 Rec 
TCT 18.8 (25) 19.7 (31) 0.863 0.353 Dom 
TTA 0.0 (0) 0.8 (1) ND ND ND 
TTT 0.0 (0) 0.0 (0) ND ND ND 
CCA 13.0 (17) 14.00 (22) 0.173 0.678 Dom/Mult 
CCT 5.8 (7) 8.1 (12) 1.153 0.283 Mult 
CTA 15.9 (21) 10.4 (16) 5.907 0.015 Rec 







TCA 35.1 (29) 39.3 (21) 0.351 0.554 Rec 
TCT 26.0 (21) 20.6 (11) 0.707 0.400 Mult 
TTA 0.0 (0) 0.0 (0) ND ND ND 
TTT 0.0 (0) 0.0 (0) ND ND ND 
CCA 15.2 (12) 18.6 (10) 0.304 0.582 Mult 
CCT 5.5 (4) 4.3 (2) 0.342 0.559 Rec 
CTA 12.4 (10) 6.5 (3) 1.141 0.285 Mult 
CTT 5.6 (4) 9.7 (5) 0.718 0.397 Dom 
CON group and ACL rupture group are represented as a frequency (%), with the number of participants (n) in
parenthesis. LR is the estimated risk. ND, not determined due to small sample size. Significant p-values
(p<0.05) are indicated by bold type-face. 
Best fit model was determined by AIC values. Models: Rec= reccesive; Dom= dominant; Mult= multiplicative, 
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Table A2.3.2 Inferred pseudohaplotypes for the COL11A1 rs3753841 and rs1676486 and COL11A2 rs1799907 
polymorphisms in the control (CON) group, and non-contact (NON) anterior cruciate ligament rupture 












TCA 37.4 (81) 40.3 (48) 0.383 0.536 Rec 
TCT 21.7 (47) 19.8 (23) 0.381 0.537 Rec 
TTA 0.0 (0) 1.5 (1) ND ND ND 
TTT 0.0 (0) 0.0 (0) ND ND ND 
CCA 13.9 (30) 12.9 (15) 0.874 0.350 Rec 
CCT 5.7 (12) 7.8 (9) 1.077 0.299 Rec 
CTA 14.7 (31) 10.3 (12) 4.360 0.037 Rec 







TCA 39.0 (52) 38.9 (35) 0.030 0.863 Dom 
TCT 18.8 (25) 21.3 (19) 1.374 0.241 Dom 
TTA 0.0 (0) 1.4 (1) ND ND ND 
TTT 0.0 (0) 0.0 (0) ND ND ND 
CCA 13.0 (17) 11.9 (10) 2.937 0.087 Rec 
CCT 5.8 (7) 8.2 (7) 1.086 0.297 Dom 
CTA 15.9 (21) 11.6 (10) 4.050 0.044 Rec 







TCA 35.1 (29) 43.7 (12) 1.162 0.281 Rec 
TCT 26.0 (21) 16.5 (4) 1.335 0.248 Mult 
TTA 0.0 (0) 1.9 (0) ND ND ND 
TTT 0.0 (0) 0.0 (0) ND ND ND 
CCA 15.2 (12) 15.6 (4) 0.131 0.717 Rec 
CCT 5.5 (4) 7.0 (2) 0.201 0.654 Rec 
CTA 12.4 (10) 7.7 (2) 0.697 0.404 Rec 
CTT 5.6 (4) 7.6 (2) 0.255 0.614 Rec 
CON group and NON ACL rupture subgroup are represented as a frequency (%), with the number of
participants (n) in parenthesis. LR is the estimated risk. ND, not determined due to small sample size.
Significant p-values (p<0.05) are indicated by bold type-face. 
Best fit model was determined by AIC values. Models: Rec= reccesive; Dom= dominant; Mult= multiplicative, 
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Table A2.4.1 Inferred pseudohaplotypes for the COL11A1 rs3753841 and rs1676486 and COL11A2 rs1799907 
polymorphisms in the control (CON) group, and anterior cruciate ligament rupture (ACL) group for all 


















TCA(AGGG) 24.7 (53) 30.2 (65) 0.839 0.360 Mult 
TCA(-) 12.8 (27) 9.5 (20) 0.708 0.400 Mult 
TCT(AGGG) 16.2 (35) 10.7 (22) 3.410 0.065 Rec 
TCT(-) 5.4 (11) 9.0 (19) 0.868 0.351 Dom 
TTA(AGGG) 0.0 (0) 0.9 (1) 0.008 0.928 Rec 
TTA(-) 0 (0) 0 (0) ND ND ND 
TTT(AGGG) 0 (0) 0 (0) ND ND ND 
TTT(-) 0 (0) 0 (0) ND ND MD 
CCA(AGGG) 11.1 (24) 10.3 (22) 0.344 0.557 Mult 
CCA(-) 2.4 (5) 4.7 (10) 0.452 0.501 Rec 
CCT(AGGG) 1.9 (4) 5.9 (12) 2.057 0.152 Mult 
CCT(-) 4.1 (8) 1.3 (2) 0.321 0.571 Rec 
CTA(AGGG) 12.9 (28) 9.2 (19) 5.302 0.021 Rec 
CTA(-) 2.0 (4) 0.0 (0) 3.350 0.067 Dom/mult 
CTT(AGGG) 4.0 (8) 4.2 (9) 0.852 0.356 Rec 













TCA(AGGG) 27.9 (37) 31.9 (49) 0.066 0.798 Mult 
TCA(-) 11.2 (14) 8.9 (14) 0.450 0.502 Rec 
TCT(AGGG) 16.2 (21) 9.0 (14) 5.602 0.018 Rec 
TCT(-) 2.6 (3) 10.1 (16) 4.650 0.031 Mult 
TTA(AGGG) 0.0 (0) 0.6 (0) 0.004 0.947 Rec 
TTA(-) 0.0 (0) 0.0 (0) ND ND ND 
TTT(AGGG) 0.0 (0) 0.0 (0) ND ND ND 
TTT(-) 0.0 (0) 0.0 (0) ND ND ND 
CCA(AGGG) 9.6 (12) 8.2 (13) 0.318 0.573 Dom 
CCA(-) 3.2 (4) 5.8 (9) 0.520 0.471 Rec 
CCT(AGGG) 1.1 (1) 6.6 (10) 2.754 0.097 Mult 
CCT(-) 4.9 (6) 1.4 (2) 0.300 0.584 Rec 
CTA(AGGG) 13.6 (18) 9.8 (15) 4.795 0.029 Rec 
CTA(-) 2.4 (3) 0.2 (0) 3.516 0.061 Dom/Mult 
CTT(AGGG) 3.5 (4) 4.7 (7) 0.576 0.448 Rec 













TCA(AGGG) 20.2 (16) 28.3 (15) 1.382 0.240 Mult 
TCA(-) 15.1 (12) 11.5 (6) 0.760 0.383 Dom 
TCT(AGGG) 17.4 (14) 13.3 (7) 0.112 0.738 Mult 
TCT(-) 8.4 (6) 6.7 (3) 1.239 0.266 Mult 
TTA(AGGG) 0.0 (0) 1.1 (0) ND ND ND 
TTA(-) 0.0 (0) 0.0 (0) ND ND ND 
TTT(AGGG) 0.0 (0) 0.0 (0) ND ND ND 
TTT(-) 0.0 (0) 0.0 (0) ND ND ND 
CCA(AGGG) 13.1 (10) 16.7 (9) 0.796 0.372 Rec 
CCA(-) 1.7 (1) 0.0 (0) 0.171 0.679 Dom/Mult 
CCT(AGGG) 3.1 (2) 4.1 (2) 0.161 0.688 Rec 
CCT(-) 3.0 (2) 2.1 (1) 1.562 0.211 Dom/Mult 
CTA(AGGG) 11.7 (9) 4.0 (2) 1.358 0.244 Mult 
CTA(-) 1.1 (0) 3.8 (2) 0.315 0.575 Dom/Mult 
CTT(AGGG) 3.8 (3) 7.0 (3) 0.274 0.600 Rec 
CTT(-) 1.5 (1) 1.3 (0) 1.433 0.231 Dom 
CON group and ACL rupture group are represented as a frequency (%), with the number of participants (n) in 
parenthesis. LR is the estimated risk. ND, not determined due to small sample size. Significant p-values 
(p<0.05) are indicated by bold type-face.  
Best fit model was determined by AIC values. Models: Rec= reccesive; Dom= dominant; Mult= multiplicative, 
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Table A2.4.2 Inferred pseudohaplotypes for the COL11A1 rs3753841 and rs1676486 and COL11A2 rs1799907 
polymorphisms in the control (CON) group, and non-contact (NON) anterior cruciate ligament rupture 


















TCA(AGGG) 24.7 (53) 32.7 (39) 3.820 0.051 Rec 
TCA(-) 12.8 (27) 8.1 (9) 1.206 0.272 Dom 
TCT(AGGG) 16.2 (35) 8.2 (9) 4.710 0.030 Rec 
TCT(-) 5.4 (11) 11.2 (13) 1.931 0.165 Mult 
TTA(AGGG) 0.0 (0) 1.4 (1) ND ND ND 
TTA(-) 0 (0 0.0 (0) ND ND ND 
TTT(AGGG) 0 (0 0.0 (0) ND ND ND 
TTT(-) 0 (0 0.1 (0) ND ND ND 
CCA(AGGG) 11.1 (24) 7.9 (9) 0.130 0.718 Rec 
CCA(-) 2.4 (5) 4.5 (5) 0.178 0.673 Rec 
CCT(AGGG) 1.9 (4) 6.8 (8) 1.767 0.184 Dom 
CCT(-) 4.1 (8) 1.6 (1) 0.227 0.634 Rec 
CTA(AGGG) 12.9 (28) 10.4 (12) 3.359 0.067 Rec 
CTA(-) 2.0 (4) 0.0 (0) 1.310 0.252 Dom 
CTT(AGGG) 4.0 (8) 3.4 (4) 0.419 0.517 Rec 













TCA(AGGG) 27.9 (37) 34.4 (31) 2.215 0.137 Rec 
TCA(-) 11.2 (14) 5.6 (5) 0.731 0.392 Dom 
TCT(AGGG) 16.2 (21) 5.6 (5) 3.392 0.066 Rec 
TCT(-) 2.6 (3) 14.6 (13) 7.099 0.008 Mult 
TTA(AGGG) 0.0 (0) 0.8 (0) ND ND ND 
TTA(-) 0.0 (0) 0.0 (0) ND ND ND 
TTT(AGGG) 0.0 (0) 0.0 (0) ND ND ND 
TTT(-) 0.0 (0) 0.0 (0) ND ND ND 
CCA(AGGG) 9.6 (12) 6.5 (5) 1.633 0.201 Rec 
CCA(-) 3.2 (4) 4.9 (4) 0.214 0.643 Rec 
CCT(AGGG) 1.1 (1) 7.3 (6) 2.300 0.129 Dom 
CCT(-) 4.9 (6) 1.3 (1) 0.223 0.637 Rec 
CTA(AGGG) 13.6 (18) 7.7 (7) 3.102 0.078 Rec 
CTA(-) 2.4 (3) 3.8 (3) 1.519 0.218 Dom/Mult 
CTT(AGGG) 3.5 (4) 6.9 (6) 0.268 0.605 Rec 













TCA(AGGG) 20.2 (16) 29.0 (8) 1.586 0.208 Mult 
TCA(-) 15.1 (12) 15.0 (4) 0.309 0.578 Dom 
TCT(AGGG) 17.4 (14) 9.8 (2) 1.339 0.247 Rec 
TCT(-) 8.4 (6) 6.4 (1) 0.670 0.413 Mult 
TTA(AGGG) 0.0 (0) 1.9 (0) ND ND ND 
TTA(-) 0.0 (0) 0.0 (0) ND ND ND 
TTT(AGGG) 0.0 (0) 0.0 (0) ND ND ND 
TTT(-) 0.0 (0) 0.0 (0) ND ND ND 
CCA(AGGG) 13.1 (10) 14.9 (4) 0.373 0.541 Rec 
CCA(-) 1.7 (1) 0.0 (0) 0.651 0.420 Dom/Mult 
CCT(AGGG) 3.1 (2) 7.7 (2) 0.280 0.596 Dom 
CCT(-) 3.0 (2) 0.0 (0) 1.385 0.239 Dom/Mult 
CTA(AGGG) 11.7 (9) 8.2 (2) 0.653 0.419 Mult 
CTA(-) 1.1 (0) 0.0 (0) ND ND ND 
CTT(AGGG) 3.8 (3) 2.7 (0) 0.107 0.743 Rec 
CTT(-) 1.5 (1) 4.4 (1) 0.741 0.389 Dom 
CON group and ACL rupture group are represented as a frequency (%), with the number of participants (n) in 
parenthesis. LR is the estimated risk. ND, not determined due to small sample size. Significant p-values 
(p<0.05) are indicated by bold type-face.  
Best fit model was determined by AIC values. Models: Rec= reccesive; Dom= dominant; Mult= multiplicative, 
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A3 Chapter 4- Supplementary Tables 
Table A3.1 Genotype Effects on descriptive measures for COL11A1 rs3753841 and rs1676486 and COL11A2 









Age 0.062 0.866 0.586 0.861 
Height 0.817 0.636 0.948 0.625 
Weight 0.808 0.529 0.946 0.419 
BMI 0.885 0.143 0.997 0.661 
Gender 0.936 0.771 0253 0.342 
P-values are tabulated.
Table A3.2 Inferred allele combinations for the COL11A1 rs3753841, COL11A1 rs1676486 and COL11A2 









TC 57.8 (172) 63.3 (106) 4.751 0.029 Rec 
TT 1.2 (3) <0.5 (0) 1.195 0.274 Mult 
CC 20.5 (61) 19.5 (32) 2.158 0.142 Rec 




TA 41.2 (132) 37.17 (67) 0.539 0.463 Dom 
TT 16.9 (84) 26.89 (48) 7.830 0.005 Mult 
CA 27.4 (88) 26.21 (88) 3.212 0.073 Dom 




CA 55.2 (182) 49.5 (90) 4.300 0.038 Rec 
CT 23.1 (76) 32.5 (59) 6.576 0.010 Mult 
TA 13.5 (44) 14.0 (25) 0.413 0.520 Rec 






TCA 40.6 (137) 37.1 (67) 0.744 0.388 Dom 
TCT 17.2 (58) 26.2 (47) 7.790 0.005 Mult 
TTA 1.2 (4) 0.4 (0) 1.176 0.278 Mult 
TTT 0.0 (0) 0.0 (0) N/A N/A N/A 
CCA 14.4 (48) 13.1 (24) 1.913 0.167 Rec 
CCT 6.1 (20) 6.3 (11) 1.284 0.257 Rec 
CTA 12.4 (42) 13.0 (23) 0.450 0.502 Mult 
CTT 8.0 (27) 3.9 (7) 3.694 0.055 Dom 
CON and TEN are represented as a frequency, with the number of participants (n) in parenthesis. LR is the 
estimated risk. ND, not determined due to small sample size. * represents a significant p-value (p<0.05).  











APPENDIX A: Supplementary Tables 
132 
Table A3.3 Inferred allele combinations for the COL11A1 rs3753841, COL11A1 rs1676486 and COL11A2 












T/AGGG 37.2 (104) 49.2 (80) 8.322 0.004 Mult 
T/- 20.8 (58) 14.7 (24) 5.306 0.021 Rec 
C/AGGG 29.4 (82) 29.7 (48) 7.041 0.030 Gen 






C/AGGG 49.8 (142) 63.5 (106) 11.128 <0.001 Dom 
C/- 28.4 (81) 18.6 (31) 5.716 0.016 Rec 
T/AGGG 16.7 (47) 15.6 (26) 0.514 0.474 Mult 






A/AGGG 45.3 (139) 49.5 (86) 0.448 0.503 Dom 
A/- 23.5 (72) 13.7 (23) 10.055 0.002 Mult 
T/AGGG 21.3 (65) 29.6 (51) 5.788 0.016 Dom 












TCA(AGGG) 29.2 (98) 25.6 (47) 0.731 0.393 Dom 
TCA(-) 11.6 (39) 11.9 (21) 3.604 0.058 Mult 
TCT(AGGG) 9.1 (30) 25.2 (46) 13.386 <0.001 Mult 
TCT(-) 8.0 (27) 0 (0) 1.531 0.216 Rec 
TTA(AGGG) 0 (0) 0 (0) ND ND ND 
TTA(-) 1.2 (3) 0 (0) ND ND ND 
TTT(AGGG) 0 (0) 0 (0) ND ND ND 
TTT(-) 0 (0) 0.5 (0) ND ND ND 
CCA(AGGG) 8.8 (29) 11.5 (21) 0.443 0.506 Rec 
CCA(-) 5.3 (18) 1.2 (2) 4.148 0.043 Mult 
CCT(AGGG) 4.0 (13) 2.4 (4) 0.629 0.428 Dom 
CCT(-) 2.2 (7) 4.8 (8) 0.396 0.529 Rec 
CTA(AGGG) 7.3 (24) 10.7 (19) 0.085 0.770 Dom 
CTA(-) 5.3 (17) 2.2 (4) 4.336 0.037 Mult 
CTT(AGGG) 7.9 (26) 4.0 (7) 2.928 0.087 Dom 
CTT(-) 0 (0) 0 (0) ND ND ND 
CON and TEN are represented as a frequency, with the number of participants (n) in parenthesis. LR is the 
estimated risk. ND, not determined due to small sample size. Significant values are indicated by bold typeface. 
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Appendix B- Forms 
B1.1 ACL Rupture: Ethics Approval 
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B1.2 ACL Rupture: Informed Consent 
 
 
Department of Human Biology 
UCT IM RC RESEARCH U NIT FOR EXERCISE SciENCE & S PORTS M EDICINE 
Faculty of Health Sciences , University of Cape Town 
Private Bag, Rondebosch 7700 , South Africa 
Tel: + 27 21 650 4561 
Fax: + 27 21 686 7530 
GENETIC BASIS OF EXERCISE·INDUCED LIGAMENT INUJURY 
INFORMED CONSENT 
I, the undersigned, have been full y informed about the UCT/MRC Research Unit for Exercise Science and 
Sports Medicine within the Department of Human Biology of the University of Cape Tovvn's study on the genetic 
basis of exercise induced chronic ligament pathology. I have agreed to donate five millili tres of venous blood or 
a Buccal mouthwash sample, which will be used for the extraction and analysis of genetic material (DNA ). I 
have also agreed to complete personal particulars , sporting participation, medical history, stretching and warm 
up questionnaires and understand that all the information that is collected during the study will be treated with 
the strictest confidentiali ty and will only be used for scientific research purposes. I also understand that my 
name and personal particulars will be not released under any circumstances and that all data will be analysed 
anonymously. 
I agree to participate in the study and I have been informed that I will be free to withdraw from the study at any 
time if I so wish. I understand that my DNA sample will be destroyed on completion of the study on the genetic 
basis of ligament pathology. I also unders tand that I will be free to request that my DNA sample be destroyed 
before the completion of the study. 
I understand that the DNA will be genotyped (analysed) for variations (polymorphisms) within genes relating to 
the genetic basis of li gament injuries. I understand that whil st there is no direct benefi t to myself, if a genetic 
predisposition for ligament injuries can be establi shed, then future generations will be able to establi sh their risk 
for this condition. This may allow better prevention and treatment options in the future. I understand that I will 
receive the overall results of the study. I have read (or where appropriate, have had read to me) and understand 
the information about this study, and any questions I have asked have been answered to my satisfaction. I 
agree to participate in the study, reali sing that I have the right to request that my DNA sample be destroyed at 
any time. I agree that research data provided by me or with my permission during the project may be induded in 
a thesis, presented at conferences and publi shed in journals on the condition that either my name not any other 
identifying information is used. 





The University of Cape Town is committed to pol icies of equal opportunity and affirmative action 
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B1.3 ACL Rupture: Participant Information 
 
 
Department of Human Biology 
UCT/ MRC RESEARCH UNIT FOR EXERCISE SciENCE & S PORTS MEDICINE 
Faculty of Health Sciences , University of Cape Town 
Private Bag, Rondebosch 7700 , South Africa 
Tel: + 27 21 6504561 
Fax: + 27 21 686 7530 
THE GENETIC BASIS OF EXERCISE-INDUCED LIGAMENT INJURY 
Al though there is a high incidence of ligament injuries as a result of participation in exercise and sporting 
activities, the cause(s ) of these injuri es are poorly understood. Some researchers have suggested thaI there 
is a genetic component to exercise-induced ligament injuri es. In an attempt to determine whether there is a 
genetic basis for ligament pathology, we are interested in studying whether certain genes are associated with 
ligament injuries. This project is being done in collaboration with the UCT/M RC Research Unit for Exercise 
Science and Sports Medicine within the Department of Human Biology of the University of Cape Town. 
You will be required to visit the Sports Science Institute of South Africa (SS ISA) in Boundary Road, 
Newlands. During the visit, which should take 15 minutes, you will be asked to donate 5 ml (1 teaspoon) of a 
blood sample for DNA analysis. You will also be required to complete personal particulars, sporting detail s, 
medical history and stretching and warm up questionnaires . 
Al l the information retri eved from this study will be treated with the strictest confidentiali ty and will be used 
only for scientific research purposes. Your name and personal particulars will not be released under any 
circumstances and all data will be analysed anonymously. Your DNA sample will be destroyed on completion 
of the study on the genetic basis of li gament injury. You are also free to request that your DNA sample be 
destroyed before the completion of the study. 
If you are part of the li gament pathology group, we would appreciate it if you could help us by recruiting two 
other people of same (or similar) age whom you know and who has trained without suffering any ligament or 
tendon injuries for the control group. 
We will keep you informed about the outcomes of this study and look forward to working together with you. If 
you have any questions about this study, please feel free to contact us at:. 
Melanie Hay, BSc (Med) (Hons) 
(021 ) 650-4569/ 082 781 0102 
melanie.hay@ucl.ac.za 
Dr Ali son September, PhD 
(021 ) 650 4559 
alison.september@uct.ac.za 
Dr Mike Posthumus, PhD 
(021) 650 4572 
michael.posthumus@ucl.ac.za 
Prof. Malcolm Collins, PhD 
(021) 650 4574 
malcolm.collins@uct.ac.za 
The University of Cape Town is committed to pol icies of equal opportunity and affirmative action 
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B1.4 ACL Rupture: Questionnaires 
 
Department of Human Biology 
UCT/MRC RESEARCH U NIT FOR EXERCISE SciENCE & S PORTS MEDICINE 
Faculty of Health SCiences , University of Cape Town 
Private Bag, Rondebosch 7700 , South Africa 
Tel: + 27 21 6504561 
Fax: + 27 21 6867530 
GENETIC BASIS OF LIGAMENT INJURY QUESTIONNAIRES 
A. PERSONAL PARTICULARS 
Surname 
Fi rst Name 
Postal Address 
Code 
E-mail address Phone (day time) 
Dale of birth , , , \1 M o 0 Cell 
Height (em) Gender Male 0 Female 0 
Weight (kg ) Pre-Injury: Current: 
Ethnic group Black/African 0 White 0 Indian 0 
(Only Required and 
Used for Research 
Purposes) Mixed Ancestry (Coloured) 0 Asian 0 Other 0 
Ancestry: Tribal 
0 or national Father Unknown 
background 
(eg Xhosa , Dutch, 
0 ZUIU'n~errnan , Mother Unknown 
Italian 
Country of Birth 
Dominant Hand Left 0 Right 0 D I Dominant Ambi Leg I Left 0 Right 0 Ambi 0 
Smoker 
Yes (Current) 0 Yes (Ex smoker) 0 I No, never 0 
If yes, Number of If stopped, when 
years 
If yes , number per day 
Genetic Basis of ligament Injury Questionnaires 
The University of Cape Town is committed to pol iCies of equal opportunity and affirmative action 














(If you participate or have participated in more than 6 sports , please complete 
additional Sporting Details Questionnaires , Part B) 
B. SPORTING DETAILS 
Please record your sporting activities in order of importance 
Type of sport{s) you have 
Main sport 1 Other sport 2 Other sport 3 
participated in (please name) 
Current or past participation Current 0 Past 0 Current 0 Past 0 Current 0 Past D 
Year started participation 
Number of years involved in the 
sport 
Position played prior to injury (if 
appropriate) 
Playing level prior to injury (if 
appropriate) 
Number of years played prior to 
the injury. 
Type of sport{s) you have 
Other sport 4 Other sport 5 Other sport 6 
participated in (please name) 
Current or past participation Current 0 Past 0 Current 0 Past 0 Current D Past D 
Year started participation 
Number of years involved in the 
sport 
Position played prior to injury (if 
appropriate) 
Playing level prior to injury (i f 
appropriate) 















I C. ANTERIOR CRUTIATE LIGAMENT INJURY DETAILS 
Date of ACL injury? 
Which side was injured? D Left D Right D Both 
To what extent was your o Complete D Partial D None o Unknown ligament ruptured? 
Investigation done to confirm D MRI D Surgery the diagnosis 
How bad IS your pain today? 
(mark line: 
I·· --- ---- ---- ------- ---- ------- --- -------- --- -------- --- -------- --- ---- I 
e. g .1--- ---- ---- --1---- ---- --- ------1 ) f'..b pain Pain as bad as it can be 
o Direct impact 
How was the ACL ruptured? o Twisting and bending with contact 
(please also explain exactly o Twisting and bending without contact 
how the injury occurred) o Other non-contact 
D Other .. 
o Ice application 
What was the initial treatment? 
o Compresion 
(You may tick more than one o Immobili sation 
block. ) D Medication 
D Other .. 
D Surgery 
What was the final treatment? D Reabili tation 
D Other .. 
D Pain 
What are your current o Swelling 
symptoms? (You may lick D Instabili ty 
more than one block.) D Weakness 
D Other .. . .. . ..... . .. . ........ . ... •• ...• . .. .•. . 
D None 
What is your current sports o Limited to non-weight bearing exercise 
participation? o Limited , not to same level as pre-injury 














o Wet and soft ground 
If you are able to recall , what o Dry, but soft ground 
were the weather and pitch o Dry and firm ground conditions like at the time of 
injury? o Wet, but firm ground 
D Other. . 
o Meniscal tear 
D MCl tear 
Associated injuries? o Other ligament tear 
o Bone bruising 
D Other. . 
D. HISTORY OF OTHER LIGAMENT AND TENDON INJURIES IN THE PAST 
Have you ever injured a ligament in the 
Yes D No D past? 
l R l R 
Knee (ACl ) D D Wrist ligaments D D 
If yes, please specify which ligaments? Knee (MC l ) D D Finger ligaments D D 
(You may tick more than one block, 
D D D D please select either L (left) or R (right)) Ankle lateral li gaments Knee (PCl) 
Spinal ligaments D D Knee (lCl) D D 
Shoulder ligaments D D Ankle medial ligaments D D 
Elbow ligaments D D Other ligaments D D 
If Yes, please specify the famil y member 
D Mother 
D Father 
To your knowledge, have any other 
Yes D No D D Sibling members of your family suffered from 
any ligament injury? o Son I daughter 
o Other famil y member .. 
and condition: Please choose ligament 
injury from the list above 
Have you ever injured a tendon in the 















Achilles tendon DO 
Foot and ankle: 
DO Tibiali s posterior 
Plantar fascia DO 
Knee: Patellar tendon DO 
If yes , please specify which tendon? 
Elbow and wrist: o D (You may tick more than one block, Wrist extensor tendons 




Teres minor DO 
Other: . 
If Yes , please specify the famil y member 
0 Mother 
0 Father 
To your knowledge, have any other 
Yes 0 No 0 0 Sibling members of your family suffered from 
any tendon pathology? 0 Son I daughter 
0 Other famil y member: . 
Condition: Please choose tendon injury from 
the li st above 
0 Acute shou lder dislocation 
0 Chronic shoulder instabili ty 















E. MEDICAL HISTORY 
Do you currently suffer from any of these medical conditions: 
D High Blood Pressure D Angina/Heart Attack o Asthma 
o Emphysema o Rheumatoid arthri tis o Osteoarthri tis (wear & lear) 
o Malignant disease (cancer) o Elevated Blood Cholesterol o Adrenal disorders 
o Diabetes melli tus o Thyroid disorders 
If Yes, what type? o Renal disease o Amyloidosis 
Do you currently suffer from any other 
Ves 0 No 0 I lf Ves. please select from the list below Connective Tissue & Rheumalological 
Diseases & Disorders? 
Ust of some Connective Tissue and/or Rheumatic Diseases and Disorders 
o Ankylosing Spondyli tis o Lipid Storage Diseases o Pseudogout 
D Aspartylglycosaminuria (AG U) o Marfan Syndrom e o Reactive Arthritis 
o Beheet's Syndrome o Menkes Kinky Hair Syndrome o Reiter's Syndrome 
o Crohn' s Disease o MJcopolysaccharidoses o Relapsing Polychrondri tis 
o Discoid Lupus Erythematosus o Myopathies and Dystrophies o Scleroderma 
o Ehlers-Danlos syndrom e (EDS) o Ochronosis (Homocystinuri a) o Sjogren's Syndrome 
o Eosinophilic Fascitis o Osteogenesis imperfecta (0 1) o Systemic Lupus Erythematosus (SLE) 
o Giant Cell (Temporal) Arthritis o Polyarteri tis Nodosa o Systemic Sclerosis 
o Gout o Polymyalgia Rheumatica o Wegener's Granulomatosis 
o Hypersentive Vasulatis o Polymyositis & Dermatomyositis o Other 
Operation Dale 
What surgical operations have you 
had? (please list and give dates) 
If female: 
At what age did you start 
menstruating? (years) 
Are you currently using any type of 0 Ves 0 No contraception? 














D Pre-menopausal (±12 cycles per year at in tervals of 23-
33 days & bleeding lasts 3-7 days) 
Are you currently? D Menopausal (cycles are irregular and less frequent) 
D Post-menopausal (no longer menstruating) 
Family History 
If Yes, which relative? 
D Mother 
Do any other members of your famil y 
D Father 
suffer from elevated blood cholesterol? Yes D No D D Sibling 
D Son I daughter 
D Other relative . . ..... . .. . .. . .• . . 




Is there any history of arthritis in your 
Yes D No D 
D Son I daughter 
famity? D Other relative . . ..... . .. . .. . .. . .. . .. 




Drug and Allergy History 
If yes , how long ago (or how many times , where applicable) 
did you use the medication? 
Have you ever used oral corticosteroids 
Yes D No D 
D 3 months D 6 months 
(cortisone tablets)? D 12 months D 24 or more months 
Have you ever been given an injection 
Yes D No D 
D 3 months D 6 months 
..,.,.; th corticosteroids? D 12 months D 24 or more months 
Have you ever been given an injection 
Yes D No D 
D Once D Twice 
of corticosteroids in or around a 
tendon? D 3 limes D ::>3 times 
Yes D No D 
D 3 months D 6 months 
Have you ever used anabolic steroids? 
D 12 months D 24 or more months 
Have you ever used fluoroquinoline 















If yes, please select from the itst below: 
o ADCD-CIPRIN o CIPRDBAY o SANDOZ CIPROFlOXACIN 
o AVELDN o CIPRDGEN o TAFLOC 
o BACTIDRON o CPL ALLIANCE CIPROFlOXACIN o TARIVID 
o CIFLOC o DYNAFLOC o TAVANIC 
o CIFRAN o FLOXIN o TEQUIN 
o CIPlA-CIPROFlOXACIN o MAXAQUIN o UNIQUIN 
o CIPLOXX o NOROXIN o UTN-400 
o CIPRO-HEXAL o ORPIC o ZANOCIN 
o Other 
What medication, if any, are you 
currently using? (please list) 
What allergies do you have? (please 
list) 
F. OCCUPATIONAL DETAILS 
What is your current occupation? 
What was your occupation prior to injuring your 
ligament? 
Prior to injury, did your occupation involve lower limb 
D Yes o No activity? 
If yes please indicate which legs. 
Right leg 0 80th legs 0 
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B2.1 Achilles Tendinopathy: Ethics Approval 
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B2.2 Inclusion and Exclusion Criteria 
Inclusion Criteria: 
A clinician reviewed the clinical diagnosis for every participant. Briefly, participants had to have 
experienced gradual, progressive pain in the region of the Achilles tendon for more than 6 months. 
Furthermore, at least one other of the following criteria had to be fulfilled regarding the Achilles 
tendon region: 
i) Early morning pain
ii) Early morning stiffness
iii) History of swelling
iv) Tenderness to palpation
v) Palpable nodular thickening
vi) Movement of the affected area with plantar dorsiflextion (positive shift test). 
Exclusion Criteria: 
Participants with known connective tissue disease or systemic disease known to be linked to tendon
pathology were excluded from this study. Such conditions include: Ehlers-Danlos syndrome, benign
hypermobility joint syndrome, rheumatoid arthritis, systemic lupus erthyematosus,
hyperparathyroidism, renal insufficiency, diabetes mellitus and familial hypercholesterolaemia.
Furthermore, individuals that made use of fluoroquinolone antibiotics or corticosteroid injections
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Department of Human Biology 
UCT/ MRC RESEARCH U NIT FOR EXERCISE SCIENCE & S PORTS MEDICINE 
Faculty of Health Sciences , University of Cape Town 
Private Bag , Rondebosch 7700 , South Afr ica 
Tel: + 27-21-650-4561 Fax: + 27-21-686-7530 
CLI NICAL DIAG NOSIS OF ACHILLES TENDINOPATHY 
SU BJECT NAME/ NUMBER/CODE : _____________ _ 
Clinical criteria 1;2 Present 
Gradual progressive pain over the posterior lower leg - Achilles 
tendon area (> 6 weeks) 
Early morning pa in 
Early morning stiffness 
History of swelling over the Achilles te ndon area 
Tenderness to palpation over the Achilles tendon 
Palpable nodular th ickening over the affected Achilles 
Positive "shift" test (movement of the nodular area with plantar-
Idorsi-flexion) 
Other criteria Present 
Confirmation of the diagnosis by ultrasound' 
Confirmation of the diagnosis by MRI • 
Confirmation of the diagnosis by CT scan ' 
*: One of these cri teria must be present to confirm the diagnosis 




1. Schepsis AA, Jones H, Haas AL. Achilles tendon disorders in athletes. AmJ 
Sports Med 2002;30:287-305 . 
2. Kader D, Saxena A, Mavin T, Maffulli N. Achilles tendinopathy: some aspects of 
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B2.3 Achilles Tendinopathy Informed Consent 
 
Department of Human Biology 
UCT/ MRC R ESEARCH UNIT FOR EXERCISE SCIENCE & S PORTS MEDICINE 
Faculty of Health Sciences , University of Cape Town 
Private Bag, Rondebosch 7700 , Sou th Africa 
Tel: + 27-21-650-4561 Fax: + 27-21-686-7530 
IDENTIFICATION OF GENETIC RISK FACTORS UNDERLYING ACHILLES 
TENDON INJURIES: A REPEAT STUDY 
INFORMED CONSENT 
I, (the participant), have been full y informed about this study on the genetic basis of Achilles 
lend in apathy to be conducted by the UCT/MRC Research Unit for Exercise Science and Sports 
Medicine at the University of Cape. I have agreed to donate five millili tres of venous blood or a Buccal 
mouthwash/swab sample, which will be used for the extraction end analysis of genetic material (DNA). 
I agree thaI the blood sample w ill be taken by a nurse, physician or ph lebotomist. I agree to perform a 
range of motion test (sit-and -reach test or a single leg raise test) to determine my flexibili ty. I have also 
agreed to complete personal particu lars , sporting participation, personal and famil y medical history , 
muscle cramping, as well as , stretch ing and warm up questionnaires and understand that all the 
information that is collected during the study w ill be treated with the strictest confidentiality and will 
only be used for scien tific research purposes. I also understand that my name and personal 
particulars w ill not be released under any circumstances and tha t all data will be analysed 
anonymously. 
I am also prepared to visit the Sports Science Institute of Sou th Africa (SS ISA) in Boundary Road , 
Newlands for a cl inical examina tion in order to confirm my diagnosis (at no cost to myself). If 
requested , I am prepared to visit the Sports Science Institute of Sou th Africa (SS ISA) in Boundary 
Road , Newlands to undergo an ultrasound or MRI in order to confirm my diagnosis (at no cost to 
myself). If requested , I am also prepared to visit the Sports Science Institute of South Africa (SS ISA) in 
Boundary Road , Newlands for measurements to determine muscu lo-tend inous stiffness . I give 
permission that the study investigators may access my medical records (doctor/physiotherapist) in 
order to confirm my diagnosis. 
I agree to participate in the study and I have been informed that I will be free to withdraw from the 
study at any time if I so wish. I understand that my DNA sample w ill be destroyed on completion of 
the study to identify genetic risk factors associated with Achilles tendon pathology. I also understand 





The Unl~ers ity of Cape Trmn is committed to polides of equal opportunity and alfirmatl~ e ac tion 
whICh are essel1 tlal to ~s m,sslon of promot'i"lQ crr tlCal lnqu,ry and schoiarsh,p 

















The potential risks associated w ith blood collection technique from the ante-cubital veins are: infection, 
delayed healing , haem atom a, physical pain, mental discomfort and injury to a nerve or a vessel. 
These risks are small and will be minimized by the use of trained phlebotomists, use of sterile 
techniques and the use of disposable, single use materials. 
I understand that the DNA will be genotyped (analysed ) for variations (polymorphisms) w ithin the type 
V collagen gene (COL5A 1), the Tenacin-C gene (TNC ), the matrix metalloproteinase-3 gene (MMP3), 
the growth and differentiation factor-S gene (GDF5), as well as add itional genes, which may become 
relevant during the course of the investigation. 
I understand that whil st there is no direct benefit to myself , if a genetic pred isposition for Achilles 
tendon injuries can be establi shed , then future generations w ill be able to establi sh their risk for this 
condition. This may allow better prevention and treatment op tions in the future. I understand that I w ill 
receive the overall resul ts of the study. I have read (or where appropriate, have had read to me ) and 
understand the information about this study, and any questions I have asked have been answered to 
my satisfaction. I agree to participate in the study, reali sing that I have the right to request that my 
DNA sample be destroyed at any time. I agree that research data provided by me or w ith my 
permission during the project may be included in a thesis, presented at conferences and publi shed in 
journ als on the condition that neither my name nor any other identifying information is used . 
Any questions regarding this project may be directed to Dr Alison September on telephone number 
021 650 4559 or e-mail alison.september@uct.ac.za or to Prof Malcolm Collins on telephone 
number 021 6504574 or e-mail malcolm.collins@uct.ac.za. 
If you have any complaints or queries that the investigator has not been able to answer to your 
satisfaction, you may contact the Facul ty of Health Sciences Human Research Ethics Committee at 
the University of Cape Town Prof Marc Blockman on telephone number 021 4066452. 
Name of Participant: ______________ _ 
Signature: _________________ ___ Date: ______ _ 
Name of Researcher: _______________ _ 
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B2.4. Achilles Tendinopathy Participant Information 
 
  
Department of Human Biology 
U CT/M RC RESEARCH UNIT FOR EXERCISE S a ENCE & SPORTS MEDICINE 
Faculty of Health Sciences , University of Ca pe Town 
Private Bag, Ron debosch 7700, South Africa 
Tel: + 27-21-650-4561 Fax : + 27-21-686-7530 
THE IDENTIFICATION OF GENETIC RISK FACTORS UNDERLYING ACHILLES 
TENDON INJ URIES: A REPEAT STUDY 
INFORMATION SHEET 
Al though there is a high incidence of tendon overu se injuries as a result of participation in exercise 
and sportin g activities , the ca use(s) of these injuries are poorly understood . Some resea rchers 
have suggested that there is a genetic component to exerci se-in duced tendon injuries . In an 
attempt to determin e wh ether there is a genetic basis for tendon patholog y, we are interested in 
studyin g wh ether certain genes are associated with chronic tendinopathies. This project is bein g 
done in the UCT/MRC Research Unit for Exercise Science and Sports Med icine within the 
Department of Human Biology at the University of Cape Town. 
You will be required to visit the Sports Science In stitute of South Africa (SS ISA) in Boundary Road , 
Newlands. During the visit, wh ich should take at least 1 hour, you will be asked to donate 5 ml (1 
teaspoon) of a blood sample for DNA analysis. You will also be required to (1) perform a range of 
motion test to determin e your flexib ili ty, and (2) complete personal particulars, sportin g 
participation, personal and family med ica l history, mu scle crampin g, as well as , stretchin g and 
wa rm up questionnaires. At a later stage , some participants will be asked to visit a doctor 
(rad iolog ist) for a tendon scan at no cost to themselves. 
All the in formation retrieved from this study will be treated with the strictest confidentiali ty and will 
be used only for scientific research pu rposes. Your name and personal particulars will not be 
released under any circumstances and a ll da ta will be analysed anonymously. Your DNA sample 
will be destroyed on com pletion of the study on the genetic basis of tendon patholog y. You are 
a lso free to request that your DNA sampl e be destroyed before the com pletion of the study. 
You will not be reimbu rsed or compensated if you participated in this study. In addition you will not 
receive personal genetic resul ts. You will however be in formed about the overall results of the 
study and your personal flex ibility results . 
The University of Cape Town (UCT) has an appropriate in surance policy to cover payment for any 
trial-related injury. 
If you are part of th  tendon pathology group , we would appreciate it if you could help us by 
recrui ting !\No other people of same (or similar) age wh om you know and who has train ed without 
suffering any tendon injuries for the control group. 
We will keep you in formed about the ou tcomes of this study and look forward to workin g together 
wi th you. If you have any questions abou t this study, please feel free to contact us at:-
Dr Alison September, PhD 
(021 ) 650 4559 
alison .september@uct.ac .za 
Prof. Ma lcolm Collin s, PhD 
(021 ) 650 4574 
ma lcolm .collin s@uct.ac.za 
Pro f. Martin Schwellnu s, MBChB, MD 
(021 ) 650 4576 
ma rtin . schwelln u s@uct.ac.za 
~ 
The Uni verni\~ 01 Cape Town is commil ll!<f 10 pol ic ies 01 equal o pponooly and affi rmat ive ""l ion 
which a", ess""lial lo its m iss ion 01 pmmOli,,!; crit ical inouiry aoo scholarship I M R C 
"""""'" 
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B2.5 Achilles Tendinopathy Questionnaire 
 
Department of Human Biology 
UCTIMRC RESEARCH U~T FOR EXERCISE S CIENCE & SPORTS M EDICINE 
Faculty of Health Sciences, University of Cape Town 
Private Bag, Rondeboscl1 7700, South Afr ica 
Tel: + 27·2 1-650-4561 Fax: + 27-21-686-7530 
The identification of genetic susceptibility loci underlying Achilles 
tendon pathology: A Repeat Study. 
Instructions 
Please answer each question by filling in the details in the allocated space or 

















Please complete! all twelve sections A to L 
Personal Details Page 2 
Sporting Details Page 3 
Flexibility Training History Page 4 
Lifestyle and habits history Page 4 
General Personal Medical History Page 5 
Fami ly Medical History Page 6 
History of Medication Use Page 7 
Muscle Cramping Page 8 
Past History of Skeletal Muscle Injury Page 9-10 
History of Tendon, Ligament or Joint Capsule Injury Pages 11 
Medical Deta il s of Tendon Injuries Pages 12-13 
History if Any Other Chronic Current Injury Pages 14 
Subject Numb er: ___ _ 
1l1" Uni""""ly 01 Cape Town i. OOO1"';11ed 10 pcH id"" 01 "'1",,1 opponunily and affirmal i"" aCl ioo 
"'him are " • .enlial ~ il' missi on 01 prornol ir>g C1il ica l i "'lllir ~ and sch<Nars hip 
Discovery 0 H ea lth 
SPO RTS 
SCIIiNO : 
'''w, .... . " 
Vers ion 3 














Subj ect No : ___ _ 




I Postal! Zip Code 
E-mail address 
Alternate E-mail address Phone (day time) ,Ot -
Date of birth , - Cell (Mobile) 
Height om So< Maie D Female D 
Weight kg Ag' Y" 
Ethnic group Black/African 0 White 0 Indian 0 
(Orlly Required arrd Used for 
0 0 0 Research Purposes) Mixed Ancestry (Coloured ) Asian Other 
Ancestry: Tribal or Father: Unknown 0 
national background 
(eg Xhosa, Dutch, Zulu, 
0 Germarl, Italiarl) Mother: Unknown 
Country of Birth 
Dominant Hand Left D Right [ J Both D I Domin ant Leg I Left D Right D Both D 
Current Occupation 
Sitting: -- % 
What percentage of your Standing: % 
working day is spent in --
the following activities? Walking (Lower body activity) -- % 
Manual Labour (upper and body activity) -- % 
Occupation prior to muscle injury? I 
Prior to injury, did your occupation involve lower or upper limb activity? I Yes 0 No 0 
If yes please indicate Right arm 0 Left arm D Both arms 0 















5 b"act No U I 
Section B. Sporting Details 
Please record your sport ing acti vi ti es in order of importance 
Use an additional form if y ClU parti cipate(d) in more than 6 sports 
Type of sport(s) you have participated M,ain sport 1 Other sport 2 Other sport 3 
in (please name) 
Current or past participation Curre,n! D Past D Current 0 Past D Current D Past 0 
Year started participation 
Number of years involved in the sport 
Years in competitive sport 
Professional or amateur 
Hours of training per week 
(last 3 months) 
Hours of training per week 
(3-12 months) 
Hours of training per week 
(12-24 months) 
Type of sport(s) you have participated Other sport 4 Other sport 5 Other sport 6 
in (please name) 
Current or past participation Current D Past 0 Current 0 Past 0 Current D Past 0 
Year started participation 
Years involved in the sport 
Years in competitive sport 
Professional or amateur 
Hours of training per week 
(last 3 months) 
Hours of training per week 
(3-12 months) 
Hours of training per week 















Subj ect No: ___ _ 
Section E. General Personal Medical History 
Do you curren tly su ffer from any of these medical condit ions: 
I ~ High Blood Pressure o Angin a/Heart Attack o Asthma o Emphysem a o Rheumatoid arthritis o Osteoarthritis (wear & tea r) o Malignant disease (cancer) o Elevated B lood Cholestero l o Adrenal disord ers 
If Yes , what type? o Diabe tes melli tus o Thyroid disord ers o Rena l dise ase o Amyloidosis 
Do you curren tly suffer f rom any other 
Connective Tissue , Rheumatological Yes 0 No O If Yes , please se lect from the list below 
Or Muscle Diseases & D isorders? 
List of some Conn ective Tiss ue and/or Rheum atic D iseases and D isord ers 
D Ankylosing Spondylitis D Lipid Storage Diseases D Pseudogout 
D Aspartylglycosaminuria (AGU) D Marfan Syndrome D React ive Arthritis 
D Be hcet's Syndrome D Menkes Kinky Hair Syndrome D Reiter's Syndrome 
D Crohn's Disea sa D Mucopolysacctlaridoses D Relapsing Polychrondrijis 
D Discoid Lupus Erythematosus D Myopathies and Dystrophies D Scleroderma 
D Ehlers-Danlos syndrome (EDS) D Ochronosis (Homocystinuria) D Sjogren's Syndrome 
D Eosinophilic Fascitis D Osteogenesis imperfecta (01 ) D Systemk: l upus Erythematosus (SlE) 
D Giant Cell (Temporal) Ar thriti s D Polyarteritis Nodosa D Systemic Sclerosis 
D Gout D Polymyalgia Rheumatica D Wegener's Granulomatosis 
D Hypersentive Vasulatis D Polymyositis & Dermatomyositis D Rhabdomyolysis 
D Muscular dystrophy D Myopathy 0 Other 
Operation Date 
Wh at su rgica l o perations have you 
had? (please list and give dates ) 
If female: 
At what age did you start menstruating? (years) 
Are you currently using any type of contraception? 0 y" o No 
If Yes , w hat type of con traception are you using? 0 Pill o Injection o IUD 
o Pre-menopausa l (112 cycl es per yea r at intervals of 23- 33 days & 
bleeding lasts 3-7 days ) 
Are you currently? o Menopausal (cycles are irregul ar and less frequ ent) 















5 b' ect No U I 
Section C. Flexibility training histor~' 
Do you perform flexibility training (regular stretching exercises )? Yes 0 No D 
If YES. please complete the rest of the flexibilil-Y training history section below:-
If NO, continue completing the questionnaire from section 0 
On average , how many days a week do you pnrform a stretching 
days/week 
session? 
On average , how times a da~ do you perform a stretching session? tim es/d ay 
o Hamstrings 
D Quadriceps 
Please tick which muscle groups do you includ e in your 
o Ca lf (gastrocn emiu s) o Ca lf (sol eus) stretching session? o Groin (inner thigh) o Upper body limbs o Other: 
o Before Exercise 
Please tick when you stretch? (before. during Ilnd/or after exercising o During Exercise You can tick more than one box) 
D After Exercise 
Wh en you stretch an individual muscle group, .:)n average , how lon g do 
second s 
~ou hol d the stretch for? 
o Once 
D Twice 
When you stretch an individual muscle group, .:>n average , how D 3 times 
man~ times do ~ou str etch the m uscl e for? D 4 times 
D 5 times 
D 6 or more tim es 
Sect ion D. Lifestyle and habits history 
Please indicate your smoking status I Current smoker D Ex smoker D I Never smoked D 
If you answered yes , Number of years of :smoking: If stopped, how many years ago: 
(past or current 
smoker) please 
complete the section on What is (was) the average number of cigarettes per day: 
the righ t 
--- glasses beer/cider per we ek 
On average , how much alcohol do you drink pBr w eek (tots , 
glasses wine per week 
glasses) of spirits, wine or beer? ---















Subj ect No : ___ _ 
Section E. General Personal Medical History 
Do you currently suffer f rom any of these med ical conditions: 
o High Blood Pressure o Angin a/Heart Attack D Asthma 
D Emphysema D Rheumatoid arthri tis D Osteoarthritis (wear & tea r) 
D Malignant disease (ca ncer) D Elevated Blood Cholesterol D Adrenal disord ers 
If Yes . what type? D Diabetes mellitus o Thyroid disord ers 
D Renal disease D Amyloidosis 
Do you currently suffer from any other 
Connective Tissue, Rheumatological Yes D NoO If Yes , please select from the list below 
Or Muscle Diseases & Disorders? 
List of some Conn ective Tissue and/or Rheumatic Diseases and Disorders 
D Ankylosing Spondylitis D Lipid Storage Diseases D Pseudogout 
D Aspartylglycosaminuria (AGU) D Marfan Syndrome D Reactive Arthritis 
D Behcet's Syndrome D Menkes Kinky Hair Syndrome D Reiter's Syndrome 
D Crohn's Disease D Mucopolysacctlaridoses D Relapsing Polychrondriji s 
D Discoid Lupus Erythematosus D Myopathies and Dystrophies D Scleroderma 
D Ehlers·Danlos syndrome (EDS) D Ochronosis (Homocystinuria) D Sjogren's Syndrome 
D Eosinophilic Fascitis D Osteogenesis imperfecta (01) D Systemk: l upus Erythematosu s (Sl E) 
D Giant Cell (Temporal) Arthritis D Polyarteritis Nodosa D Systemic Sclerosis 
D Gout D Polymyalgia Rheumatica D Wegener's Granulomatosis 
D Hypersentive Vasulatis D Polymyositis & DSfmatomyositis D Rhabdomyolysis 
D Muscular dystrophy D Myopathy 0 Other 
Operation Date 
Wh at su rgica l operations have you 
had? (please list and give dates ) 
If f emal e: 
At what age did you start menstruating? (years) 
Are you curre ntly using any type of contraception? 0 y" 0 No 
If Yes , what type of contraception are you us ing? 0 Pill 0 Injection o IUD 
D Pre-menopausa l (11 2 cycl es per yea r at in tervals of 23- 33 days & 
bleedin g lasts 3·7 days ) 
Are you curre ntly? o Menopausal (cycles are irregul ar and less frequ ent) 















S b"ect No U I 
Section F. Family Medical History 
Have any of your blood (bi ological ) relatives ever had the following? 
Please tick yes or no. If yes, please tick the relat ionship of that person 10 yo u (You may l ick 
more than one of the relationship b locks) . 
Descript ion If Yes, please indicate the re lat ionship 
Chronic Achilles tendon 
o Father o Mothe r o Brother 
Injury 
y" D No [] o Sister o Child 
o Grandfather 0 Grandmother 
o Father o Mother o Brother 
Ach illes tendon rupture y" D No[] o Sister o Child 
o Grandfather 0 Grandmother 
o Father o Mother o Brother 
Any othe r (not Achi lles) y" D No[] o Sister o Child tendon inj urylrupture 
o Grandfather 0 Grandmother 
o Father o Mother o Brother 
Any ligament injury y" D No[] o Sister 0 Child 
n Grandfather n Grandmother 
o Father o Mother o Brother 
Exercise associated muscle y" D No[] o Sister 0 Child cramps o Grandfather D Grandmother 
D Father o Mother o Brother 
Night muscle cramps y" D No[] o Sister o Child 
D Grandfather D Grandmother 
Do any other members of D Father o Mother o Brother 
your famil y suffer from y" D No[] o Sister o Child 
elevated blood cholesterol? D Grandfather D Grandmoth er 
Is there any history of 
D Father o Moth er o Brother 
y" D No[] D Sister o Child 
arthritis in your family? o Grandfather D Grandmother 
o Father o Mother o Brother 
Heart Disease y" D No [] o Sister o Child 
D Grandfather D Grandmother 
D Father o Mother o Brother 
Diabetes y" D No [] o Sister o Child 
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Section G. History of Medication LIse 
Name of medication Years taken 
What medication, if any, are you 
currently using? (please list) 
Have you ever used oral o 3 months D 6 months 
corticosteroids (cortisone YesDNoD D 12 months D 24 or more months tablets)? (if yes , how long ago?) 
Have you ever been given an 
YesDNo D 
o 3 months o 6 months 
injection with corticosteroids? (If o 12 months D 24 or more months yes , how long ago?) 
Have you ever used D 3 months D 6 months 
f1uoroquinoline antibiotics? (refer YesDNoD D 12 months D 24 or more months to the following list) 
list of some f1uoroquinoline antibiotics (may be used in treatm ent of chlamydia, pneumonia, 
acute bronchitis, urinary tract infections, skin and soft tissue infection): 
ADCO-CIPRIN CIPROBAY SANDOZ CIPROFLOXACIN 
AVELON CIPROGEN TAFLOC 
BACTIDRON CPL ALLIANCE CIPROFLOXACIN TARIVID 
CIFLOC DYNAFLOC TAVANIC 
CIFRAN FACTIVE TEQUIN 
CIPLA-CIPROFLOXACIN FLOXIN UNIQUIN 
CIPLOXX MAXAQUIN UTIN-400 
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Section H. Muscle Cramping 
Have you eve r in your athletic career suffered from muscle cramping (painful, 
spontaneous, sustained spasm of a muscle) during or immediately (within 6 hours) Yes D No D 
after exercise (in training or competition) 
If YES, please complete the rest of the muscle! cramping section below:-
If NO, continue completing the questionnaire f rom section I. 
For how many years have you suffered from cramping? (years ) 
Did you suffer from cramping during or after e:(ercise in the last 12 months? Yes 0 No D 
With what type of exercise is your cramping associated o Swimming o Cycling o Running (You can tick more than one form ofexercise),? 
In the last 10 races or 
training sessions , how many Races : __ 11 0 
times have you experienced Tra ining sessions: __ 11 0 
cramping? 
[ J Stretchin g o Resting 
What treatmenUs have you had that [ J Drin king flu id o Ice application 
successfuillt relieved an acute cramp? [J Massage 0 Magnes ium 
(can tick more than one) [ ] Salt (tablets or solution) 
[J Other (Specify: ) 
At what p:oint in the race or training run 
~:J First quarter g Second quarter 
[ J Third quarter o Fourth quarter do you usually first experience cramping? 
i~ Afte r the race Fi No pattern 
In which muscles do you usually cramp [ ] Calves o Hamstrings 
(please list the muscle by the one which [J Quadriceps (thigh) o Foot muscles cramps most frequently (as 1) and the 
others after that (2-4)? [ J Other (Specify: ) 
Have you ever suffered from cramping in you r' who le bodlt (arms and legs)? Yes 0 No D 
Have you ever been admitted to hosp:ital following cramping? Yes 0 No D 
Have you ever been confused or in a coma ,juring or after a cramping episode? Yes 0 No D 
Have you ever had " dark urine" in the 3 days; following a cramping episode? Yes 0 No D 
If you cramp. how long does the cramp usually last for (min )? I (minu tes) 
If you cramp, how severe is o Mild: <: 5 minutes and you are able to continu e exercisin g 
the cramp usually? (please o ModeratB: 5-15 minu tes and you are able to continue exercisin g 
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SECTION I. Past History of Skeletal Muscle Injury (Muscle StrainlTear) 
Please complete this section for each musc le injured . If you have had more than one muscle injury 
additional forms w ill be available. 
Ha ve you ever injured a muscle in the past? I Y EiS 0 No D 
If YES, please complete the rest of Skeletal Muscle Injury section below:-
If NO, continue completinq the Questionnaire from section J. 
Muscle Partial Complete 
Muscle Group Tear Tear 
(L-Ieft, R-rioht) L R L R 
Vastus Lateralis ~ 
If yes, please specify which Quadriceps Vastus Medialis 0 0 0 
muscle? Vastus Intermedius I U U U 
(You may tick more than one Rectus Femoris I 
block, please select either L 
Semitendinosus DO 0 0 (left) or R (rig ht)) 
Semim embranosus DO 0 0 
Also Indicate if you partially or Hamstring Biceps femoris long DO 0 0 completely tore the muscle. 
DO 0 0 Biceps femoris short 
Partial tear re fers to tearing of a Adductor longus DO 0 0 
few muscle fibres with minor 
Hip adductor (nroin) Adductor magnu D O 0 0 swelling, possible loss of 
strength and restriction of Adductor brevi DO 0 0 
moveme nt. Gastrocnemius DO 0 0 
Complete tear refers to a tear Ca lf Plantaris D O 0 0 
extendin g across the whole Soleus DO 0 0 
muscle resulting in complete 
Anterior Left D RightD loss of muscle luction (loss of Chronic 
Left D RightD strength, movement and ability compartment Lateral 
to contract the muscle). syndrom e of th e Superficial posterior Left D Right D 
lower leg 
Deep posterior Left D Right D 
Other: (Please Specify) . 
D Contact wit.h another player 
D Contact with another object (e.g. equipment) 
D No contact. (sprinting) 
How was the muscle injured? D No contact (l anding) 
(pl ease also explain exactly D No contact (kicking) 
how the injury occurred) D No contact (falling) 
D No contact Uumpin g) 
D No contact (Other) 
D Other: (PIE!aSe Specify) . 
After sustaining the muscle 
injury approximate ly how many 
days were you off from training Approximate nlUmb er of days : . . . . . . . 
or competition? 
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Investigation done to confirm D Ultrasound OMRI D CT scan o None the diagnosis 
If Yes , please specify the family member 
0 Mother 
To your knowledge , have any 0 Father 
other members of your family 
y" 0 No [J 0 Sibling suffered from any muscle 0 Son I daughter 
pathology? 0 Other family memb er: 
Condition: Pleas e cho ose musc le in jury f rom the lis 1 
above 
W Rest o Ice application 
What was the ini tial treatment o Compresskm 
(first 5 days)? o Elevation 
(Yo u may tick more than one o 1m mobilisat ion block.) o Medication (analg esics - pain killers) o Medication (anti. inflamm atory drugs) o Other: (PIE!aSe Specify ) . 
W Re habilitation (stretching) 
What was the fina l treatment? o Re habilitation (strengthening) 
(You ma y l ick more than one o Re habili tation (other) 
block.) D Strapping/taping 
D Surg ery 
D Other: (Ple'ase Specify) . 
Followin g this injury please 
D No return to any sport 
Return to sport but . 
indicate whether you were able D Limited to non-sprinting exe rcise 
to return to sports (indicate D Limited to non-jumping exercise category). D Lirnited , not to same level as pre -injury 
D Return to full participation in sport 
D W et and soft ground 
If you are able to recall, what o Dry, but so·ft ground 
were the weather and pitch o Dry and firm ground conditions like at the time of 
injury? o Wet, but firm ground 
D Other: (Please Specify) . 
o Other musGie injury 
Associated injuries (Injuries D Tendon injury 
sustained at the same time as D Ligament Injury 
the muscle injury)? o Bone bruising 
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Section J. Past History of Tendon, Ligament or Joint Capsule Injury 
Please complete this section for each injury. If you have had more than one past injury additional forms 
will be available. 
Have you eve r in your suffered from a tendon or ligament injury (pain, swelling, 
stiffness) in any tendon (including Achilles tenelon, knee tendons, and shoulder Yes D No D 
tendons) or ligaments (partial or complete tear)? 
If YES, please complete the rest of the section below:-
If NO, continue completing the questionnaire from section L. 
longstanding Acute Tearl 
T,!ndon Pain Rupture 
(Tendinopathy) 
l eft Righi left Right 
Foot and ankle: 
[J Achilles tendon DD DD 
Please tick which [J Tibialis posterior DD DD 
lendon/s you have [J Plantar fascia DD DD injured? (next column 
on the tright) 
Knee : [J Patellar tendon 
Also indicate (tick) if 
DD DD 
your injured tendon 
was longsatnding pain 
Elbow and wrist: [ J Wrist extensor te ndon DD DD (tendinopathy) or an 
acute tear/rupture 
Shou lder: [J Rotator cuff DD DD 
Other: DD DD 
Sprain 
Complete 
ligament left Right 
Tear 
left Right 
D Shou lder ligaments DD DD 
Please tick which D Elbow ligaments DD DD 
ligamenUs you have D Wrist ligaments DD DD 
injured? (next column D Finger ligaments DD DD on the tright) D Knee (ACl) DD DD 
D Knee (MCl) DD DD 
Also indicate if your D Knee (PCl ) DD DD sprained or completely o Knee (lCl ) DD DD tore the ligamant. 
D Ankle lateralligarnents DD DD 
D Ankle medial ligaments DD DD o Spinal ligaments DD DD 
D Other: DD DD 
~ Acute shoulder dislocation 
Have you ever suffered from any of the o Chronic shoulder instabili ty 
















Subject No: ___ _ 
SECTION K. MEDICAL DETAILS OF TENDON INJURIES 
Symptoms 
How many times have Tendon InjurEid 
Date of Acute or Sudden DC 
In·urv Chronic In·urv Gradual2 Onset 
you had lendon injuries? 
1 
l Sudden onset is within a 2 
few seconds or minutes 
3 
2Gradual onset is over 4 
days or weeks 
5 
Please complete a separate fo rm, Part K only, for each Tendon Injury you have had 
Injury Number (1,2,3,4,or 5) o 1 [12 o 3 04 05 0 ---
Rotator cuff tendon 0 Pate ttar tendon 0 
· Supraspinatus 0 Wrist extensor tendons 0 Which tendon did you injure? · Infraspinatus 0 Achittes tendon 0 · teres minor 0 
Which side was injured? D Left D Right D Both 
D Upper 1/3 D Middle 1/3 D Lower 1/3 
Which region of your tendon was 
injured? Please indicate on a 
diagram. (Only if applicable) 
To what extent was your Tendon 
D Complete D Partial D None 
ruptured? 
How were you injured? 
(e.g. sport , walking) 
D pain only after exercise 
D pain dLlring exercise , but did not cause you to alter training 
D pain dLlring exercise , which causes you to alter training 
D pain which causes you to stop training 
Grade of injury at the time of D no pain 
injury D not sure 
D Other (Specify ) 
D pain only after exercise 
D pain dLlring exercise , but did not ca use you to alter training. 
D pain dLlring exercise, which causes you to alter training 
D pain which causes you to stop Iraining 
Grade of injury currently D no pain 
D not sure 















Subj ect No: 
D Pain (l!lsS than 1 week) D Stiffness 
Which of the following symptoms 
were present be fore the injury D Pain (1 -4 weeks) D Swelling 
D Pain (> 4 weeks) D None 
D Pain (l!lsS than 1 week) D Stiffness 
Which of the following symptoms 
were present after the injury D Pain (1 -4 weeks) D Swelling 
D Pain (> 4 weeks) D None 
If you have or had chronic 
tendon pain, what seems to 
alleviate the pain? 
Diagnosis 
Which type of Tendon Disease were you I 
diagnosed with e.g. Rupture, Tendinitis, etc. 
Diagnosed by D Doctor 
D Phy siotherapist 
(Please indicate the name and D BiokinElticist 
contact number of the clinician D Pod iatrist 
who diagnosed you) D Other 
If you had a tendon rupture. 
D Surgica lly DNon -surgically How was it treated? 
If applicable, who was the 
Surgeon Phone surgeon? 
If applicable, what diagnostic D Ultraso und D MRI D CT Other imaq inq was performed? 
If applicable, who did the 
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Section l. Details of Any Other Chronic (Longstanding) Curren t Injury 
Please complete this section for each injury. If you ha .... e had more than one past injury additional forms 
will be available. 
What was the approximate date when you first became aware of the 
injury? 
Please indicate which side of your body is injured (if applicable) DRight D Left 
o Head o Elbow o Hamstring 
D Neck D Forearm D Quadriceps o Face o Wrist o Knee 
Please indicate which anatomical area is o Front chest D Finger D Shin 
currently injured o Back chest D Lower back D Achilles 
o Shoulder D Hip D Ankle 
o Upper arm D Thigh DFoot 
Other (Specify: ) 
o Muscle D Ligament 
Please indicate the type of structure that was D Tendon o Joint 
injured o Bone 
Other (Specify): ) 
Please indicate in which sport (discipline) the 
o Running 0 Soccer o Rugby o Cricket 
injury occurred o Hockey 
Other (Specify: , 
o I only experience symptoms after exercise - Grade 1 
Please indicate the o I experience symptoms during exercise, but it does not interfere with exercise 
severity of the injury - Grade 2 
(tick one box o I experience symptoms during exercise that may interfere with my tra iningl 
please) competit ion - Grad!l 3 o I am so painful that I may not be able to train or compete - Grade 4 
o Rest o Tablets o Stretches o Cortisone injection 
Please indicate how your injury was treated 
o Phys iotherapy o Other injection o Surgery o Orthotics 
to date (you can tick more than one)? o Strengthening exercises 
o Equipment change 
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Appendix C- Detailed Methods and Solutions 
C.1 DNA Extraction from Blood 
Briefly, the blood samples were allowed to thaw at room temperature, and then transferred to 15ml 
polypropylene tubes. Two volumes of TKM1 buffer (10mM Tris-HCl pH 7.6, 10mM KCl, 10mM MgCl2 
and 2mM EDTA) containing 2.5% Nonidet P-40 (Sigma, St. Louis, MO, USA) was added to lyse the red 
blood cells, followed by a 10 min incubation at room temperature. The white blood cells were 
pelleted by centrifugation at 1200 x g at room temperature for 10 minutes and washed with one 
volume of TKM1 buffer. The pellet was resuspended and pelleted in the same manner until the 
pellet was clean. The washed pellets were resuspended in 800 ml of TKM2 buffer (10mMTris-HCl pH 
7.6, 10mM KCl, 10mM MgCl2, 0.4M NaCl2and 2mM EDTA) to which 50 ml of 10% sodium 
dodecylsulfate was added, and incubated for 60 minutes at 55 °C or until the pellets had dissolved. 
One hundred and fifty microlitres of 5M NaClO4 and 500 µl of chloroform were added to each 
sample, which was then mixed by vortexing for 15–20 seconds. The samples were transferred to 
1.5ml microfuge tubes and the protein precipitated by centrifugation at 13 000 r.p.m. (15 000 x g) 
for 5 min at room temperature. Five hundred microlitres of the top aqueous phases was transferred 
to new microfuge tubes containing 1ml of absolute ethanol, mixed and the DNA pelleted by 
centrifugation at 13 000 r.p.m.(15 000 x g) for 2 min at room temperature. The precipitated DNA was 
air dried and resuspended in 200 µl of TE buffer (10mM Tris-HCl, 1mM EDTA, pH 8.0) and incubated 
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C.2 Solutions
10% SDS (200ml) 
20 g SDS 
200 ml dH2O 
autoclave 
1 x TE Buffer (pH 8.0) (100 ml) 
0.121 Tris base 
0.037 g EDTA 
dH2O to 100 ml 
HCl to correct pH 
autoclave 
5M NaClO4 (100 ml) 
61.2 g NaClO4  
dH2O to 100 ml 
autoclave 
TKM1 buffer 
10mM Tris-HCl pH 7.6 
10mM KCl  
10mM MgCl2  
2mM EDTA  
TKM1 Buffer +NP-40 
10mM Tris-HCl pH 7.6 
10mM KCl  
10mM MgCl2  
2mM EDTA  
2.5% Nonidet P-40 
TKM2 buffer 
10mMTris-HCl pH 7.6 
10mM KCl  
10mM MgCl2  
0.4M NaCl2 
2mM EDTA 
